 NET PHARMACEUTICAL FORMULATIONS UNDERSTANDING PROGESTERONE AND USES OF THESE
专利摘要:
liquid pharmaceutical formulations comprising progesterone and uses thereof. the present invention relates to pharmaceutical formulations for oral use in hormone replacement therapy comprising ultra-micronized progesterone, wherein the ultra-micronized progesterone is combined with a suitable excipient. preferred excipients comprise medium chain fatty acid glycolic esters and a nonionic surfactant comprising a polyethylene glycol fatty acid ester. in some embodiments, the glycerol and polyethylene glycol c8 to c18 fatty acid esters are the preferred nonionic surfactants. 公开号:BR112014031837B1 申请号:R112014031837-9 申请日:2013-06-18 公开日:2020-09-15 发明作者:Janice Louise Cacace；Peter H.R. Persicaner 申请人:Therapeuticsmd, Inc； IPC主号:
专利说明:
REMISSIVE REFERENCE TO RELATED DEPOSIT REQUESTS [001] This application claims priority for the following US patent applications: U.S. Provisional Application Serial No. 61 / 661,302, entitled "ESTRADIOL FORMULATIONS," which was filed on June 18, 2012; U.S. Provisional Application Serial No. 61 / 662,265, entitled "PROGESTERONE FORMULATIONS," which was filed on June 20, 2012; US patent application serial number 13 / 684,002, entitled "NATURAL COMBINATION HORMONE REPLACEMENT FORMULATIONS AND THERAPIES," which was filed on November 21, 2012; US patent application serial number PCT / US2013 / 023309, entitled "TRANSDERMAL HORMONE REPLACEMENT THERAPIES," which was filed on January 25, 2013; and US Patent Application Serial No. 13 / 843,362, entitled "TRANSDERMAL HORMONE REPLACEMENT THERAPIES," which was filed on March 15, 2013. All of the aforementioned applications are incorporated herein by reference in their entirety. FIELD OF THE INVENTION [002] The disclosure is related to progesterone formulations. Various progesterone formulations can be used in hormonal therapies for women in menopause, peri-menopause and post-menopause, for example, to mitigate the side effects of estrogen replacement therapy. In addition, several progesterone formulations can be used to prevent premature birth in pregnant women who have a shortened cervix. BACKGROUND OF THE INVENTION [003] Hormone replacement therapy (HRT) is a medical treatment that involves the use of one or more of a group of medications designed to supplement hormone levels in women who do not have adequate hormone production. It can mitigate and prevent symptoms caused by decreased circulating hormones estrogen and progesterone. [004] HRT is available in several forms. A therapy involves administering low doses of one or more estrogens or one or more chemical analogues. Another involves the administration of progesterone or one or more chemical analogs. Among other effects, the administration of progesterone acts to mitigate certain undesirable side effects of administration or elevated naturally occurring blood levels of estradiol including endometrial hyperplasia (thickening) and prevention or inhibition of endometrial cancer. Progesterone is a C-21 steroidal sex hormone involved in the female menstrual cycle, pregnancy (supports pregnancy) and embryogenesis of humans and other species. Pro-gesterone belongs to a class of hormones called progestogens, and is the main naturally occurring progestogen in humans. Like other steroids, progesterone consists of four interconnected cyclic hydrocarbons. Pro-gesterone is hydrophobic, having a reported aqueous solubility of 0.007 ± 0.0 mg / ml. Progesterone is poorly absorbed when administered orally. [005] Conventional progesterone therapies include the administration of PROMETRIUM (progesterone, USP) (Abbott Laboratories, Chicago, IL, USA). PROMETRIUM is a drug approved by the FDA, formulated in a medium based on peanut oil, containing micronized progesterone, but with a fraction with relatively large particle size. [006] The active ingredient is considered structurally identical to the naturally occurring progesterone produced by a woman's body (also known as a "bioidentical"). [007] Clinical tests involving PROMETRIUM showed significant variability among patients. For example, a clinical trial involving postmenopausal women who were administered PROMETRIUM once daily for five days resulted in the average pharmacokinetic parameters mentioned in Table 1 (see Table 1, label for PROMETRIUM). Table 1. Pharmacokinetic parameters of PROMETRIUM capsules [008] The extraordinarily high variability in Cmax and AUG, as evidenced by the large reported standard deviation, indicates that a significant percentage of patients are administered with an overdose or receive a dose that is below the optimum. [009] The presence of peanut oil in the formulation excludes patients who are allergic to peanut oil. Peanut oil, like other peanut products, can act as an allergen. In fact, there is a portion of the population that has severe reactions to peanut oil. Peanut allergies are becoming a significant health concern. Food allergies are a major cause of anaphylaxis, with approximately 200 deaths occurring annually in the United States. Although the incidence and prevalence are not entirely known, it is suspected that about 6% of children and 4% of adults in North America are affected by food allergies. Many food allergies experienced by children usually go away in adulthood with the exception of peanut allergies. [010] Progesterone and its analogs can be used to treat a variety of medical conditions, including acute illnesses or disorders, as well as chronic illnesses and disorders associated with long-term reductions in natural levels of progesterone. [011] Consequently, improved progesterone formulations would be advantageous. SUMMARY [012] Various pharmaceutical formulations are disclosed herein. For example, pharmaceutical formulations comprising ultra-micronized progesterone are disclosed. In addition, pharmaceutical formulations comprising ultra-micronized progesterone formulations are disclosed, wherein the ultra-micronized progesterone is combined with a suitable excipient. [013] Thus, in various illustrative embodiments, the invention comprises an encapsulated liquid pharmaceutical formulation to orally administer progesterone to a mammal that needs it, said formulation comprising: progesterone, as the only active pharmaceutical ingredient, in micronized form, in solubilized form, or in micronized and partially soluble form in a vehicle comprising a medium chain fatty acid glycolic ester or mixtures thereof and a nonionic surfactant comprising a polyethylene glycol fatty acid ester. In some of these modalities, progesterone is ultra-micronized. In some of these embodiments, at least about 80% by weight of the total progesterone is micronized. Fatty acids can be predominantly (> 50% by weight): C6 to C12 fatty acids, C6 to C10 fatty acids, C8 to C12 fatty acids, or C8 to C10 fatty acids, esters can be mono-, di-, or triples or mixtures thereof, and the glycols may be glycerol, polyethylene glycol or propylene glycol or mixtures thereof. Some embodiments comprise a non-ionic surfactant comprising esters of C8 to C18 fatty acid glycerol and polyethylene glycol. BRIEF DESCRIPTION OF THE DRAWINGS [014] The accompanying drawings are included to provide an additional understanding of the disclosure and are incorporated and form a part of this specification, illustrate description modalities, and together with the description serve to explain the principles of the description. [015] Figure 1 illustrates a process for the production of filling material according to various modalities; [016] Figure 2 illustrates a process for the production of soft gel capsules according to various modalities; [017] Figure 3 illustrates a process for the production of soft gel capsules according to various modalities; and [018] Figure 4 illustrates a study to dissolve a formulation according to several modalities. [019] Figure 5 shows a graph of the particle distribution obtained in example 10. [020] Figure 6 illustrates a study of the dissolution of a formulation according to various modalities of the invention. DETAILED DESCRIPTION OF THE ILLUSTRATED MODALITIES [021] In accordance with various modalities, a pharmaceutical formulation comprising ultra-micronized progesterone is provided. As described in details here, various vehicles, lubricants, and other excipients may be included. In additional embodiments, ultra-micronized progesterone formulations provide improved bioavailability and other pharmacokinetic enhancements. Definitions [022] Except where otherwise specified, the following definitions apply. [023] The term "ultra-micronized progesterone", as used herein, includes micronized progesterone having an X50 value below about 20 microns and / or having an X90 value below about 25 microns. [024] A chemical structure of progesterone is shown below: [025] The term "administer," "administration," "release" or "release" (collectively "administration"), for use in the present invention, means administration to the structure through, without limitation, tablets, capsules, soft gel capsules, injections, transdermal patches, creams, gels, vaginal suppositories that include gel capsules or other mechanisms known in the art or further developed. The term "administration" can also mean the direct application of the contents of a soft gel to the vagina, such as by accessing the contents of the soft gel by opening or breaking the soft gel capsule to release the contents there. [026] The term "X50," as used here, means that half of the particles in a sample have a diameter less than a given number. For example, ultra-micronized progesterone having a 5 micron X50 means that, for a given sample of ultra-micronized progesterone, half of the particles have a diameter of less than 5 microns. In this sense, similar terms, in the form XYY mean that YY percent of the particles in the sample have a diameter smaller than a given number. For example, X90 means that ninety percent of the particles in a sample have a diameter less than a given number. [027] The term "medium chain", as used here, means any substance containing medium chain carbon, including C4-C18, and including substances C6-C12, glycerol fatty acid esters, fatty acids, and mono-, di - and triglycerides of these substances. For further illustration, C6-C14 fatty acids, C6-C12 fatty acids, and C8-C10 fatty acids are all medium-chain fatty acids and can be used in cases where this specification requires the use of medium-chain fatty acids, for example, medium chain fatty acid esters of glycerol or other glycols. [028] The term "uniform distribution" means at least one among uniform dispersion, solubility, or lack of progesterone clumping in gastric juices compared to PROMETRIUM. [029] The term "gastric juices" means a watery acidic digestive fluid that is secreted by various glands in the mucous membrane of the stomach and consists mainly of hydrochloric acid, pepsin, renin and mucin. [030] The term, "API", for use in the present invention, refers to an active pharmaceutical ingredient. In formulations, the API is progesterone. [031] The term "excipients", for use in the present invention, refers to non-API substances such as vehicles, solvents, lubricants and others used in the formulation of pharmaceutical products. They are generally safe for administration to humans, according to established government standards, including those promulgated by the FDA (United States Food and Drug Administration). [032] The term "vehicle", as used here, means any substance or mixture of substances that can be mixed with or contain an API (for example, ultra-micronized progesterone). [033] The term "capsule", as used here, refers to a generally safe wrapper, easily dissolvable for carrying certain pharmaceutical products, and includes capsules with a hard or soft wrap. [034] The term "soft gel" includes soft-wrapped capsules, including soft gelatin capsules and soft vegetable-based capsules, and soft capsules made from other materials that provide the composition of these soft capsules are compatible with formulations of various modalities described here. A soft gel can comprise two primary phases: a vegetable-based gel or capsule and a pharmaceutical formulation filler, as described here. [035] The term "bioavailability," as used here, means the concentration of an active ingredient (for example, progesterone) in the blood (serum or plasma). Relative bioavailability can be measured as the concentration in the blood (serum or plasma) as a function of time. Other pharmacokinetic indicators (PK) can be used to measure and assess bioavailability, determined by an appropriate metric, including AUC, Cmáx, and optionally, Tmax. [036] The terms "pharmacokinetics" and "pharmacokinetic measurements" include assessments and determinations for studying the absorption, distribution, metabolism, and excretion of a drug. [037] The term "AUC," as used here, refers to the area under the curve that represents changes in the blood concentration of progesterone over time. [038] The term, "Cmax" as used here, refers to the maximum value of blood concentration shown on the curve that represents changes in blood concentrations of progesterone over time. [039] The term "Tmax", as used here, refers to the time it takes for the blood progesterone concentration to reach its maximum value. [040] Optionally, the term, "T1 / 2" as used here, refers to the time it takes for blood progesterone concentration to drop to half the maximum level. [041] Collectively AUC, Cmax and, optionally, Tmax and Ty2 are the main pharmacokinetic parameters that can characterize the pharmacokinetic responses of a particular pharmaceutical product such as progesterone in an animal or human individual. description [042] In general, the pharmaceutical formulations described herein are prepared and administered as filled capsules, typically soft capsules of one or more materials well known in the art including, for example, but not limited to, soft gelatin capsules. Micronized progesterone, as described herein, can also be prepared for administration in tablets or other well-known orally administered dosage forms using standard techniques. [043] Another aspect of the present description includes a pharmaceutical formulation of micronized progesterone, micronized progesterone with partially solubilized progesterone and fully solubilized progesterone, wherein said formulation can provide increased progesterone bioavailability in a treated individual compared to the bioavailability provided by Prometrium ® when administered at equal dosing forces. [044] In illustrative embodiments, the total progesterone, that is, dissolved and micronized, is 20 to 50% by weight, for example, 30 to 35% by weight, based on the weight of the entire filler, ie the formulation liquid pharmaceutical. [045] Other modalities presented here also provide: more uniform dissolution of progesterone, and reduced variability of intra- and inter-patient blood level in the progesterone formulations of the present description, compared to equal dosages of PROMETRIUM. Blood level variability is also compared at equal sampling times after administration. [046] According to PROMETRIUM prescribing information, clinical tests have shown significant variability between patients. For example, a clinical trial involving postmenopausal women who were given PROMETRIUM once a day for five days resulted in the average pharmacokinetic parameters (PK) mentioned in the following table: [047] In particular illustrative aspects and modalities of this invention, it is possible, although not necessary, to reduce standard deviations in one or more of these PK parameters. [048] A more uniform dissolution of progesterone in a formulation of the present description compared to dissolving PROMETRIUM at equal dosage strengths and using the same USP apparatus can be determined using standard techniques established for API dissolution tests, including the which is described in the examples below. [049] The reduced intra- and inter-patient variability of progesterone formulated in accordance with the present disclosure compared to PROMETRIUM can be demonstrated through a fed biostudy as described below. [050] Other aspects of the present description include the use of the formulations as described here in which progesterone is at least an API in said formulation for the treatment of an animal, especially a mammal, including humans: for endometrial hyperplasia; for secondary amenorrhea; as a treatment method for premature birth, when said animal has a shortened cervix, and other disease states or conditions treated with supplementary progesterone (collectively, "progesterone-deficient states") in an individual in need of treatment, and with an effective non-toxic amount of said formulations; As used herein, the term "treatment", or a derivative thereof, contemplates partial or complete inhibition of the declared disease state when a formulation as described herein is administered prophylactically or after the onset of the disease state for which this formulation is administered. For the purposes of the present description, "prophylaxis" refers to the administration of the active ingredient (s) to an animal, especially a mammal, to protect the animal from any of the disorders described herein, as well as others. [051] Exemplifying strengths for progesterone for use in the formulations described herein include, but are not limited to 25, 50, 75, 100, 125, 150, 175, 200 mg, 250 mg, 300 mg, 350 mg and 400 mg. [052] The active pharmaceutical ingredient progesterone can be micronized using any of the multiple methods typically used by those skilled in the art. [053] The particle size can be determined in any suitable way. For example, a Beckman Coulter LS 13 320 laser diffraction particle size analyzer (the "Beckman device") can be used to determine the particle size. The particle size can be represented by various measures, for example, through an X50 particle size, and / or X90 particle size, or similar particle size descriptions. [054] The Beckman device can be used with several modules to introduce a sample for analysis. The Beckman device can be used with the LS 13 320 ("ULM") universal liquid module. ULM is able to suspend samples in the size range from 0.017 pm to 2,000 pm. The ULM is a liquid-based module that allows the sample to be released into the detection zone. The ULM recirculates the sample through the Beckman device. ULM comprises two hoses, one for fluid release and one for waste. The total volume used can be 125 ml or less. A sample mass of about 1 mg to about 10 g can be used. The ULM can interact with the Beckman device through pins that fit into slots in the ULM. ULM can use a variety of suspended fluids, for example, water, butanol, ethanol, chloroform, heptanes, toluene, propanol, COULTER type 1B dispersant ("Coulter 1B"), and a variety of other suspended fluids. Surfactants can also be used, although the pump speed must be adjusted to prevent excessive bubbling. The Coulter 1B device may comprise one or more of acetaldehyde, ethylene oxide, and / or 1,4-dioxane. The Beckman device can be configured to use a variety of optical theories, including the Fraunhofer optical model and Mie Theory. [055] The Beckman device can comprise a program to control the Beckman device while the ULM is in use. The program can control, for example, the speed of the pump, use of the de-bubbling routine, rinsing routine, sonication routine, and filling routine, among others. The parameters related to the sample test can also be configured. For example, the test length can be adjusted. Although any suitable test length can be used, in various embodiments, a time period of 30 seconds to 120 seconds, and preferably between 30 seconds and 90 seconds can be used. [056] The Beckman device can be used with the LS 13 320 ("MLM") liquid micro module. MLM is capable of suspending samples in the size range from 0.4 pm to 2,000 pm. The MLM is a liquid-based module that allows the sample to be released into the detection zone. MLM includes a stirrer. The total volume used can be 12 ml or less. MLM can use a variety of fluids in suspension, both aqueous and non-aqueous. [057] In several modalities, ultrononized progesterone has an X50 value less than about 15 microns, less than about 10 microns, less than about 5 microns and / or less than about 3 microns, and a value X90 less than about 25 microns, less than about 20 microns, and / or less than about 15 microns. [058] In several modalities, ultra-micronized progesterone is formulated with excipients free from peanuts and peanut oil. [059] In several modalities, the vehicle is selected to accentuate the dissolution and suspension properties of progesterone. In several additional modalities, the vehicle is selected to enhance the absorption of API by the cells of a mammal. For example, certain vehicles can be selected to enhance the absorption of the other components of the formulation, including the API. Absorption can comprise absorption in any cell and, in particular, absorption in cells of the digestive system, such as intestinal cells, and cells of the female reproductive system, such as the vagina and the cervix. Selected mono / di / triglycerides are particularly suited to assist cellular absorption. [060] In various embodiments, the vehicle may comprise medium chain fatty acids. Suitable vehicles include caproic fatty acid; caprylic fatty acid; capric fatty acid; lauric acid; myristic acid; linoleic acid; succinic acid; glycerin; propylene glycol; caprylic / capric triglycerides; caproic / caprylic / capric / lauric triglycerides; caprylic / capric / linoleic triglycerides; caprylic / capric / succinic triglycerides; polyethylene glycol; Propylene Glyol Dicaprilat / Dicaprato; and combinations and derivatives thereof. [061] Suitable vehicles also include esters of coconut oil and saturated palm kernel and derivatives thereof, including fractionated coconut oils and palm kernel oils thereof; and triglycerides of fractionated vegetable fatty acids, and derivatives thereof and their combinations. In several additional embodiments, the vehicle can comprise one or more monoglycerides, diglycerides, triglycerides, and combinations thereof. Such a suitable vehicle is commercially available under the trademark MIGLYOL (caprylic / capric triglyceride) (Sasol Germany, GmbH). MIGLYOL products comprise esters of caprylic and capric fatty acids derived from coconut oil and saturated palm kernel, glycerin and / or propylene glycol. Suitable MIGLYOL products include MIGLYOL 810 (caprylic / capric triglyceride), MIGLYOL 812 (caprylic / capric triglyceride), MIGLYOL 818 (caprylic / capric / linoleic triglyceride) and MIGLYOL 829 (caprylic / capric / succinic triglyceride). [062] Additional examples include a polyethylene glycol glyceride (Gelucire®; GATTEFOSSE SAS, Saint-Priest, France); a propylene glycol; a caproic / caprylic / capric / lauric triglyceride; a caprylic / capric / linoleic triglyceride; a caprylic / capric / succinic tri-glyceride; propylene glycol monocaprylate; propylene glycol monocaprate; (Capmul® PG-8 and 10; CAPMUL brands are owned by ABITEC, Columbus Ohio, USA); propylene glycol tipprilat; propi-lenoglycol tipprilat; medium chain mono and diglycerides (CAPMUL MCM); a diethylene glycol mono ester (including 2- (2-ethoxy-ethoxy) ethanol: Transcutol); diethylene glycol monomethyl ether; saturated coconut oil and palm kernel esters and derivatives of these substances; triglycerides of fractionated vegetable fatty acids and combinations and derivatives of these substances. In other aspects and modalities, progesterone is completely solubilized using, for example, but not limited to sufficient amounts of: TRANSCUTOL (diethylene glycol monomethyl ether) and MIGLYOL; TRANSCUTOL, MIGLYOL and CAPMUL PG-8 (propylene glycol monocaprilate) and / or CAPMUL PG-10 (propylene glycol monocaprate); CAPMUL MCM (mono and medium chain diglycerides); CAPMUL MCM and a non-ionic surfactant; and CAPMUL MCM and GELUCIRE (a polyethylene glycol glyceride). [063] Various reasons for these oils can be used for the suspension and / or solubilization of progesterone. CAPMUL MCM and a nonionic surfactant, for example, GELUCIRE 44/14 (macrogol-32 EP lauroyl glycerides, polyoxyl-32 NF lauroyl glycerides, polyoxylglyceride lauroyl (USA FDA IIG)), can be used for about 99 : 1 to 2: 1, inclusive, for example, but not limited to: 60:40, 65:35, 70:30, 75:25, 80:10, 80:15, 85:20, 90:10, and 98: 1. The ratios between oil (for example, medium chain fatty acid esters of monoglycerides and diglycerides) and nonionic surfactant can be significantly higher. For example, in certain examples, below, CAPMUL MCM and GELUCIRE were used in ratios of up to about 65: 1, for example, 8: 1.22: 1.49: 1.65: 1 and 66: 1. In this way, the useful ratios can, for example, be 8: 1 or more, for example, 60 to 70: 1. [064] The combinations of these oils can produce partially solubilized progesterone, depending on the amount of progesterone unit dose desired. The greater the amount of progesterone per unit dose, the less pro-gesterone can be solubilized. The upper limit of the dosage strength per unit dose is generally limited only by the practical size of the final dosage form. [065] In illustrative embodiments, oils used to suspend, partially solubilize or completely solubilize progesterone include esters of medium-chain fatty acid (eg esters of glycerol, polyethylene glycol or propylene glycol) and mixtures thereof. In illustrative embodiments, medium-chain fatty acids are C6 to 014 or C6 to 012 fatty acids. In illustrative embodiments, medium-chain fatty acids are saturated or predominantly saturated, for example, more than about 60% or more than about 75% saturated. In illustrative embodiments, progesterone is soluble in oils at room temperature, although it may be desirable to heat certain oils initially during manufacture to improve viscosity. In illustrative embodiments, the oil or oil / surfactant is liquid between room temperature and about 50 ° C, for example, at or below 50 ° C, at or below 40 ° C, or at or below 50 ° C. In illustrative embodiments, GELUCIRE 44/14 is heated to about 65 ° C and CAPMUL MCM is heated to about 40 ° C to facilitate mixing of the oil and the non-ionic surfactant, although this heating is not necessary to dissolve the estradiol or progesterone. [066] In illustrative embodiments, the solubility of estradiol in oil (or oil / surfactant) is at least about 0.5% by weight, for example, 0.8% by weight or more, or 1.0% by weight. weight or more. Illustrative examples of mono and diglycerides of medium chain fatty acids include, but are not limited to, CAPMUL MCM, CAPMUL MCM C10 (glyceryl monocaprate), CAPMUL MCM C8 (glyceryl monocaprylate), and CAPMUL MCM C8 EP (glyceryl monocaprylate). These oils are mono and diglycerides of C8 and C10 fatty acid. Illustrative examples of oils that are medium chain fatty acid triglycerides include, but are not limited to, MIGLYOL 810 and MIGLYOL 812. [067] Illustrative examples of oils that are propylene glycol medium chain fatty acid esters include, but are not limited to, CAPMUL PG-8, CAPMUL PG-2L EP / NF (propylene glycol dilaurate), CAPMUL PG-8 NF (monocaprylate) propylene glycol), CAPMUL PG-12 EP / NF (propylene glycol monolaurate) and CAPRYOL (propylene glycol monocaprylate (type II) NF). Other illustrative examples include MIGLYOL 840 (propylene glycol Dicaprilat / Dicaprato). [068] Illustrative examples of oils that are polyethylene glycol medium chain fatty acid esters include, but are not limited to, GELUCIRE 44/14 (PEG-32 EP glyceryl laurate), which is mono, di and polyethylene glycol glycerides triglycerides and polyethylene glycol mono- and diesters. Without intending to stick to any specific mechanism, it appears that at least in formulations comprising small amounts of GELUCIRE, for example, 10% by weight or less, the primary function of this oil is as a non-ionic surfactant. [069] These illustrative examples comprise predominantly saturated fatty acids with medium chain length, specifically, predominantly, saturated fatty acids C8 to C12. [070] It will be understood that commercially available fatty acid esters of glycerol and other glycols are often prepared from natural oils and therefore may comprise components in addition to the fatty acid esters that comprise the predominant component (s) ( s) (by weight) and which are therefore used to characterize the product. These other components can be, for example, other triglycerides of fatty acid, mono- and diesters, free glycerol, or free fatty acids. So, for example, when an oil / solubilizing agent is described in the present invention as a glycerol-saturated C8 fatty acid mono- or diester, it will be understood that the predominant component of the oil, i.e.> 50% by weight ( for example,> 75% by weight,> 85% by weight or> 90% by weight) are caprylic monoglycerides and caprylic diglycerides. For example, the technical data booklet made by ABITEC for CAPMUL MCM C8 describes CAPMUL MCM C8 as being composed of mono and diglycerides of medium chain fatty acids (mainly caprylic) and describes the alkyl content as <= 1% of C6, > = 95% C8, <= 5% C10, and <= 1.5% C12 and more. [071] By way of additional example, MIGLYOL 812 is generally described as a C8-C10 triglyceride because the fatty acid composition is at least about 80% caprylic acid (C8) and capric acid (C10). However, it can also comprise small amounts of other fatty acids, for example, less than about 5% caproic acid (C6), lauric acid (C12), and myristic acid (014). [072] Specifically, a product information sheet for SASOL's MIGLYOL provides the fatty acid composition as follows: [073] When certain embodiments of this invention are described as comprising (or consisting essentially of) a capsule wrap, estradiol solubilized in C8-C10 triglycerides, and a thickening agent, it will be understood that the fatty acid esters component of The formulation can be, for example, MIGLYOL 812 or a similar product. [074] By way of additional illustration, GELUCIRE 44/14 is generally described as lauroyl polyoxyl-32 glycerides, that is, lauryl polyoxyethylene 32 glycerides (which are a mixture of mono, di, and triesters of glycerol and mono and di - PEGs) because the fatty acid composition is 30 to 50% lauric acid and smaller amounts of other fatty acids, for example, up to 15% caprylic acid, up to 12% capric acid, up to 25% myristic acid, up to 25% palmitic acid, and up to 35% stearic acid. The product may also contain small amounts of non-esterified glycols. When certain embodiments of this invention are described as comprising (or consisting essentially of) a capsule wrap, estradiol solubilized in triglycerides, and a thickening agent that is a nonionic surfactant comprising esters of glycerol and polyethylene glycol C8 to C18 fatty acid It is understood that the thickening agent component of the formulation can be, for example, GELUCIRE 44/14 or a similar product. [075] Similarly, when certain embodiments of this invention are described as comprising (or consisting essentially of) a capsule wrap, estradiol solubilized in triglycerides, and a thickening agent that is a nonionic surfactant comprising PEG-6 stearate, ethylene glycol palmitoestearate, and PEG-32 stearate, it will be understood that the thickener component of the formulation may be, for example, TEPHOSE 63 (PEG-6 palmitoestearate and ethylene glycol palmitoestearate) or a similar product. [076] In illustrative embodiments of the invention, the selected oil does not require excessive heating in order to solubilize the progesterone. For example, when the formulation comprises mono and diglycerides of medium chain fatty acid (eg CAPMUL MCM) and polyethylene glycol glycerides (eg GELUCIRE) as a surfactant, the oil and / or the surfactant can be heated, for example , up to about 65 ° C in the case of the surfactant and less in the case of the oil, to facilitate mixing the oil with the surfactant. Progesterone can be added when the mixture cools, for example, to below about 40 ° C or below about 30 ° C, even to room temperature. [077] In certain embodiments, an anionic and / or non-ionic surfactant is used. Exemplifying non-ionic surfactants may include one or more of fatty acid esters of glycerol and polyethylene glycol, for example, macrogol-32 lauroyl glycerides and / or polyoxyl-32 lauroyl glycerides, commercially available as GELUCIRE, including, for example, GELUCIRE 44 / 11 and GELUCIRE 44/14. These surfactants can be used in concentrations greater than about 0.01%, and typically, in various amounts from about 0.01% to 10.0%, 10.1% to 20%, and 20.1% to 30 %. In certain examples, below, GELUCIRE 44/14 is used as a surfactant in quantities of 1 to 10% by weight. See the tables below. Other non-ionic surfactants include, for example, LABRASOL (capricocaproyl macrogol-8 EP glycerides, polyoxyl-8 NF caprilocaproyl glycerides, caprylic / capric glycerides from PEG-8 (USA FDA IIG)) (Gattefosse) and LABARAFIL (PEG-6 esters of corn / apricot oil) (Gattefosse). [078] In several modalities, a lubricant is used. Any suitable lubricant can be used, for example, but not limited to, lecithin, and in various embodiments, a mixture of polyethylene glycol ("PEG") esters, glycerides, and PEG, as available for sale under the trade name GELUCIRE (Gattefosse, FR) can also be used as a lubricant. Suitable lubricants may also comprise calcium stearate, ethyl oleate, ethyl laureate, glycerin, glyceryl palmitostearate, hydrogenated vegetable oil, magnesium, oxide, magnesium stearate, poloxamer, glycols, and phospholipid mixtures. In particular, a mixture of polyethylene glycol esters, glycerides, and PEG such as GELUCIRE 44/14, can be used as a lubricant. GELUCIRE 44/14 is a water-dispersible non-ionic surfactant, also known as macrogol-32 EP lauroyl glycerides and NF polyoxyl-32 lauroyl glycerides. In several embodiments, GELUCIRE 44/14 acts as a suspending agent. [079] In several modalities, an antioxidant is used. Any suitable antioxidant can be used, for example, but not limited to, butylated hydroxy-luene. Butylated hydroxytoluene, a derivative of phenol, is lipophilic and is therefore suitable to be intermixed with ultra-micronized progesterone and the vehicles presented or contemplated in the present invention. [080] For example, in various embodiments, a pharmaceutical formulation comprises about 20% to about 80% by weight of vehicle, about 0.1% to about 5%, by weight of lubricant, and about 0, 01% to about 0.1% by weight of antioxidant. [081] The choice of excipient will depend largely on factors such as the particular mode of administration, the effect of the excipient on solubility and stability, and the nature of the dosage form. Excipients used in various modalities can include colorants, flavoring agents, preservatives and flavor masking agents. Dyes, for example, can comprise from about 0.1% to about 2% by weight. Preservatives can comprise methyl and propylparaben, for example, in a ratio of about 10: 1, and a ratio of about 0.005% and 0.05% by weight. [082] As with all oils, solubilizers, excipients and any other additives used in the formulations described here, each must be non-toxic and pharmaceutically acceptable. [083] As mentioned above, the formulations of the present description are generally administered orally, typically through, for example, capsules, as soft capsules. The present formulations can also be used to form transdermal patches using standard technology known in the art. The solubilized formulations of the present invention can also be formulated for intraperitoneal administration using techniques well known in the art. [084] Thus, an illustrative embodiment of a pharmaceutical composition of the invention comprises progesterone, in which at least 75% of the progesterone is solubilized (the remainder being micronized, as discussed elsewhere in this document), and an oil, in which the oil is mono and diester of medium chain fatty acid of one or more glycols, with or without surfactant. In certain embodiments, a specification for progesterone is set to> 80% solubilized, <20% micronized or> 85% solubilized, <15% micronized. [085] Pharmaceutical formulations according to various modalities comprise ultra-micronized progesterone. In additional embodiments, a pharmaceutical formulation comprises ultra-micronized progesterone, a carrier, and a lubricant. In still further embodiments, a pharmaceutical formulation comprises ultra-micronized progesterone, a vehicle, a lubricant, and optionally, an antioxidant. In still further embodiments, a pharmaceutical formulation comprises ultra-micronized progesterone, and a medium chain triglyceride as a carrier. In still further embodiments, a pharmaceutical formulation comprises ultra-micronized progesterone, and caprylic / capric acid monoglycerides / diglycerides / triglycerides as a carrier. Several additional embodiments also comprise lecithin and, optionally, butylated hydroxy-luene. [086] In additional embodiments, a pharmaceutical formulation comprises ultra-micronized progesterone and at least one vehicle, a lubricant, optionally, an antioxidant, and other pharmaceutically acceptable excipients. For example, in various embodiments, a pharmaceutical formulation comprises about 20% to about 80% by weight of vehicle, about 0.1% to about 5% by weight of lubricant, and about 0.01% to about 0.1% by weight of antioxidant. [087] The choice of excipient will depend largely on factors such as the particular mode of administration, the effect of the excipient on solubility and stability, and the nature of the dosage form. Excipients used in various modalities can include colorants, flavoring agents, preservatives and flavor masking agents. Dyes, for example, can comprise from about 0.1% to about 2% by weight. Preservatives can comprise methyl and propylparaben, for example, in a ratio of about 10: 1, and a ratio of about 0.005% and 0.05% by weight. [088] Formulations according to various modalities can be administered alone or in combination with one or more other drugs (or as any combination thereof). For example, formulations according to various embodiments can also comprise estradiol. [089] In several modalities, ultrononized progesterone is administered in a capsule. Capsules can be prepared using one or more film-forming polymers. Suitable film-forming polymers include natural polymers, such as gelatin, and synthetic film-forming polymers, such as modified celluloses. Suitable modified celluloses include, but are not limited to, hydroxy propyl methyl cellulose, methyl cellulose. [090] Capsules with a hard or soft wrap can be used to administer the API. In certain embodiments, the capsules can be prepared by forming the two halves of the capsule, filling one of the halves with the filling solution, and then sealing the capsule halves together to form the finished capsule. [091] Hard capsules can be prepared by combining the "body" with the "cap". The "body" of the capsule is filled with the "filler mass" and then closed with the "lid". The "body" / "cover" interface is then sealed / joined. [092] Soft gelatin capsules can be prepared using a rotating matrix encapsulation process, as further described below. [093] Suitable capsule additives, for capsules with duct or soft wrap, may include plasticizers, opacifiers, dyes, humectants, preservatives, flavorings, and buffering and acid salts, and combinations thereof. The main ingredients of the capsule wrap are mainly gelatin (or a gelatin substitute for non-gelatinous capsules), plasticizer, and purified water. Capsules with a hard or soft wrap differ mainly in the amount of plasticizer present that is used in the capsule wrap. [094] Plasticizers are chemical agents added to gelatin to make the material softer and more flexible. Suitable plasticizers include, but are not limited to, glycerin, sorbitol solutions which are mixtures of sorbitol and sorbitan, and other polyhydric alcohols such as propylene glycol and maltitol or combinations thereof. [095] Opacifiers are used to opacify the capsule wrap when the encapsulated active agents are sensitive to light. Suitable opacifiers include titanium dioxide, zinc oxide, calcium carbonate and combinations thereof. [096] Dyes can be used for the purposes of marketing and product identification / differentiation. Suitable dyes include synthetic and natural dyes and combinations thereof. [097] Flavoring agents can be used to mask unpleasant odors and flavors from fill formulations. Suitable flavorants include synthetic and natural flavorings. The use of flavorings can be problematic due to the presence of aldehydes that can crosslink gelatin. As a result, buffering salts and acids can be used in conjunction with flavorings that contain aldehydes to reduce crosslinking of gelatin. [098] According to various modalities, a soft gel dosage form is used. [099] A soft gel comprises two primary phases: a gel capsule and a filling material. The soft gel can comprise a gelatin material in a relatively solid or rigid form. The soft gel can define an internal volume that can contain the filling material. The dissolution of the soft gel can begin at several points, such as along the digestive tract (mouth, esophagus, stomach and intestines), or other body cavities, such as the vaginal cavity. [0100] When the soft gel dissolves, the internal volume can enter into fluid communication with the digestive system, allowing the filling material to leave the soft gel. A soft gel can also be punctured, cut and otherwise opened outside a body. The padding material can then be poured or pressed out of the gel capsule and applied over or inside the body, such as inside the vaginal cavity. [0101] Humectants can be used to suppress the water activity of the soft gel. Suitable humectants include glycerin and sorbitol, which are often components of the plasticizer composition. Due to the low water activity of properly stored dry soft gels, the greatest risk for microorganisms comes from mold and yeast. For this reason, preservatives can be incorporated into the capsule wrap. Suitable preservatives include alkyl esters of p-hydroxy benzoic acid such as methyl, ethyl, propyl, butyl and heptyl esters (collectively known as "parabens") or combinations thereof. [0102] The filling material may comprise a liquid, such as an oil, a solution, a suspension, or other acceptable forms. The active ingredient or active ingredient may be contained within the liquid. [0103] Formulations according to various modalities can be administered orally. Oral administration may involve swallowing for the compound to enter the gastrointestinal tract, or oral or sub-ligual administration, whereby the compound enters the bloodstream directly from the mouth. [0104] Ultrasonized progesterone according to various modalities can be formulated as a vaginal suppository or vaginal cream for administration over the vulva or inside the vagina, cervix, or uterus of a human being. Capsules (for example, soft gels) containing ultra-micronized progesterone can also be administered through the vagina, including inserting a capsule directly into the vaginal cavity or releasing the capsule's contents into the vaginal cavity. Ultra-micronized progesterone, according to various modalities, can be formulated for intraperitoneal administration, and atomization, such as with administration of nasal mist. [0105] In accordance with various modalities, intensified bioavailability of progesterone is provided, as with conventional progesterone formulations in which commercially available progesterone formulations are known to be poorly or inconsistently absorbed. Although not limited by theory, the elements of the present formulation provide enhanced performance characteristics as further described here, including, for example, but not limited to, improved bioavailability and the potential to be able to reduce the dosage strength administered in compared to currently available progesterone formulations. Comparisons of bioavailability to commercially available forms, such as tablet forms, can be determined by standard pharmacokinetic techniques. [0106] According to various modalities, the effects of food are reduced, for example, compared to comparative progesterone products. [0107] According to various modalities, the formulations do not include peanut oil. The lack of peanut oil reduces the risk imposed on those who are allergic to peanuts. [0108] The capsules can be placed in blister packs or cartridges or bottles. [0109] According to various modalities, a 28-day or monthly capsule regimen can be packaged in a single kit (for example, a blister pack) with the application days identified to improve adherence and reduce associated symptoms, among others. One or more of the capsules may not contain estradiol, for example, and / or progesterone. Capsules that do not comprise API or hormone (for example, progesterone) can be called placebos. A blister pack can have a plurality of points or perforations separating the blister pack in 28 days. Each day can additionally comprise a single blister or a plurality of blisters. In various embodiments, each dose (for example, each soft gel) can contain ultra-micronized progesterone in amounts of 100 mg, 150 mg, 200 mg, and 250 mg, although other dosage ranges are contemplated here. In addition, kits having other configurations are also contemplated here. For example, but without limitation, kits containing these blister packs can contain any number of capsules. [0110] Formulations according to various modalities can be used to treat or prevent premature birth in pregnant women, including certain women who have a shortened cervix. In various embodiments, a capsule, for example, a soft gel capsule, can be opened and the filling material applied to or inside the vagina. However, in various modalities, the capsules are taken orally. [0111] Formulations according to various modalities can be used to treat or prevent endometrial hyperplasia. [0112] Formulations according to various modalities can be used to treat or prevent secondary amenorrhea. [0113] Formulations according to various modalities can be used to mitigate or treat the effects of estradiol supplementation. In particular, formulations according to various modalities can be co-administered with estradiol and / or co-formulated with estradiol. [0114] Formulations according to various modalities can be used to treat symptoms related to menopause, including vasomotor symptoms, for example, in relation to the treatment of symptoms related to hypoestrogenesis including hot flashes and night sweats (vasomotor symptoms), disorders sleep, mood changes, vulvo-vaginal atrophy; and osteoporosis and reduction of endometrial hyperplasia. [0115] Additional objectives of the present description include: to provide increased patient compliance secondary to ease of use; provide increased physician adoption secondary to ease of use / instructions with less concern for side effects related to misuse; provide reduction in side effects related to misuse (decrease in irregular bleeding); provide better efficacy / control of symptoms secondary to proper use; reduce the metabolic and vascular side effects of the synthetic progestins commonly used when administered alone or in combination with an estrogen (norethindrone acetate, progesterone medroxy acetate, etc.) including, for example, stroke, heart attacks, blood clots and cancer breast. Specific modalities [0116] Through comprehensive trial and error testing of various esters of glycerol fatty acid and other glycols, modalities of the invention have been invented that have one or more favorable characteristics for development as a human pharmaceutical product. These favorable characteristics include those described above, for example, improved PK and reduced variability. [0117] These modalities include an encapsulated liquid pharmaceutical formulation for orally administering progesterone to a mammal that needs it, said formulation comprising: progesterone, as the only active pharmaceutical ingredient, in micronized form suspended in a vehicle comprising an ester medium chain glycolic acid or mixtures thereof and a nonionic surfactant comprising a polyethylene glycol fatty acid ester. [0118] A more specific modality is a formulation in which progesterone is ultra-micronized. [0119] In certain of these modalities, progesterone is suspended and / or solubilized in one or more glycerol mono, di, or tri-esters of C6 to C12, for example, one or more C6 to C14 triglycerides, for example , one or more C6 to C12 triglycerides, as one or more C8-C10 triglycerides. An example of a vehicle that provides beneficial properties is saturated triglyceride C8, C10, or C8 and C10, for example, but not limited to MIGLYOL, for example, MIGLYOL 812. [0120] In these general and more specific modalities, the non-ionic surfactant is an ester or diester of polyethylene glycol saturated or unsaturated fatty acid. In certain of these modalities, the non-ionic surfactant comprises esters of C8 to C18 fatty acid glycerol and polyethylene glycol. An example of a non-ionic surfactant that provides beneficial properties is GELUCIRE, for example, GELUCIRE 44/14. [0121] In certain of these modalities, the non-ionic surfactant has an HLB value of around 15. An illustrative example of this surfactant is GELUCIRE 44/14. [0122] As noted above, these formulations are liquid at room temperature, not gels, hard fats, or any other solid form. The non-ionic surfactant serves to increase viscosity. In some of these modalities, the non-ionic surfactant, for example, GELUCIRE or TEPHOSE, can be solid at room temperature and requires melting to be mixed with estradiol solubilized in glycolic fatty acid esters, but the resulting formulation is advantageously liquid, and not solid. [0123] The formulation of these modalities is typically encapsulated in a soft gelatin capsule or another soft capsule. [0124] Typically, these formulations do not comprise a bioadhesive agent (i.e., mucus-adhesive), a gelling agent, or a dispersing agent, or at least do not comprise one or two of these components. [0125] In more specific formulations, the capsule wrap, the active pharmaceutical ingredient, the fatty acid esters and the non-ionic surfactant are the only essential ingredients. Non-essential ingredients, for example, dyes, antioxidants or other preservatives, etc., can of course be included, but other ingredients in amounts that would substantially change the solubility of progesterone, the PK of the encapsulated formulation, or other clinically relevant properties, for example For example, other oils or esters of fatty acid, lecithin, mucus-adhering agents, gelling agents, dispersing agents, or the like would not be included. These modalities of the invention can be described as essentially consisting of the capsule wrap, the active pharmaceutical ingredient, the fatty acid esters and non-ionic surfactant, as described in the immediately preceding paragraphs which describe the illustrative modalities for which favorable characteristics have been discovered. [0126] As an example of these modalities for which such favorable characteristics have been discovered, mention is made of the product identified in Example 2, table 3, below. Examples Example 1 [0127] In an exemplary embodiment, a capsule is provided containing a filling material comprising: Table 2 [0128] The above formulation is prepared as follows: MIGLYOL is heated to about 45 ° C. GELUCIRE 44/14 is added and mixed until dissolved. BHT is added and mixed until dissolved. Progesterone is suspended and passed through a colloid mill. The resulting filler mass can be used for encapsulation. Example 2 [0129] In an exemplary embodiment, a capsule is provided containing a filling material comprising: Table 3 [0130] In various modalities, the amounts of MIGLYOL can be present in a range of about 35 to 95% by weight; GELUCIRE 44/14 of about 0.5 to 30% by weight; and BHT of about 0.01 to 0.1% by weight. Example 3 Progesterone solubility [0131] In several embodiments, both estradiol and progesterone can be dissolved in a solvent. In several embodiments, the solubility of estradiol and progesterone will be such that a therapeutically effective dose can be obtained in a reasonably sized mass, generally considered to be between 1 mg and 1,200 mg, preferably suitable for encapsulation in an oval or oblong capsule of size 3 to 22. For example, in various embodiments, 50 mg to 100 mg of progesterone can be dissolved in a volume of solvent; that is, the solubility would be 50 mg to 100 mg per capsule. MIGLYOL has been tried, and although it can be considered a good vehicle for progesterone, it alone did not provide a desirable level of estradiol solubilization (for example, a solubility of 12 mg / g may be desirable in several modalities). Accordingly, MIGLYOL, including, but not limited to, MIGLYOL 812, can be used in embodiments comprising a progesterone suspension. [0132] As can be seen in Table 9, the solubility of progesterone in CAPMUL MCM is approximately 73 mg / g. Therefore, by suspending 200 mg of progesterone in 400 mg of solvent, part of the dose (approximately 14%) is already dissolved and the rest is still a suspension. In some aspects and modalities, it is desired to reduce the partial solubility of progesterone in the formulation in order to reduce the possibility of recrystallization. [00133] Based on a solubility of 73 mg / g, the capsule size needed to make a 50 mg capsule of solubilized progesterone would be 685 mg. Table 4 [0134] In addition, the solubility of progesterone in a CAPMUL MCM solvent in combination with GELUCIRE 44/14 in a 9: 1 ratio has been found to increase solubility up to approximately 86 mg / g. Therefore, in several modalities, progesterone and / or estradiol can be dissolved in a CAPMUL MCM and GELUCIRE 44/14 system, where the ratio between CAPMUL MCM and GELUCIRE 44/14 is 9: 1. Table 5 Example 4 [0135] In an exemplary embodiment, a capsule containing a filling material having suspended progesterone is provided, comprising: Table 6 [0136] The above formulation is prepared as follows: MIGLYOL is heated to about 45 ° C. GELUCIRE 44/14 is added and mixed until dissolved. BHT is added and mixed until dissolved. Progesterone is suspended and passed through a colloid mill. The resulting filler mass can be used for encapsulation. [0137] In an exemplary embodiment, a capsule containing a filling material having partially solubilized progesterone is provided, comprising: Table 7 [0138] For progesterone and partially solubilized progesterone suspensions, GELUCIRE 44/14 can be added at 1% to 2% w / w to increase viscosity. The above formulation is prepared as follows: CAPMUL MCM is heated to about 65 ° C. GELUCIRE 44/14 is added and mixed until dissolved. The heat is removed. Progesterone is added and the mixture is passed through a colloid mill. The resulting filler mass can be used for encapsulation. Example 5 [0139] In an exemplary embodiment, a capsule containing a filling material having suspended progesterone is provided, comprising: Table 8 [0140] In various modalities, the quantities of MIGLYOL can be present in a range of about 35 to 95% by weight; GELUCIRE 44/14 of about 0.5 to 30% by weight; and BHT of about 0.01 to 0.1% by weight. Example 6 Bioavailability assessment - fasting [0141] A randomized, single-dose bioequivalence study comparing a 200 mg capsule test product of ultra-micronized progesterone (T) and a 200 mg capsule reference product from PROMETRIUM® (progesterone) (Abbott Laboratories , Abbott Park, IL, USA) (R) is conducted. Subjects are administered a single 200 mg dose of test product (T) or reference product (R) under fasting conditions, for example, subjects fasting at least 10.0 hours prior to administration. Blood is collected before dosing and after dosing. Pre-dosing samples are collected at approximately -01.00, -00.50, and 00.00 hours. Post-dosage samples are collected at approximately 01.00, 02.00, 03.00, 04.00, 05.00, 06.00, 07.00, 08.00, 09.00, 10.00, 12 , 00, 18.00, 24.00, 36.00 and 48.00 hours. Standard meals are provided 04.00.09.00, 13.00, 25.00, 29.00, 33.00 and 37.00 hours after dosing. [0142] Pharmacokinetic measurements are evaluated, including Cmax, AUC and, optionally, Tmax. The comparative bioavailability of the test product (T) and the reference product is assessed. Example 7 Bioavailability assessment - fed [0143] The procedures for determining bioavailability under fasting conditions are repeated except that individuals are administered a single dose of 200 mg of the test product (T) or reference product (R) immediately after a high content meal. of fat, for example, within 30 minutes of dosing. Blood is collected before dosing and after dosing. Pre-dosing samples are collected at approximately -01.00, -00.50, and 00.00 hours. Post-dosage samples are collected at approximately 01.00, 02.00, 03.00, 04.00, 05.00, 06.00, 07.00, 08.00, 09.00, 10.00, 12 , 00, 18.00, 24.00, 36.00 and 48.00 hours. Standard meals are provided 04.00, 09.00, 13.00, 25.00, 29.00, 33.00 and 37.00 hours after dosing. Pharmacokinetic measurements are evaluated, including Cmax, AUC and, optionally, Tmax. The bioavailability of the test product (T) in relation to the reference product is assessed. The effect of food on the comparative bioavailability of the test product (T) and the reference product (R) is also assessed. Example 8 [0144] The manufacturing method according to various modalities is shown in figures 1 to 3. With reference to figure 1, the method of preparing the filler material 100, i.e. filler, is shown. Step 102 comprises mixing a vehicle, a lubricant, and an antioxidant as described here. For example, lecithin and butylated hydroxytoluene can be mixed with one or more mono, di or medium chain triglycerides, or combinations of the same. Mixing can be facilitated by an impeller, agitator, or other suitable means. Step 102 can be done under an atmosphere of inert gas or relatively inert, such as nitrogen gas N2. Mixing can be done in any suitable bottle, such as a stainless steel bottle. [0145] Step 104 may comprise mixing ultrononized progesterone in the mixture of the vehicle, lubricant and antioxidant. A pasty substance is thus formed. Mixing can take place in a steel tank or vat. Mixing can be facilitated by an impeller, agitator, or other suitable means. Step 104 can be done under an atmosphere of inert gas or relatively inert, such as nitrogen gas N2. Step 106 comprises degassing. The mixture resulting from step 106 may comprise a filler material suitable for production in a soft gel capsule. [0146] With reference to figure 2, the production of the soft gel capsule, i.e. gel mass 200, is shown. Step 202 comprises mixing glycerin with water. The water used in step 202 can be purified by any suitable means, such as reverse osmosis, ozonation, filtration (for example, through a carbon column) or the like. Mixing can be facilitated by an impeller, agitator, or other suitable means. Step 202 can be done under an atmosphere of inert gas or relatively inert, such as nitrogen gas N2. Heating can be done until the temperature reaches 80 ° ± 5 ° C. [0147] Step 204 comprises the addition of gelatin to the mixture of glycerin and water. Mixing can be facilitated by an impeller, agitator, or other suitable means. Step 204 can be done under an atmosphere of inert gas or relatively inert, such as nitrogen gas N2. A vacuum can be extracted at step 204 to de-aerate. [0148] Step 206 comprises the addition of a coloring agent as a dye. A coloring agent may comprise products sold under the trademark OPATINT or another suitable agent. Step 206 can be done under an atmosphere of inert gas or relatively inert, such as nitrogen gas N2. Step 208 comprises degassing. The mixture resulting from step 208 may comprise a gel capsule material suitable for use as a gel capsule in the production of a soft gel capsule. [0149] With reference to figure 3, the assembly process of the soft gel capsule 300 is shown. Step 302 comprises heating the filling material. The filling material can be heated to any suitable temperature. In various embodiments, the filling material is heated to 30 ° C +/- 3 ° C. The filling material can be heated in a filling filler tank. A filler hopper can comprise a device configured to hold a volume of the filler and / or to dispense the filler in controlled volumes. [0150] Step 304 comprises filling a gel mass. A gel mass can be removed from the gel capsule material produced in step 208 of figure 2. The filling can be done by injecting, placing or otherwise disposing of the filling material within a volume defined by the material of the capsule. gel. Filling can take place in an encapsulator. The distribution boxes can be at a temperature of 55 ° C +/- 10 ° C. The wedge temperature can be 38 ° C +/- 3 ° C. The drum's cooling temperature can be 4 ° C +/- 2 ° C. The encapsulator can be lubricated using MIGLYOL 812. Step 304 thus produces one or more soft gel capsules. The filling may comprise producing a ribbon with a thickness of 0.85 ± 0.05 mm using the buttons of the distribution box. The filling material can be injected into the gel to produce a filling weight having a target weight ± 5% (i.e., 650 ± 33 mg and 325 ± 16.3 mg). [0151] Step 306 comprises drying the soft gel capsules. Drying can be done in a tumble dryer, tray dryer, or combinations thereof. For example, drying can be done in a tumble drying basket for about 10 minutes to about 120 minutes. Drying can continue in a drying room for about 24 hours to about 72 hours. Polishing can be done with isopropyl alcohol. Example 9 Stability study [0152] According to various modalities, formulations according to various modalities have an exemplary shelf life of 3 months with storage at 25 ± 2 ° C / 60 ± 5% relative humidity in 75 ml opaque white HDPE bottles, with a white cover with 38/400 mm child protection. [0153] The packaging during the test comprises a 75 ml round HDPE bottle and a 33 mm cap A Brasken FPT 300F resin is associated with the cap. The test criteria include visual appearance, progesterone test, dissolution, content uniformity and test of microbial limits. [0154] Three test groups are created. Test group 1 comprises a test at 40 ° C / 75% relative humidity. Test group 2 comprises a test at 30 ° C / 65% relative humidity. Test group 3 comprises a test at 25 ° C / 60% relative humidity. Test group 1 is tested for visual appearance, ultra-micronized progesterone test, and dissolution in months 1,2, 3 and 6. Test group 2 is tested for visual appearance, ultra-micronized progesterone test, and dissolution in months 0, 1,2, 3, 6, and 12. Test group 3 is tested for visual appearance, ultra-micronized progesterone assay, and dissolution in months 0, 1,2, 3, 6, 12 and 24. Example 10 [0155] A particle size analysis is conducted using a Beckman Coulter LS 13 320 laser diffraction particle size analyzer (the "Beckman device"). The Beckman device uses laser diffraction to determine the particle size. A sample of a formulation is provided according to several modalities. The Beckman device's particle sensor reports that the sample has an X50 of 6.67 pm, an X75 of 14.78 pm, and an X25 of 2.193 pm. Example 11 [0156] A dissolution study was done using a formulation according to several modalities. The results of the dissolution study are shown in figure 4. [0157] The dissolution study was done using a North American pharmacopoeia 3 dissolving apparatus (reciprocating cylinder) ("USP 3 apparatus"). The USP 3 device was set to 30 immersions per minute. Two hundred and fifty ml_ (250 ml_) of a solution of 0.1 N HCL with 3% sodium lauryl sulfate was used at 37 ° C. [0158] Figure 4 shows the percentage of dissolution on the y axis over time in minutes on the x axis. A formulation according to various modalities has been shown to have circular dots, and is identified as formulation 402. An existing commercial pharmaceutical product containing progesterone is shown with square dots and is identified as an existing product 404. As shown in figure 4, formulation 402 achieves a higher level of dissolution in a shorter time than the existing product 404. Example 12 [0159] For the purposes of this example, a particle size analysis is conducted using a Beckman device. An API sample comprising micronized progesterone according to various modalities is provided for analysis. [0160] Approximately 0.01 g of an API sample according to various modalities was combined with Coulter 1B and 10 ml_ of deionized water. The call was made for 15 seconds. The Beckman device, equipped with an ULM, performed an analysis for 90 seconds. The Beckman device was configured to use the Fraunhofer optical model. The Beckman device reported that the sample has an X50 of 4,279 pm, an X75 of 7,442 pm, and an X25 of 1,590 pm. The Beckman device also reported that the average particle size is 4,975 pm, the median particle size is 4,279 pm, the mode particle size is 6,453 pm, and the standard deviation is 3,956 pm. A graph of the particle distribution obtained is shown in Figure 5. Example 13 [0161] Study 352 - Study of combination of progesterone and estradiol under fed conditions. The following study protocol was used to establish bioavailability and bioequivalence parameters for a combined product of the present description comprising progesterone (200 mg) and estradiol (2.0 mg) as prepared using the process described in Example 14 and compared to 200 mg of PROMETRIUM (Catalent Pharmaceuticals, St. Petersburg, FL (and 2.0 mg ESTRAGE (estradiol vaginal cream, USP, 0.01%)) (Bristol-Myers Squibb Co. Princeton, NJ, USA) administered to twenty-four ( 24) normal, healthy, postmenopausal adult female human subjects under fed conditions. [0162] The pharmaceutical formulation of the invention used in these PK studies substantially contained the following formula: [0163] Design of the study. A bidirectional intersection study with an open, balanced, randomized label, of two treatments, two periods, two sequences, of a single dose. [0164] Subjects were housed in the clinical facility from at least 11.00 hours prior to dosing to at least 48.00 hours after dosing in each period, with a washout period of at least 14 days between the days of successive administration. [0165] Subjects were fasted for at least about 10.00 hours before a high-fat, high-calorie breakfast was served, followed by administration and then followed by an additional fasting period. 04.00 hours after administration. [0166] Standard meals were provided approximately 04.00, 09.00, 13.00, 25.00, 29.00, 34.00 and 38.00 hours after dosing, respectively. [0167] Water was restricted at least about 1 hour before administration until about 1 hour after administration (except for the water given during administration). At other times, drinking water was provided at will. [0168] Individuals were instructed to refrain from consuming products containing caffeine and / or xanthine (ie coffee, tea, chocolate, and soda containing caffeine, colas, etc.) for at least about 24.00 hours before administration and throughout the study, pomelo and / or its juice and food containing poppy for at least about 48.00 hours prior to administration and throughout the study. [0169] The subjects remained seated in an upright position for about the first 04.00 hours after administration and only the necessary movements were allowed during this period. Subsequently, individuals were allowed to walk freely during the remainder of the study. Individuals were not allowed to lie down (except as instructed by the doctor after adverse events) during the restriction period. [0170] The subjects were instructed not to take any prescription drugs within 14 days prior to entry into the study and throughout the study. The individuals were instructed not to take any over-the-counter medicinal products, herbal medicines, etc. within 7 days before entering the study and throughout the study. [0171] After an overnight fast of at least about 10.00 hours, a fat and high calorie breakfast was served about 30 minutes before administration of the product (s) being investigated. All subjects were asked to consume their entire breakfast within about 30 minutes of serving, a single dose of the test product (T) of 200 mg progesterone & 2 mg estradiol tablets or 200 mg capsule of soft gel of the reference product (R) PROMETRIUM (progesterone) and 2 mg tablets of ESTRACE® (estradiol) (according to the randomization schedule) were administered with about 240 ml_ of water under the feeding conditions , at room temperature in each period in a sitting posture. A complete mouth assessment was done to assess adherence to administration. [0172] All administered study participants were evaluated for laboratory tests at the end of the study or as applicable. [0173] In each period, twenty-three (23) blood samples were collected. Pre-dosage blood samples (10 ml_) at -01.00, -00.50, 00.00 hours and post-dose blood samples (08 ml_ each) were collected at 00.25, 00.50, 00.67, 00.83, 01.00, 01.33, 01.67, 02.00, 02.50, 03.00, 04.00, 05.00, 06.00, 07.00, 08, 00, 10.00, 12.00, 18.00, 24.00 and 48.00 hours in vacuum containers - K2EDTA labeled through a permanent cannula placed in one of the veins of the individuals forearms. Each permanent intravenous cannula was kept in place as long as possible by injecting about 0.5 ml_ of 10 IU / ml_ of heparin in normal saline to maintain the cannula for post-dosage sample collection. In these cases, blood samples were collected after discarding the first 0.5 ml_ of blood containing heparin. Each cannula was removed after the 24.00 hour sample was taken either earlier or blocked. [0174] At the end of the study, the samples were transferred to the bioanalytical facility in a box containing enough dry ice to maintain the integrity of the samples. These samples were stored at a temperature of -70 ° C ± 20 ° C in the bioanalytical facility until analysis. [0175] Progesterone (corrected and uncorrected) and estradiol (unconjugated) and estrone (total) in plasma samples are tested using a validated LC-MS / MS method. [0176] The pharmacokinetic parameters Cmax, AUCO-t & AUC0-∞ were calculated in the data obtained from 24 subjects for the test product and the reference product. In general, the bioavailability of progesterone and estradiol were similar, but bioequivalence has not been established. [0177] The corrected pharmacokinetic profile summaries are shown in Table 9, below, for progesterone. Table 9: Summary of the primary pharmacokinetic profile of the test product (T) as a function of the reference product (R) for progesterone (corrected) * Estimation of the mean of the least squares used to calculate the geometric mean [0178] Study 351 - Study of combination of progesterone and estradiol under fasting conditions. [0179] Fasting studies using the above protocol and test and reference products were also conducted. However, instead of the high-fat meal before administration of the test and reference drug, each individual fasted for a period of at least twelve (12) hours prior to administration of the dosage. [0180] The Cmax, AUCO-t & AUCO-∞ pharmacokinetic parameters were calculated in the data obtained from 23 subjects under fasting conditions for the test product and the reference product. In general, the bioavailability of progesterone and estradiol were similar, but bioequivalence has not been established. [0181] The corrected pharmacokinetic profile summaries are shown in Table 10, below, for progesterone. Table 10: Summary of the primary pharmacokinetic profile of the test product (T) versus the reference product (R) for progesterone (corrected) * Estimation of the mean of the least squares used to calculate the geometric mean [0182] Data indicate good inter-patient and intra-patient variability (ie low) in relation to PROMETRIUM. Example 14 Dissolution [0183] Dissolution studies were done using a formulation of this invention comparing the dissolution of progesterone with the dissolution of PROMETRIUM and comparing the dissolution of estradiol with the dissolution of Strept. In one study, a capsule formulation of the invention comprising 200 mg of progesterone and 2 mg of estradiol was used. In a second study, a capsule formulation of the invention comprising 50 mg of progesterone and 2 mg of estradiol was used. The two formulations comprised: [0184] The dissolution study was done using a USP dissolution device (North American pharmacopoeia) (reciprocating cylinder) ("USP 3 device"). The device was set to 30 immersions per minute. 250 ml of a 0.1 N HCI solution with 3% sodium lauryl sulfate was used at 37 ° C. [0185] In both studies, progesterone was dissolved faster, and with smaller standard deviations, from the capsules of the invention than from PROMETRIUM. The dissolution of estradiol was comparable, but marginally less from the capsules of the invention than from Estrace. For illustrative purposes, a graph showing the dissolution of progesterone from the 200 mg progesterone capsule of the invention and from PROMETRIUM is attached as figure 6. [0186] Both capsules of the invention were stable to storage in white HDPE bottles. Positive stability data were obtained with the formulation of 200 mg of progesterone over 6 months (data of> 6 months not available) and with the formulation of 50 mg of progesterone over 3 months (data of> 3 months unavailable). [0187] It will be evident to those skilled in the art that various modifications and variations can be made in the present disclosure without deviating from the spirit or scope of the description. Accordingly, it is understood that the present disclosure covers the modifications and variations of this disclosure, provided that they are within the scope of the attached claims and their equivalents. [0188] Similarly, several characteristics and advantages have been presented in the description below, including several alternatives together with details of the structure and function of the devices and / or methods. The disclosure is intended to be illustrative only and is therefore not intended to be exhaustive. It will be apparent to those skilled in the art that various modifications can be produced, especially in terms of structure, materials, elements, components, shape, size and arrangement of parts, including combinations within the principles of the description, to the full extent indicated by the general meaning and of the terms in which the appended claims are expressed. To the extent that these various changes do not deviate from the spirit and scope of the attached claims, it is intended that they are covered there.
权利要求:
Claims (18) [0001] 1. Liquid pharmaceutical formulation encapsulated to administer progesterone orally to a mammal in need of it, CHARACTERIZED by the fact that the formulation comprises: progesterone; 20% by weight to 80% by weight of a vehicle comprising one or more glycerol C6-C14 fatty acid mono-, di- or triesters; and glycerides of lauroyl macrogol-32 EP as a nonionic surfactant, in which progesterone is still present in 20 to 50 weight percent of the formulation. [0002] 2. Pharmaceutical formulation, according to claim 1, CHARACTERIZED by the fact that progesterone is the only active ingredient. [0003] 3. Pharmaceutical formulation, according to claim 1 or 2, CHARACTERIZED by the fact that the progesterone is partially or completely solubilized. [0004] 4. Pharmaceutical formulation, according to claim 3, CHARACTERIZED by the fact that the vehicle comprises a first Cê-Cu fatty acid, a second CΘ-CU fatty acid OR a combination of these. [0005] 5. Pharmaceutical formulation, according to claim 4, CHARACTERIZED by the fact that the first CΘ-CU fatty acid is a Ce fatty acid. [0006] 6. Pharmaceutical formulation according to claim 4 or 5, CHARACTERIZED by the fact that the second Ce-C14 fatty acid is a C10 fatty acid. [0007] 7. Pharmaceutical formulation according to any one of claims 1 to 6, CHARACTERIZED by the fact that the vehicle is migliol 812. [0008] 8. Pharmaceutical formulation according to any one of claims 1 to 7, CHARACTERIZED by the fact that the amount of progesterone is from 25 mg to 200 mg. [0009] Pharmaceutical formulation according to any one of claims 1 to 8, CHARACTERIZED by the fact that the amount of progesterone is 75 mg or 150 mg. [0010] 10. Pharmaceutical formulation according to any one of claims 1 to 9, CHARACTERIZED by the fact that the amount of progesterone includes a solubilized amount of progesterone and a suspended amount of pro-gesterone. [0011] 11. Pharmaceutical formulation according to any one of claims 1 to 10, CHARACTERIZED by the fact that the formulation is supplied in a gelatin capsule. [0012] 12. Pharmaceutical formulation, according to the claim, 1 CHARACTERIZED by the fact that the carrier predominantly comprises one or more mono-, di- or triesters of glycerol CΘ-C-M fatty acid, or mono- or diester of one glycol. [0013] 13. Pharmaceutical formulation, according to claim 1, CHARACTERIZED by the fact that it comprises: 75, 150, 200 or 300 mg of progesterone; a vehicle that predominantly comprises a Ce-C-io triglyceride; and polyoxyl-32 lauroyl glycerides (Gelucire 44/14). [0014] 14. Pharmaceutical formulation, according to claim 13, CHARACTERIZED by the fact that the formulation comprises: 35 to 80% by weight of said vehicle; 0.5 to 30% by weight of polyoxyl-32 lauroyl glycerides; and 0.01 to 0.1% by weight of butylated hydroxytoluene. [0015] 15. Use of the formulation, as defined in any of claims 1 to 14, CHARACTERIZED by the fact that it is for the preparation of a medication for the prevention of endometrial hyperplasia. [0016] 16. Use, according to claim 15, CHARACTERIZED by the fact that the amount of progesterone is 150 mg. [0017] 17. Use of the formulation, as defined in any of claims 1 to 14, CHARACTERIZED by the fact that it is for the preparation of a medication for the treatment of amenorrhea. [0018] 18. Use, according to claim 17, CHARACTERIZED by the fact that the amount of progesterone is 300 mg.
类似技术:
公开号 | 公开日 | 专利标题 BR112014031837B1|2020-09-15|NET PHARMACEUTICAL FORMULATIONS UNDERSTANDING PROGESTERONE AND USES OF THESE JP2018024685A|2018-02-15|Natural combination hormone replacement formulations and therapies JP2019214598A|2019-12-19|Natural combination hormone replacement formulations and therapies US20140370084A1|2014-12-18|Estradiol formulations and therapies US20190381068A1|2019-12-19|Progesterone formulations having a desirable pk profile US11033626B2|2021-06-15|Progesterone formulations having a desirable pk profile JP2017509630A|2017-04-06|Progesterone preparation BR112014031910B1|2021-12-14|PHARMACEUTICAL FORMULATIONS AND USE THEREOF FOR NATURAL COMBINATION THERAPIES FOR HORMONE REPLACEMENT BR112014012444B1|2021-12-14|A PHARMACEUTICAL COMPOSITION COMPRISING SOLUBILIZED ESTRADIOL, PROGESTERONE AND A SOLUBILIZING AGENT, AND USES THEREOF TO TREAT A MENOPAUSE-RELATED SYMPTOM IN A WOMAN
同族专利:
公开号 | 公开日 US20130338122A1|2013-12-19| CA2876964A1|2013-12-27| AU2013277235B2|2018-04-19| BR112014031824A2|2017-06-27| AU2013277233B2|2018-05-31| AU2018222947A1|2018-09-20| AU2018222947B2|2020-06-18| US20190008968A1|2019-01-10| EP3560500B1|2021-12-22| EP3560500A1|2019-10-30| JP2015520235A|2015-07-16| EP2861233A4|2015-10-07| JP6342389B2|2018-06-13| EP2861234A1|2015-04-22| EP2861234A4|2015-10-28| EP2861233B1|2019-11-06| US10052386B2|2018-08-21| US20150148323A1|2015-05-28| EP2861234B1|2019-03-27| JP2015520236A|2015-07-16| BR112014031837A2|2017-06-27| WO2013192248A1|2013-12-27| JP6298460B2|2018-03-20| MX2014015897A|2015-03-03| US10639375B2|2020-05-05| EP2861233A1|2015-04-22| ZA201500212B|2017-04-26| AU2013277233A1|2015-01-22| AU2013277235A1|2015-01-22| MX2014015900A|2015-07-17| CA2876947A1|2013-12-27| WO2013192250A1|2013-12-27|
引用文献:
公开号 | 申请日 | 公开日 | 申请人 | 专利标题 US1967351A|1930-10-06|1934-07-24|President And Board|Hormone and process of obtaining the same| US2232438A|1934-08-04|1941-02-18|Schering Corp|Unsaturated pregnanolones and pregnandiones and a method of producing the same| GB452238A|1934-08-24|1936-08-19|Chem Ind Basel|Process for purifying progesterone preparations| US2379832A|1936-06-02|1945-07-03|Schering Corp|Process for the manufacture of unsaturated ketones of the cyclopentano polyhydro phenanthrene series| US2649399A|1951-02-01|1953-08-18|Ayerst Mckenna & Harrison|Conjugated oestrogenic quaternary ammonium salts and their preparation| GB720561A|1952-04-17|1954-12-22|Frederick Victor Wells|Improvements in preparations for application to the hair and scalp| GB848881A|1955-12-27|1960-09-21|Upjohn Co|Improvements in or relating to hormone compositions and the preparation thereof| GB874368A|1957-12-09|1961-08-02|Irwin Irville Lubowe|Improvements in anti-seborrheic and scalp preparations| FR1368727A|1961-05-04|1964-08-07|Roussel Uclaf|Estradiol derivatives and method of preparation| US3916898A|1964-05-20|1975-11-04|Searle & Co|Administration of medicaments and the like| US3755575A|1965-01-26|1973-08-28|Squibb & Sons Inc|Pharmaceutical compositions| FR5519M|1966-06-07|1967-11-06| US3478070A|1967-12-26|1969-11-11|American Home Prod|Process for selectively acylating the 3-ol group in polyhydroxy 13-alkyl gona- - 1,3,5 - - trienes and delta - 7 -,delta - 8,delta - 9 -,and delta - 8,14 - dehydro derivatives thereof| GB1261348A|1968-04-02|1972-01-26|Leo Ab|Treatment of hair and scalp and compositions therefor| US3755573A|1970-07-10|1973-08-28|Warner Lambert Co|Fertility control empoying quinestrol and quingestanol acetate| US3710795A|1970-09-29|1973-01-16|Alza Corp|Drug-delivery device with stretched, rate-controlling membrane| US3923997A|1971-05-11|1975-12-02|Rhodia|Process for repelling dogs and cats from a selected area or from each other using {65 -n-alkyl-{65 -butyrolactones and {67 -n-alkyl-{67 -valerolactones| US3729566A|1971-05-25|1973-04-24|Upjohn Co|Rodent sterilant process| US3948254A|1971-11-08|1976-04-06|Alza Corporation|Novel drug delivery device| US3993072A|1974-08-28|1976-11-23|Alza Corporation|Microporous drug delivery device| US4016251A|1972-08-17|1977-04-05|Alza Corporation|Vaginal drug dispensing device| US3903880A|1972-08-17|1975-09-09|Alza Corp|Intrauterine device for managing the reproductive process| US3971367A|1972-12-27|1976-07-27|Alza Corporation|Intrauterine device having means for changing from uterine-retentive shape to nonuterine-retentive shape| US3921636A|1973-01-15|1975-11-25|Alza Corp|Novel drug delivery device| US3916899A|1973-04-25|1975-11-04|Alza Corp|Osmotic dispensing device with maximum and minimum sizes for the passageway| US4014987A|1974-06-04|1977-03-29|Alza Corporation|Device for delivery of useful agent| IL48277A|1974-10-18|1978-03-10|Schering Ag|Vaginal ring| US4155991A|1974-10-18|1979-05-22|Schering Aktiengesellschaft|Vaginal ring| US4093709A|1975-01-28|1978-06-06|Alza Corporation|Drug delivery devices manufactured from poly and poly| NL7506407A|1975-05-30|1976-12-02|Akzo Nv|PROCESS FOR PREPARING AN ORAL ACTIVE PHARMACEUTICAL PREPARATION.| US3977404A|1975-09-08|1976-08-31|Alza Corporation|Osmotic device having microporous reservoir| US4008719A|1976-02-02|1977-02-22|Alza Corporation|Osmotic system having laminar arrangement for programming delivery of active agent| US4014334A|1976-02-02|1977-03-29|Alza Corporation|Laminated osmotic system for dispensing beneficial agent| US4154820A|1976-02-23|1979-05-15|Akzona Incorporated|Compositions containing alkali metal sulfate salts of conjugated estrogens and antioxidants as stabilizers| FR2408345B1|1976-11-30|1981-08-14|Besins Jean Louis| US4310510A|1976-12-27|1982-01-12|Sherman Kenneth N|Self administrable anti-fertility composition| US4393871A|1977-06-27|1983-07-19|Vli Corporation|Vaginal device| GB1589946A|1977-12-14|1981-05-20|Kali Chemie Pharma Gmbh|Enterally absorbable preparations and process for the production thereof| US4372951A|1979-10-11|1983-02-08|Nichols Vorys|Vaginal delivery for physiologic follicular-luteal steroid treatment| US4215691A|1978-10-11|1980-08-05|Alza Corporation|Vaginal contraceptive system made from block copolymer| US4402695A|1980-01-21|1983-09-06|Alza Corporation|Device for delivering agent in vagina| US4732763A|1978-10-17|1988-03-22|Stolle Research And Development Corporation|Active/passive immunization of the internal female reproductive organs| US4756907A|1978-10-17|1988-07-12|Stolle Research & Development Corp.|Active/passive immunization of the internal female reproductive organs| US4237885A|1978-10-23|1980-12-09|Alza Corporation|Delivery system with mated members for storing and releasing a plurality of beneficial agents| US4384096A|1979-08-27|1983-05-17|The Dow Chemical Company|Liquid emulsion polymers useful as pH responsive thickeners for aqueous systems| GB2079158B|1980-06-09|1985-01-09|Ahi Operations Ltd|Intra-vaginal devices| DE3040978A1|1980-10-28|1982-05-27|Schering Ag, 1000 Berlin Und 4619 Bergkamen|VAGINAL RING| US4327725A|1980-11-25|1982-05-04|Alza Corporation|Osmotic device with hydrogel driving member| US4423151A|1981-09-24|1983-12-27|Peter S. Brune|Process for preparation of control for use in estrogen receptor tests| US4629449A|1982-07-29|1986-12-16|Alza Corporation|Vaginal dispenser for dispensing beneficial hormone| US4961931A|1982-07-29|1990-10-09|Alza Corporation|Method for the management of hyperplasia| US4826831A|1983-08-05|1989-05-02|Pre Jay Holdings Limited|Method of hormonal treatment for menopausal or post-menopausal disorders involving continuous administration of progestogens and estrogens| US6309669B1|1984-03-16|2001-10-30|The United States Of America As Represented By The Secretary Of The Army|Therapeutic treatment and prevention of infections with a bioactive materials encapsulated within a biodegradable-biocompatible polymeric matrix| US4610687A|1984-08-06|1986-09-09|Board Of Trustees Operating Michigan State University|Method for breeding control in female bovines| DE3510555A1|1985-03-21|1986-09-25|Schering AG, 1000 Berlin und 4709 Bergkamen|ESTRIOLESTER| US4816257A|1985-09-20|1989-03-28|Research & Education Institute, Harbor-Ucla Medical Center Inc.|Method for producing an in vivo environment suitable for human embryo transfer| US4762717A|1986-03-21|1988-08-09|The General Hospital Corporation|Continuous delivery of luteinizing hormone releasing hormone compositions in combination with sex steroid delivery for use as a contraceptive| US5140021A|1986-04-16|1992-08-18|Genesis Systems Corporation|Method and dosage form for treatment of premenstrual syndrome| JPH0419773B2|1986-05-23|1992-03-31|Matsushita Electric Works Ltd| US6139868A|1986-08-28|2000-10-31|Lts Lohmann Therapie-Systeme Gmbh & Co. Kg|Transdermal therapeutic system, its use and production process| AU601528B2|1986-12-22|1990-09-13|Ortho-Mcneil Pharmaceutical, Inc.|Resilient transdermal drug-delivery device and compositions and devices employing fatty acid esters/ethers of alkanediols and percutaneous absorption enhancers| CN1021196C|1986-12-29|1993-06-16|新泽西州州立大学|Prepn. method of progestin unit and system| US4876249A|1987-01-12|1989-10-24|Rajadhyaksha Vithal J|Compositions and method comprising heterocyclic compounds containing two heteroatoms| US4746515A|1987-02-26|1988-05-24|Alza Corporation|Skin permeation enhancer compositions using glycerol monolaurate| US4865848A|1987-02-26|1989-09-12|Alza Corporation|Skin permeation enhancer compositions using sucrose esters| US4788062A|1987-02-26|1988-11-29|Alza Corporation|Transdermal administration of progesterone, estradiol esters, and mixtures thereof| US5538736A|1987-04-28|1996-07-23|Lts Lohmann Therapie-Systeme Gmbh|Active substance-containing plaster for the controlled administration of active substances to the skin| US4900734A|1987-08-27|1990-02-13|Maxson Wayne S|Novel pharmaceutical composition containing estradiol and progesterone for oral administration| US5108995A|1987-09-24|1992-04-28|Jencap Research Ltd.|Hormone preparation and method| US5276022A|1987-09-24|1994-01-04|Jencap Research Ltd.|Hormone preparation and method| US4906475A|1988-02-16|1990-03-06|Paco Pharmaceutical Services|Estradiol transdermal delivery system| US5719197A|1988-03-04|1998-02-17|Noven Pharmaceuticals, Inc.|Compositions and methods for topical administration of pharmaceutically active agents| US5656286A|1988-03-04|1997-08-12|Noven Pharmaceuticals, Inc.|Solubility parameter based drug delivery system and method for altering drug saturation concentration| US5474783A|1988-03-04|1995-12-12|Noven Pharmaceuticals, Inc.|Solubility parameter based drug delivery system and method for altering drug saturation concentration| US4938763B1|1988-10-03|1995-07-04|Atrix Lab Inc|Biodegradable in-situ forming implants and method of producing the same| US4942158A|1988-10-13|1990-07-17|Eastman Kodak|Transdermal steroid penetrant compositions and methods utilizing isopropanol and isobutanol| ES2081823T3|1988-10-27|1996-03-16|Schering Ag|AGENT FOR TRANSDERMIC APPLICATION, CONTAINING GESTODEN.| US5064654A|1989-01-11|1991-11-12|Ciba-Geigy Corporation|Mixed solvent mutually enhanced transdermal therapeutic system| US4973468A|1989-03-22|1990-11-27|Cygnus Research Corporation|Skin permeation enhancer compositions| DE3916112C2|1989-05-16|1992-04-30|Schering Ag Berlin Und Bergkamen, 1000 Berlin, De| AT107517T|1989-05-25|1994-07-15|Takeda Chemical Industries Ltd|TRANSDERMAL THERAPEUTIC AGENT.| DE69007886T2|1989-07-21|1994-11-17|Izhak Blank|Oestradiol containing agents and methods for topical use.| US5130137A|1989-08-09|1992-07-14|The General Hospital Corporation|Continuous delivery of luteinizing hormone releasing hormone compositions in combination with sex steroid delivery for use in treating benign ovarian secretory disorders| US5252334A|1989-09-08|1993-10-12|Cygnus Therapeutic Systems|Solid matrix system for transdermal drug delivery| CA1340994C|1989-09-21|2000-05-16|Rudolf Edgar Dr. Falk|Treatment of conditions and disease| DE3933460C2|1989-10-06|1992-03-26|Lts Lohmann Therapie-Systeme Gmbh & Co. Kg, 5450 Neuwied, De| US5288496A|1990-05-15|1994-02-22|Stolle Research & Development Corporation|Growth promoters for animals| DE4104385C1|1991-02-09|1992-08-13|Marika Dr.Med. 6509 Framersheim De Ehrlich| FR2673840B1|1991-03-14|1995-03-10|Lvmh Rech| US5340585A|1991-04-12|1994-08-23|University Of Southern California|Method and formulations for use in treating benign gynecological disorders| US5211952A|1991-04-12|1993-05-18|University Of Southern California|Contraceptive methods and formulations for use therein| US5340586A|1991-04-12|1994-08-23|University Of Southern California|Methods and formulations for use in treating oophorectomized women| US5811547A|1992-10-14|1998-09-22|Nippon Shinyaju Co., Ltd.|Method for inducing crystalline state transition in medicinal substance| US6342491B1|1991-05-21|2002-01-29|American Home Products Corporation|Method of treating estrogen receptor positive carcinoma with 17 α-dihydroequilin| GB9113726D0|1991-06-25|1991-08-14|Inst Of Animal Physiology And|Artificial animal foster mothers| US5653983A|1991-07-19|1997-08-05|Lvmh Recherche|Compositions for the pigmentation of the skin or of the hair containing an extract of Marrubium vulgare, the process for it's manufacture and it's| US5676968A|1991-10-31|1997-10-14|Schering Aktiengesellschaft|Transdermal therapeutic systems with crystallization inhibitors| US7704983B1|1992-03-02|2010-04-27|Eastern Virginia Medical School|Antiprogestin method for reducing side effects associated with low dosage HRT and oral contraception| MX9301121A|1992-03-02|1993-09-01|Schering Ag|METHOD AND EQUIPMENT FOR ORAL CONTRACEPTION AND REGULATION OF MENSTRUATION WITH ESTROGEN / PROGESTIN / ANIPROGESTIN.| US6010715A|1992-04-01|2000-01-04|Bertek, Inc.|Transdermal patch incorporating a polymer film incorporated with an active agent| US5393528A|1992-05-07|1995-02-28|Staab; Robert J.|Dissolvable device for contraception or delivery of medication| US5607691A|1992-06-12|1997-03-04|Affymax Technologies N.V.|Compositions and methods for enhanced drug delivery| FR2695561B1|1992-09-17|1994-12-02|Lvmh Rech Gie|Cosmetic or dermatological composition containing at least one ginsenoside-type saponin, and its applications, in particular for hair care.| ES2211871T3|1992-09-28|2004-07-16|Adeza Biomedical Corporation|PROCEDURE FOR DETECTION OF A PREMATURE BIRTH.| US5527534A|1992-10-21|1996-06-18|Gynetech Laboratories, Ltd.|Vaginal sponge delivery system| US5639743A|1992-11-13|1997-06-17|University Of Georgia Research Foundation|Compositions and methods for treating exocrine gland atrophy| FR2699406B1|1992-12-21|1995-03-10|Commissariat Energie Atomique|Films based on copolymers, their applications in transdermal systems and their preparation processes.| MY113268A|1992-12-29|2002-01-31|Insite Vision Incorporated|Plasticized bioerodible controlled delivery system| DE4301783C1|1993-01-23|1994-02-03|Lohmann Therapie Syst Lts|Transdermal system per admin. of galanthamine - esp. for treatment of Alzheimer's disease and alcohol addiction| US5843979A|1993-02-25|1998-12-01|Bristol-Myers Squibb Company|Transdermal treatment with mast cell degranulating agents for drug-induced hypersensitivity| US5468736A|1993-02-25|1995-11-21|The Medical College Of Hampton Road|Hormone replacement therapy| SE9301171D0|1993-04-07|1993-04-07|Ab Astra|PHARMACEUTICAL COMPOSITION CONTAINING LIPOPHILIC DRUGS| US5762952A|1993-04-27|1998-06-09|Hercon Laboratories Corporation|Transdermal delivery of active drugs| DE4336557C2|1993-05-06|1997-07-17|Lohmann Therapie Syst Lts|Estradiol-containing transdermal therapeutic system, process for its preparation and its use| FI95768C|1993-06-17|1996-03-25|Leiras Oy|Intravaginal dosing system| US5595970A|1993-07-16|1997-01-21|Schering Aktiengesellschaft|Treatment of climacteric disorders with nitric oxide synthase substrates and/or donors| DE4329242A1|1993-08-26|1995-03-02|Schering Ag|Agent for transdermal application containing gestodenester| US5543150A|1993-09-15|1996-08-06|Columbia Laboratories, Inc.|Method of progesterone delivery and affect thereof| CA2167526A1|1993-09-29|1995-04-06|Lina Tormen Taskovich|Monoglyceride/lactate ester permeation enhancer| DE4341444C2|1993-12-04|1996-03-14|Lohmann Therapie Syst Lts|Active substance-containing plaster and process for its production| DE4344463A1|1993-12-22|1995-06-29|Schering Ag|Combination product for contraception| DE4344405C2|1993-12-24|1995-12-07|Marika Dr Med Ehrlich|Anti-ovulation agent and method for hormonal contraception| DE4400770C1|1994-01-13|1995-02-02|Lohmann Therapie Syst Lts|Plaster containing an active substance for delivery of oestradiol with at least one penetration enhancer, method of producing it and its use| DE4405898A1|1994-02-18|1995-08-24|Schering Ag|Transdermal therapeutic systems containing sex steroids| US6228383B1|1994-03-03|2001-05-08|Gs Development Ab|Use of fatty acid esters as bioadhesive substances| JP3021661B2|1994-03-07|2000-03-15|セラテック・インコーポレーテッド|Transdermal release devices for drug-containing adhesive composites| GB9405304D0|1994-03-16|1994-04-27|Scherer Ltd R P|Delivery systems for hydrophobic drugs| FR2717689B1|1994-03-28|1996-07-05|Lhd Lab Hygiene Dietetique|Transdermal matrix system for the administration of an estrogen and / or a progestin based on a styrene-isoprene-styrene copolymer.| FR2717688B1|1994-03-28|1996-07-05|Lhd Lab Hygiene Dietetique|Transdermal matrix system for administration of an estrogen and / or an EVA-based progestin.| JP4259610B2|1994-04-08|2009-04-30|キューエルティー・ユーエスエイ・インコーポレーテッド|Liquid delivery composition| AU1958295A|1994-04-13|1995-11-10|Novartis Ag|Temporally controlled drug delivery systems| US6538039B2|1994-04-29|2003-03-25|Laboratoire L. Lafon|Pharmaceutical dosage form for transdermal administration| JPH09512562A|1994-05-05|1997-12-16|メルクフロストカナダインコーポレーテツド|Localized polymer drug delivery system| US5811416A|1994-06-06|1998-09-22|Board Of Regents The University Of Texas System|Endothelin antagonist and/or endothelin synthase inhibitor in combination with a progestin, an estrogen, a cyclooxygenase inhibitor, or a nitric acid donor or substrate| US5709844A|1994-06-09|1998-01-20|The Regents Of The University Of California|Transgenic mice expressing HPV early region oncogene develop progressive cervico-vaginal neoplasia| DE69529665T2|1994-06-27|2004-02-19|Neutron Therapies Inc., San Diego|HORMONE ANALOGS CONTAINING BOR AND METHOD FOR THEIR USE FOR IMAGING OR KILLING CELLS THAT HAVE HORMONE RECEPTORS| FR2722102B1|1994-07-11|1996-08-23|Cird Galderma|USE OF DEFORMABLE HOLLOW PARTICLES IN A COSMETIC AND / OR DERMATOLOGICAL COMPOSITION CONTAINING FAT MATERIALS| FR2722984B1|1994-07-26|1996-10-18|Effik Lab|PROCESS FOR THE PREPARATION OF DRY PHARMACEUTICAL FORMS AND THE PHARMACEUTICAL COMPOSITIONS THUS PRODUCED| US5633011A|1994-08-04|1997-05-27|Alza Corporation|Progesterone replacement therapy| US6586006B2|1994-08-04|2003-07-01|Elan Drug Delivery Limited|Solid delivery systems for controlled release of molecules incorporated therein and methods of making same| DE4429374C1|1994-08-12|1996-02-01|Jenapharm Gmbh|Pharmaceutical preparations for contraception / hormone substitution with biogenic estrogen component| US5916176A|1994-08-25|1999-06-29|Caillouette; James C.|Estrogen or estradiol need determination by vaginal or urethral acidity determination| US5762614A|1994-08-25|1998-06-09|Caillouette; James C.|Estrogen or estradiol need determination by vaginal acidity determination| US5735801A|1994-08-25|1998-04-07|Caillouette; James C.|Estrogen or estradiol need determination by vaginal acidity determination| US6402705B1|1994-08-25|2002-06-11|James C. Caillouette|Body moisture test apparatus and method| PT781122E|1994-09-14|2000-11-30|Minnesota Mining & Mfg|MATRIX FOR TRANSDERMIC DISTRIBUTION OF DRUGS| US6613757B1|1994-09-22|2003-09-02|Board Of Regents, The University Of Texas System|Combination of prostacyclin with an estrogen or progestin for the prevention and treatment of atherosclerotic vascular disease including preeclampsia and for the treatment of hypertension, and for hormone replacement therapy| CA2159419C|1994-10-17|2006-07-04|Pieter De Haan|Solid pharmaceutical composition comprising an excipient capable of binding water| FR2725623B1|1994-10-18|1997-02-21| US5595759A|1994-11-10|1997-01-21|Alza Corporation|Process for providing therapeutic composition| US5571933A|1994-11-17|1996-11-05|Duquesne University Of The Holy Ghost|Derivatives of estra 1,3,5triene-17-one, 3-amino compounds and their use| KR970706805A|1994-11-18|1997-12-01|나까토미 히로타카|Percutaneous Absorption Patch | US5686100A|1994-11-22|1997-11-11|E.R. Squibb & Sons, Inc.|Prophylactic and therapeutic treatment of skin sensitization and irritation| US5885974A|1994-12-06|1999-03-23|Michael M. Danielov|Therapeutic methods utilizing naturally derived bio-active complexes and delivery systems therefor| FR2728463B1|1994-12-21|1997-02-21| DE4446600A1|1994-12-24|1996-06-27|Lohmann Therapie Syst Lts|Transdermal absorption of active ingredients from supercooled melts| US6344211B1|1994-12-24|2002-02-05|Lts Lohmann Therapie-Systeme Gmbh|Transdermal absorption of active substances from subcooled melts| US6024974A|1995-01-06|2000-02-15|Noven Pharmaceuticals, Inc.|Composition and methods for transdermal delivery of acid labile drugs| DE19500662C2|1995-01-12|2001-04-26|Lohmann Therapie Syst Lts|Plaster containing estradiol and its use| US5516528A|1995-01-13|1996-05-14|Wake Forest University|Dietary phytoestrogen in estrogen replacement therapy| US5547948A|1995-01-17|1996-08-20|American Home Products Corporation|Controlled release of steroids from sugar coatings| FR2729854B1|1995-01-26|1997-03-07| US5629021A|1995-01-31|1997-05-13|Novavax, Inc.|Micellar nanoparticles| US5565199A|1995-02-07|1996-10-15|Page; Elliot W.|Systems and methods for the synthesis of natural base steroidal hormones and more especially estrogens and progesterone and estrogen-like and progesterone-like compounds and their derivatives derived as phytohormones from herbaceous plants| US5609617A|1995-02-21|1997-03-11|C. Norman Shealy|Method for enhancement of dehydroepiandrosterone| FR2732223B1|1995-03-30|1997-06-13|Sanofi Sa|PHARMACEUTICAL COMPOSITION FOR TRANSDERMAL ADMINISTRATION| MY118354A|1995-05-01|2004-10-30|Scarista Ltd|1,3-propane diol derivatives as bioactive compounds| US6262115B1|1995-05-22|2001-07-17|Alza Coporation|Method for the management of incontinence| US5912268A|1995-05-22|1999-06-15|Alza Corporation|Dosage form and method for treating incontinence| US5882676A|1995-05-26|1999-03-16|Alza Corporation|Skin permeation enhancer compositions using acyl lactylates| US5785991A|1995-06-07|1998-07-28|Alza Corporation|Skin permeation enhancer compositions comprising glycerol monolaurate and lauryl acetate| US5747058A|1995-06-07|1998-05-05|Southern Biosystems, Inc.|High viscosity liquid controlled delivery system| US7833543B2|1995-06-07|2010-11-16|Durect Corporation|High viscosity liquid controlled delivery system and medical or surgical device| US5693335A|1995-06-07|1997-12-02|Cygnus, Inc.|Skin permeation enhancer composition for use with sex steroids| US5780050A|1995-07-20|1998-07-14|Theratech, Inc.|Drug delivery compositions for improved stability of steroids| DE19526864A1|1995-07-22|1997-01-23|Labtec Gmbh|Hormone patches| US5679573A|1995-07-27|1997-10-21|Abbott Laboratories|Stabilized aqueous steroid immunoassay standards with cyclodextrins| US6245347B1|1995-07-28|2001-06-12|Zars, Inc.|Methods and apparatus for improved administration of pharmaceutically active compounds| US5567831A|1995-08-16|1996-10-22|Duguesne University Of The Holy Ghost|Non-steroidal sulfatase inhibitor compounds and their method of use| US5840327A|1995-08-21|1998-11-24|Alza Corporation|Transdermal drug delivery device having enhanced adhesion| US5906830A|1995-09-08|1999-05-25|Cygnus, Inc.|Supersaturated transdermal drug delivery systems, and methods for manufacturing the same| US5902603A|1995-09-14|1999-05-11|Cygnus, Inc.|Polyurethane hydrogel drug reservoirs for use in transdermal drug delivery systems, and associated methods of manufacture and use| FR2739032B1|1995-09-27|1997-11-21|Lhd Lab Hygiene Dietetique|TRANSDERMAL MATRIX SYSTEM FOR ADMINISTRATION OF AN ESTROGEN AND / OR AN EVA-BASED PROGESTIVE, PROCESS FOR PREPARATION AND THERAPEUTIC USE| FR2739031B1|1995-09-27|1997-11-21|Lhd Lab Hygiene Dietetique|TRANSDERMAL MATRIX SYSTEM FOR ADMINISTRATION OF AN ESTROGEN AND / OR A PROGESTIVE BASED ON STYRENE-ISOPRENE-STYRENE COPOLYMER, PREPARATION METHOD AND THERAPEUTIC USE| US5897539A|1995-09-28|1999-04-27|Schering Aktiengesellschaft|Hormone replacement therapy method and hormone dispenser| US6551611B2|1995-09-28|2003-04-22|Schering Aktiengesellschaft|Hormone replacement therapy method| FR2739558B1|1995-10-05|1997-11-28|Innothera Lab Sa|UNITAL GALENIC FORM FOR LOCAL HORMONOTHERAPY OF VAGINAL DROUGHT| US5736152A|1995-10-27|1998-04-07|Atrix Laboratories, Inc.|Non-polymeric sustained release delivery system| DE19540253C2|1995-10-28|1998-06-04|Jenapharm Gmbh|Multi-phase preparation for contraception based on natural estrogens| GB9522403D0|1995-11-01|1996-01-03|Hoechst Roussel Ltd|Intravaginal drug delivery device| US5612051A|1995-11-17|1997-03-18|Yue; Samuel K.|Method of treating involuntary muscle dysfunction with relaxin hormone| US5770176A|1995-12-08|1998-06-23|Chiron Diagnostics Corporation|Assays for functional nuclear receptors| DE19548332A1|1995-12-22|1997-07-10|Rotta Res Bv|hormone patches| DE19549264A1|1995-12-23|1997-06-26|Schering Ag|Contraception procedure and kit| US5789442A|1996-01-18|1998-08-04|Schering Aktiengesellschaft|Treatment of urinary incontinence with nitric oxide synthase substrates and/or nitric oxide donors alone or in combination with estrogen or progesterone and/or other agents| EP0785212A1|1996-01-22|1997-07-23|Laboratoire Theramex|New 19-nor-pregnene derivatives| EP0785211A1|1996-01-22|1997-07-23|Laboratoire Theramex|New substituted 19-nor-pregnane derivatives| AUPN814496A0|1996-02-19|1996-03-14|Monash University|Dermal penetration enhancer| US5898038A|1996-03-19|1999-04-27|Board Of Regents, The University Of Texas System|Treatment of osteoporosis and metabolic bone disorders with nitric oxide substrate and/or donors| FR2747042B1|1996-04-05|1998-06-05|Besins Iscovesco Lab|PROGESTERONE AND OESTRADIOL-BASED MEDICINE| NZ286492A|1996-05-01|1998-02-26|Dec International Nz Ltd Subst|Intra vaginal devices for synchronising oestrus of animals is made up of cured silicone rubber material with 5% by weight of progesterone| US6040340A|1996-05-07|2000-03-21|Schering Aktiengesellschaft|Implantation rates after in vitro fertilization, treatment of infertility and early pregnancy loss with a nitric oxide donor alone or in combination with progesterone, and a method for contraception with nitric oxide inhibitors| AT281170T|1996-05-09|2004-11-15|Amrad Operations Pty Ltd|USE OF STEROIDS FOR TREATING ASTHMA AND RESPIRATORY DISEASES| WO1997043989A1|1996-05-22|1997-11-27|Diversified Pharmaceuticals, Inc.|Compositions, methods and devices for the transdermal delivery of drugs| US5744463A|1996-06-03|1998-04-28|Bair; Glenn O.|Treatment of side effects of progestins and progesterone analogues used for birth control| IT1283102B1|1996-06-06|1998-04-07|Permatec Nv|THERAPEUTIC COMPOSITION FOR THE TRANSDERMAL ADMINISTRATION OF AN ESTROGENIC OR PROGESTINIC ACTIVE SUBSTANCE OR OF THEIR MIXTURES| US6506390B2|1996-06-25|2003-01-14|Akzo Nobel|Progestogen-anti-progestogen regimens| US6139873A|1996-07-10|2000-10-31|Cedars-Sinai Medical Center|Combined pharmaceutical estrogen-androgen-progestin| DE19629468A1|1996-07-11|1998-01-15|Schering Ag|Transdermal therapeutic systems| US6228852B1|1996-07-12|2001-05-08|Carolyn V. Shaak|Transdermal application of naturally occurring steroid hormones| CA2632790A1|1996-07-22|1998-01-29|Renovo Limited|Use of sex steroid function modulators to treat wounds and fibrotic disorders| US5972372A|1996-07-31|1999-10-26|The Population Council, Inc.|Intravaginal rings with insertable drug-containing core| US6227202B1|1996-09-03|2001-05-08|Maulana Azad Medical College|Method of organogenesis and tissue regeneration/repair using surgical techniques| AU733553B2|1996-09-06|2001-05-17|Nederlandse Organisatie Voor Toegepast- Natuurwetenschappelijk Onderzoek Tno|Method of screening for side effects of anticonceptives or estrogen and/or progesterone replacements or supplements| US20040176336A1|2000-03-21|2004-09-09|Rodriguez Gustavo C.|Prevention of ovarian cancer by administration of products that induce biologic effects in the ovarian epithelium| US6028064A|1996-09-13|2000-02-22|New Life Pharmaceuticals Inc.|Prevention of ovarian cancer by administration of progestin products| FR2753626B1|1996-09-20|1998-11-06|Centre International De Rech Dermatologiques Galderma Cird Galderma|NOVEL TOPICAL COMPOSITIONS IN THE FORM OF A FLUID O / W EMULSION WITH A HIGH PRO-PENETRATING GLYCOL CONTENT| EP1027032B1|1996-10-18|2006-03-08|Union Camp Corporation|Ester-terminated polyamide gels| WO1998018416A1|1996-10-30|1998-05-07|Theratech, Inc.|Fatty acid esters of glycolic acid and its salts as permeation enhancers| US5985861A|1996-11-04|1999-11-16|Columbia Laboratories, Inc.|Progesterone for treating or reducing ischemia| US5942243A|1996-11-12|1999-08-24|Polytherapeutics, Inc.|Mucoadhesive compositions for administration of biologically active agents to animal tissue| US5814329A|1996-11-12|1998-09-29|Polytherapeutics, Inc.|Hydrophilic polystyrene graft copolymer vehicle for intravaginal administration of pharmacologically active agents| US5928666A|1996-11-12|1999-07-27|Cygnus Inc.|Crystalline form of estradiol and pharmaceutical formulations comprising same| US20060014728A1|1996-11-21|2006-01-19|Kristof Chwalisz|Hormone replacement therapy| DE19654609A1|1996-12-20|1998-06-25|Schering Ag|Therapeutic progestogens for the treatment of premenstrual dysphoric disorder| DE19701949A1|1997-01-13|1998-07-16|Jenapharm Gmbh|Transdermal therapeutic system| DE19700913C2|1997-01-14|2001-01-04|Lohmann Therapie Syst Lts|Transdermal therapeutic system for the delivery of hormones| US5993856A|1997-01-24|1999-11-30|Femmepharma|Pharmaceutical preparations and methods for their administration| US6416778B1|1997-01-24|2002-07-09|Femmepharma|Pharmaceutical preparations and methods for their regional administration| US20010023261A1|1997-01-27|2001-09-20|Lg Chemical Limited.|Novel composition for the transdermal administration of drugs| US5827200A|1997-01-27|1998-10-27|Caillouette; James C.|Method and apparatus for detecting amine producing organisms in the vagina| KR100215027B1|1997-01-27|1999-08-16|성재갑|Composition for transdermal administration of steroid drugs and formulation containing same| DE19705229C2|1997-02-12|1999-04-15|Hesch Rolf Dieter Prof Dr Med|Use of three hormonal components for hormonal contraception for the treatment and / or prophylaxis of tumors of the mammary glands| US6056972A|1997-02-26|2000-05-02|Dimera, Llc|Method for reducing coronary artery reactivity| US6093394A|1997-04-11|2000-07-25|Gynelogix, Inc.|Vaginal lactobacillus medicant| DE19718012C1|1997-04-29|1998-10-08|Jenapharm Gmbh|Process for the production of orally applicable solid pharmaceutical forms with controlled release of active substances| IT1291362B1|1997-05-13|1999-01-07|Vectorpharma Int|BIPHASIC MULTICOMPONENT PHARMACEUTICAL COMPOSITIONS CONTAINING SUBSTANCES SUITABLE TO MODIFY THE PARTITION OF THE ACTIVE SUBSTANCES| WO1998053758A1|1997-05-28|1998-12-03|Dec International Nz Limited|Intra-vaginal device for pigs| CA2294480C|1997-06-23|2008-05-20|Queen's University At Kingston|Microdose therapy of female sexual dysfunction by no, co, and their donors| US6039968A|1997-06-24|2000-03-21|Hoechst Marion Roussel|Intravaginal drug delivery device| DE19728517C2|1997-07-04|1999-11-11|Sanol Arznei Schwarz Gmbh|TTS for the administration of sex steroid hormones and process for its preparation| DE19728516C2|1997-07-04|1999-11-11|Sanol Arznei Schwarz Gmbh|TTS for administration of levonorgestrel and possibly estradiol| US6217886B1|1997-07-14|2001-04-17|The Board Of Trustees Of The University Of Illinois|Materials and methods for making improved micelle compositions| DE19739916C2|1997-09-11|2001-09-13|Hesch Rolf Dieter|Use of a combination of a progestogen and an estrogen for the continuous inhibition of ovulation and possibly simultaneous treatment and / or prophylaxis of tumors of the mammary glands| US8765177B2|1997-09-12|2014-07-01|Columbia Laboratories, Inc.|Bioadhesive progressive hydration tablets| US20040234606A1|1997-09-12|2004-11-25|Levine Howard L.|Localized vaginal delivery without detrimental blood levels| GB9720470D0|1997-09-25|1997-11-26|Ethical Pharmaceuticals South|Inhibition of crystallization in transdermal devices| US8257724B2|1998-09-24|2012-09-04|Abbott Laboratories|Delivery of highly lipophilic agents via medical devices| US8257725B2|1997-09-26|2012-09-04|Abbott Laboratories|Delivery of highly lipophilic agents via medical devices| US6201072B1|1997-10-03|2001-03-13|Macromed, Inc.|Biodegradable low molecular weight triblock poly polyethylene glycol copolymers having reverse thermal gelation properties| US5968919A|1997-10-16|1999-10-19|Macrochem Corporation|Hormone replacement therapy drug formulations for topical application to the skin| US6306914B1|1997-10-21|2001-10-23|Columbia Laboratories, Inc.|Progestin therapy for maintaining amenorrhea| US20020099003A1|1997-10-28|2002-07-25|Wilson Leland F.|Treatment of female sexual dysfunction with vasoactive agents, particularly vasoactive intestinal polypeptide and agonists thereof| WO1999021562A1|1997-10-28|1999-05-06|Asivi, Llc|Treatment of female sexual dysfunction| US20040044080A1|1997-10-28|2004-03-04|Place Virgil A.|Treatment of dyspareunia with topically administered nitroglycerin formulations| US6193991B1|1997-10-29|2001-02-27|Atul J. Shukla|Biodegradable delivery systems of biologically active substances| US6372732B1|1997-11-19|2002-04-16|Humanetics Corporation|Use of delta5-androstene-3beta-ol-7, 17-dione in the treatment of lupus erythematosus| US5891868A|1997-11-21|1999-04-06|Kaiser Foundation Health Plan, Inc.|Methods for treating postmenopausal women using ultra-low doses of estrogen| US6692763B1|1998-11-19|2004-02-17|The Regents Of The University Of California|Methods for treating postmenopausal women using ultra-low doses of estrogen| US20020031513A1|1997-11-24|2002-03-14|Shamir Leibovitz|Method and pharmaceutical composition for inhibiting premature rapture of fetal membranes, ripening of uterine cervix and preterm labor in mammals| US6030948A|1997-12-19|2000-02-29|Mann; Morris A.|Hair regeneration compositions for treatment of alopecia and methods of application related thereto| FR2772617B1|1997-12-19|2001-03-09|Besins Iscovesco Lab|PROGESTERONE TABLET AND PROCESS FOR THE PREPARATION THEREOF| WO1999032153A1|1997-12-22|1999-07-01|Alza Corporation|Monoglyceride and ethyl palmitate permeation enhancer compositions| US6054446A|1997-12-24|2000-04-25|Sri International|Anti-estrogenic steroids, and associated pharmaceutical compositions and methods of use| US6548491B2|1997-12-24|2003-04-15|Sri International|Anti-estrogenic steroids, and associated pharmaceutical compositions and methods of use| US6503896B1|1997-12-24|2003-01-07|Sri International|Anti-estrogenic steroids, and associated pharmaceutical compositions and methods of use| IT1298575B1|1998-02-06|2000-01-12|Vectorpharma Int|PHARMACEUTICAL COMPOSITIONS IN THE FORM OF NANOPARTICLES INCLUDING LIPID SUBSTANCES AND ANTIPHILIC SUBSTANCES AND RELATED PROCESS OF| US6312703B1|1998-02-06|2001-11-06|Lecigel, Llc|Compressed lecithin preparations| US6001846A|1998-02-17|1999-12-14|Ligand Pharmaceuticals Incorporated|Process for the preparation of 1,2-dihydroquinolines| US6028057A|1998-02-19|2000-02-22|Thorn Bioscience, Llc|Regulation of estrus and ovulation in gilts| DE19807791A1|1998-02-19|1999-08-26|Schering Ag|Combination preparation of estrogen with 7-aminoalkyl-estratriene antiestrogen, useful in hormone replacement therapy, e.g. for treatment osteoporosis, Alzheimer's disease and hot flushes| US6287693B1|1998-02-25|2001-09-11|John Claude Savoir|Stable shaped particles of crystalline organic compounds| US20010056068A1|1998-03-04|2001-12-27|Kristof Chwalisz|Method of treatment and prevention of nitric oxide deficiency-related disorders with citrulline and citrulline derivatives| FR2775599B1|1998-03-09|2001-08-17|Besins Iscovesco Lab|PHARMACEUTICAL COMPOSITION BASED ON SYNTHESIS NATURAL PROGESTERONE AND OESTRADIOL AND PROCESS FOR PREPARING THE SAME| FR2776191B1|1998-03-23|2002-05-31|Theramex|TOPICAL HORMONAL COMPOSITION WITH SYSTEMIC EFFECT| US20030040790A1|1998-04-15|2003-02-27|Furst Joseph G.|Stent coating| CN1644201A|1998-04-17|2005-07-27|奥索-麦克尼尔药品公司|Application of folic acid-containing pharmaceutical compositions| FR2777784B1|1998-04-27|2004-03-19|Arepa|PHARMACEUTICAL COMPOSITION BASED ON ESTROGEN AND PROGESTERONE| US6277418B1|1998-06-02|2001-08-21|Baylor College Of Medicine|Corn extract contraceptive| FR2779438B1|1998-06-03|2004-12-24|Jean Marc Aiache|STABLE GEL, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME| NZ330596A|1998-06-05|2001-02-23|Dec Res|Intravaginal devices allowing for increased uptake of active ingredients| DE19825591A1|1998-06-09|1999-12-23|Jenapharm Gmbh|Pharmaceutical combinations to compensate for a testosterone deficit in men while protecting the prostate| US6465445B1|1998-06-11|2002-10-15|Endorecherche, Inc.|Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors| NZ330726A|1998-06-18|2000-10-27|Dec Res|Intra-vaginal delivery unit or composition containing a cyclodextrin which improves absorbtion of 17-beta oestradiol or oestradiol benzoate| DE19827732A1|1998-06-22|1999-12-23|Rottapharm Bv|Transdermal patch useful for hormone replacement therapy used for treatment of menopausal symptoms| WO2000001351A1|1998-07-07|2000-01-13|Transdermal Technologies, Inc.|Compositions for rapid and non-irritating transdermal delivery of pharmaceutically active agents and methods for formulating such compositions and delivery thereof| US6294188B1|1998-07-09|2001-09-25|Aviana Biopharm Inc.|Methods involving changing the constitutive and stimulated secretions of the local reproductive system of women| US6124362A|1998-07-17|2000-09-26|The Procter & Gamble Company|Method for regulating hair growth| DE19834931A1|1998-07-28|2000-02-24|Jenapharm Gmbh|Use of biogenic estrogens for hormone replacement therapy| DE19834007C1|1998-07-29|2000-02-24|Lohmann Therapie Syst Lts|Estradiol-containing patch for the transdermal application of hormones and its use| US20070015698A1|1998-07-30|2007-01-18|United States Of America As Represented By The Secretary Of Health|Treatment of skin, and wound repair, with thymosin beta 4| US20030181353A1|1998-08-03|2003-09-25|Nyce Jonathan W.|Composition & use as analgesic, anti-inflammatory, wound healing agent, for treatment of heart conditions, assessment of heart function & tissue & cell protection & healing & reperfusion, mood disorders & symptoms & sequelae of menopause & for inducing unconsciousness, sleep & anesthesia| JP2002522425A|1998-08-07|2002-07-23|カイロンコーポレイション|Substituted isoxazoles as estrogen receptor modulators| US6087352A|1998-08-17|2000-07-11|Trout; William E.|Use of Zeranol to modulate reproductive cycles| US20020169205A1|1998-09-29|2002-11-14|Krzysztof Chwalisz|Implantation rates after in vitro fertilization, and treatment of infertility and early pregnancy loss with a nitric oxide donor or substrate alone or in combination with progesterone, and a method for contraception with nitric oxide inhibitors in combination with antiprogestins or other agents| US6387390B1|1998-10-05|2002-05-14|The Penn State Research Foundation|Compositions and methods for enhancing receptor-mediated cellular internalization| JP4399044B2|1998-10-14|2010-01-13|久光製薬株式会社|Absorption enhancer and transdermal absorption preparation comprising the absorption enhancer| US6372246B1|1998-12-16|2002-04-16|Ortho-Mcneil Pharmaceutical, Inc.|Polyethylene glycol coating for electrostatic dry deposition of pharmaceuticals| US20040120891A1|1998-12-21|2004-06-24|Craig Hill|Compounds for intracellular delivery of therapeutic moieties to nerve cells| JP2002533379A|1998-12-23|2002-10-08|イデアアクチェンゲゼルシャフト|Improved formulation for locally non-invasive use in vivo| GB9828480D0|1998-12-24|1999-02-17|Dermatech Limited|Transdermal drug delivery system| US6117446A|1999-01-26|2000-09-12|Place; Virgil A.|Drug dosage unit for buccal administration of steroidal active agents| AT252380T|1999-02-05|2003-11-15|Cipla Ltd|TOPICAL SPRAYS CONTAINING A FILM-FORMING COMPOSITION| US7919109B2|1999-02-08|2011-04-05|Intarcia Therapeutics, Inc.|Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicles| US6080118A|1999-02-25|2000-06-27|Blythe; Cleveland|Vaginal probe and method of using same| US6294192B1|1999-02-26|2001-09-25|Lipocine, Inc.|Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents| US20030104048A1|1999-02-26|2003-06-05|Lipocine, Inc.|Pharmaceutical dosage forms for highly hydrophilic materials| US7374779B2|1999-02-26|2008-05-20|Lipocine, Inc.|Pharmaceutical formulations and systems for improved absorption and multistage release of active agents| DE19911799A1|1999-03-17|2000-09-28|Lohmann Therapie Syst Lts|Multipack for the removal of filled bags in the specified order| CA2267743C|1999-03-30|2011-07-26|Robert F. Casper|Low dose estrogen interrupted hormone replacement therapy| US6589549B2|2000-04-27|2003-07-08|Macromed, Incorporated|Bioactive agent delivering system comprised of microparticles within a biodegradable to improve release profiles| US6287588B1|1999-04-29|2001-09-11|Macromed, Inc.|Agent delivering system comprised of microparticle and biodegradable gel with an improved releasing profile and methods of use thereof| US6649155B1|1999-05-03|2003-11-18|The Procter & Gamble Company|Anti-dandruff and conditioning shampoos containing certain cationic polymers| US6974569B2|1999-05-03|2005-12-13|The Procter & Gamble Company|Shampoos providing a superior combination anti-dandruff efficacy and condition| US6451300B1|1999-05-03|2002-09-17|The Procter & Gamble Company|Anti-dandruff and conditioning shampoos containing polyalkylene glycols and cationic polymers| US8663692B1|1999-05-07|2014-03-04|Pharmasol Gmbh|Lipid particles on the basis of mixtures of liquid and solid lipids and method for producing same| AT253355T|1999-05-13|2003-11-15|Hisamitsu Pharmaceutical Co|BAND AID| US6962691B1|1999-05-20|2005-11-08|U & I Pharmaceuticals Ltd.|Topical spray compositions| US6645947B1|1999-05-20|2003-11-11|Chitogenics, Inc.|Adhesive N, O-carboxymethylchitosan coatings which inhibit attachment of substrate-dependent cells and proteins| US6395300B1|1999-05-27|2002-05-28|Acusphere, Inc.|Porous drug matrices and methods of manufacture thereof| US7919119B2|1999-05-27|2011-04-05|Acusphere, Inc.|Porous drug matrices and methods of manufacture thereof| CZ20014338A3|1999-06-04|2002-03-13|Alza Corporation|Implantable gel compositions and process for producing thereof| WO2000074661A2|1999-06-05|2000-12-14|Noven Pharmaceuticals, Inc.|Solubility enhancement of drugs in transdermal drug delivery systems and methods of use| MXPA01012769A|1999-06-11|2003-06-24|Watson Pharmaceuticals Inc|Administration of non-oral androgenic steroids to women.| GB9914648D0|1999-06-24|1999-08-25|Univ Birmingham|Control of infra-ocular pressure| US20030236236A1|1999-06-30|2003-12-25|Feng-Jing Chen|Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs| US6303132B1|1999-07-16|2001-10-16|Ardell H. Nelson|Administering progesterone using EMU oil| KR20010010393A|1999-07-20|2001-02-05|김윤|Biodegradable Block Copolymer of Hydrophobic and Hydrophilic Polymers, and Composition for Drug Delivery Comprising Same| NZ337318A|1999-08-18|2002-07-26|Interag|Dispensing apparatus for dispensing same or different materials for at least two reservoirs| US20010036481A1|1999-08-25|2001-11-01|Advanced Inhalation Research, Inc.|Modulation of release from dry powder formulations| AU6938600A|1999-08-26|2001-03-19|West Virginia University|Cervical agent delivery system| JP2003532629A|1999-09-08|2003-11-05|ワトソンファーマシューティカルズ，インコーポレイテッド|Use of quaternary ammonium salts for transdermal drug release| US6610674B1|1999-09-28|2003-08-26|University Of Pennsylvania|Method of treating inflammatory conditions with progesterone analogs| US6479545B1|1999-09-30|2002-11-12|Drugtech Corporation|Formulation for menopausal women| US6720001B2|1999-10-18|2004-04-13|Lipocine, Inc.|Emulsion compositions for polyfunctional active ingredients| US6436633B1|1999-10-22|2002-08-20|The Pennsylvania State University|Human xenografts for microbicide testing and anatomical modeling| US6958327B1|1999-11-02|2005-10-25|Schering, Ag|18 Norsteroids as selectively active estrogens| US6248363B1|1999-11-23|2001-06-19|Lipocine, Inc.|Solid carriers for improved delivery of active ingredients in pharmaceutical compositions| AUPQ419099A0|1999-11-23|1999-12-16|Ko, Thomas Sai Ying|Novel compositions and methods| US20030180352A1|1999-11-23|2003-09-25|Patel Mahesh V.|Solid carriers for improved delivery of active ingredients in pharmaceutical compositions| US7384650B2|1999-11-24|2008-06-10|Agile Therapeutics, Inc.|Skin permeation enhancement composition for transdermal hormone delivery system| US20020012710A1|1999-11-29|2002-01-31|Rimonest Ltd.|Pomegranate products useful in improving health and methods of use thereof| US6708822B1|1999-11-30|2004-03-23|Cutispharma, Inc.|Compositions and kits for compounding pharmaceuticals| US20040191276A1|1999-11-30|2004-09-30|Cutispharma, Inc.|Compositions and kits for compounding pharmaceuticals| US6562370B2|1999-12-16|2003-05-13|Dermatrends, Inc.|Transdermal administration of steroid drugs using hydroxide-releasing agents as permeation enhancers| US20010032125A1|1999-12-20|2001-10-18|Sundeep Bhan|Activation of coupons based on quiz or questionnaire| US6544553B1|1999-12-28|2003-04-08|Watson Pharmaceuticals, Inc.|Dosage forms and methods for oral delivery of progesterone| GB0000313D0|2000-01-10|2000-03-01|Astrazeneca Uk Ltd|Formulation| US6967023B1|2000-01-10|2005-11-22|Foamix, Ltd.|Pharmaceutical and cosmetic carrier or composition for topical application| US6653298B2|2000-01-14|2003-11-25|Sterix Limited|Composition| US7335650B2|2000-01-14|2008-02-26|Sterix Limited|Composition| US20020004065A1|2000-01-20|2002-01-10|David Kanios|Compositions and methods to effect the release profile in the transdermal administration of active agents| IL149990D0|2000-01-28|2002-12-01|Endorech Inc|Selective estrogen receptor modulators in combination with estrogens| FR2804603B1|2000-02-04|2004-01-23|Rhodia Chimie Sa|CONTINUOUS PROCESS FOR FORMULATING IN THE FORM OF GRANULES ONE OR MORE PHARMACEUTICAL ACTIVE SUBSTANCES| US6562790B2|2000-02-05|2003-05-13|Chein Edmund Y M|Hormone therapy methods and hormone products for abating coronary artery blockage| BR0108438A|2000-02-16|2003-04-01|Bentley Pharmaceuticals Inc|Pharmaceutical Composition| AT359065T|2000-02-23|2007-05-15|Orentreich Foundation For The|USE OF AN INSULIN SENSIBILIZER IN THE TREATMENT OF ALOPECIA| US7459445B2|2000-03-10|2008-12-02|Duramed Pharmaceuticals, Inc.|Estrogenic compounds and topical pharmaceutical formulations of the same| US7989436B2|2003-07-23|2011-08-02|Duramed Pharmaceuticals, Inc.|Estrogenic compounds and pharmaceutical formulations comprising the same| US6660726B2|2000-03-10|2003-12-09|Endeavor Pharmaceuticals|Estrogenic compounds, pharmaceutical compositions thereof, and methods of using same| US6855703B1|2000-03-10|2005-02-15|Endeavor Pharmaceuticals|Pharmaceutical compositions of conjugated estrogens and methods of analyzing mixtures containing estrogenic compounds| US20010034340A1|2000-03-20|2001-10-25|American Home Products Corporation|Hormone replacement therapy| IL135335A|2000-03-29|2013-12-31|Lycored Natural Prod Ind Ltd|Use of carotenoids in the preparation of medicaments for preventing hormone induced adverse effects and pharmaceutical compositions comprising carotenoids| WO2001074839A2|2000-03-31|2001-10-11|The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services|Methods of making the 4-n-butylcyclohexanoic and the undecanoic acid esters of -dimethyl-17 beta-hydroxy-4-estren-3-one and their medical use| AT363487T|2000-04-12|2007-06-15|Bayer Schering Pharma Ag|8.BETA.-HYDROCARBYL-SUBSTITUTED ESTRATRIENE AS SELECTIVELY EFFECTIVE ESTROGENE| US7758888B2|2000-04-21|2010-07-20|Sol-Gel Technologies Ltd.|Composition exhibiting enhanced formulation stability and delivery of topical active ingredients| US7018645B1|2000-04-27|2006-03-28|Macromed, Inc.|Mixtures of various triblock polyester polyethylene glycol copolymers having improved gel properties| US8119138B2|2000-05-10|2012-02-21|Signe Biopharma Inc.|Anti-estrogen and immune modulator combinations for treating breast cancer| US6495534B2|2000-05-15|2002-12-17|Pharmacia & Upjohn Spa|Stabilized aqueous suspensions for parenteral use| KR100452972B1|2000-05-16|2004-10-14|주식회사 삼양사|Hydrogel composition for transdermal drug| GB0015617D0|2000-06-26|2000-08-16|Vectura Ltd|Improved preparations for dermal delivery of active substances| US20030114420A1|2000-06-28|2003-06-19|Salvati Mark E.|Fused cyclic modulators of nuclear hormone receptor function| US20040077605A1|2001-06-20|2004-04-22|Salvati Mark E.|Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function| US7001911B2|2000-06-28|2006-02-21|Bristol-Myers Squibb Company|Fused cyclic modulators of nuclear hormone receptor function| US20040047910A1|2000-07-07|2004-03-11|Christian Beckett|Suppository and composition comprising at least one polyethylene glycol| US6420352B1|2000-07-19|2002-07-16|W. Roy Knowles|Hair loss prevention| JP2004504342A|2000-07-24|2004-02-12|ファルマシア・アンド・アップジョン・カンパニー|Self-emulsifying drug delivery system for highly water-insoluble lipophilic drugs| US20020119174A1|2000-07-26|2002-08-29|Gardlik John Michael|Compositions useful for regulating hair growth containing metal complexes of oxidized carbohydrates| US20020035070A1|2000-07-26|2002-03-21|The Procter & Gamble Company|Method of regulating hair growth using metal complexes of oxidized carbohydrates| ES2283665T3|2000-08-03|2007-11-01|Antares Pharma Ipl Ag|COMPOSITION FOR TRANSDERMAL AND / OR TRANSMUCTIVE ADMINISTRATION OF ACTIVE COMPOUNDS THAT ENSURE THERAPEUTICALLY ADEQUATE LEVELS.| US8980290B2|2000-08-03|2015-03-17|Antares Pharma Ipl Ag|Transdermal compositions for anticholinergic agents| US7198801B2|2000-08-03|2007-04-03|Antares Pharma Ipl Ag|Formulations for transdermal or transmucosal application| US7163681B2|2000-08-07|2007-01-16|Centocor, Inc.|Anti-integrin antibodies, compositions, methods and uses| US20040092494A9|2000-08-30|2004-05-13|Dudley Robert E.|Method of increasing testosterone and related steroid concentrations in women| GB0021317D0|2000-08-30|2000-10-18|Queen Mary & Westfield College|Transdermal pharmaceutical delivery composition| DE10045380A1|2000-09-14|2002-04-04|Schering Ag|Contraception procedure and dosage form| FR2814074B1|2000-09-15|2003-03-07|Theramex|NOVEL TOPICAL ESTRO-PROGESTIVE COMPOSITIONS WITH SYSTEMIC EFFECT| KR100765670B1|2000-09-19|2007-10-10|브리스톨-마이어스스퀴브컴파니|Fused Heterocyclic Succinimide Compounds and Analogs Thereof, Modulators of Nuclear Hormone Receptor Function| AT380541T|2000-09-20|2007-12-15|Nycomed Pharma As|PREPARATION OF VITAMIN EMULSIONS AND CONCENTRATES THEREOF| US20020119187A1|2000-09-29|2002-08-29|Cantor Adam S.|Composition for the transdermal delivery of fentanyl| JPWO2002032431A1|2000-10-16|2004-02-26|久光製薬株式会社|External preparation composition| US6635274B1|2000-10-27|2003-10-21|Biochemics, Inc.|Solution-based transdermal drug delivery system| WO2002036144A1|2000-10-30|2002-05-10|University Of Zurich|Gnrh analogues for treatment of urinary incontinence| US6328987B1|2000-11-03|2001-12-11|Jan Marini Skin Research, Inc.|Cosmetic skin care compositions containing alpha interferon| US20030113268A1|2000-11-10|2003-06-19|Mina Buenafae|Degradation-resistant glucocorticosteroid formulations| US6605605B2|2000-11-13|2003-08-12|Milton Hammerly|Estrogenic substances combined with cruciferous indole compounds| US6682757B1|2000-11-16|2004-01-27|Euro-Celtique, S.A.|Titratable dosage transdermal delivery system| FR2816838B1|2000-11-17|2004-12-03|Oreal|USE OF DERIVATIVES OF 2-OXOTHIAZOLIDINE-4-CARBOXYLIC ACID AS PRODESQUAMANTS| NZ525415A|2000-11-17|2004-11-26|Warner Lambert Co|Treatment of sexual dysfunction with non peptide bombesin receptor antagonists| US20040022820A1|2001-11-28|2004-02-05|David Anderson|Reversed liquid crystalline phases with non-paraffin hydrophobes| AUPR184500A0|2000-12-01|2001-01-04|Drug Delivery Solutions Pty Ltd|Dispensing device| WO2002055020A2|2000-12-11|2002-07-18|Testocreme Llc|Topical testosterone formulations and associated methods| NZ526517A|2000-12-14|2005-09-30|Ortho Mcneil Pharm Inc|Steroid hormone products and methods for preparing them| US7018992B2|2000-12-15|2006-03-28|Novo Nordisk A/S|Hormone composition| EP1216712A1|2000-12-20|2002-06-26|Schering Aktiengesellschaft|Cyclodextrin-drospirenone inclusion complexes| EP1216699A1|2000-12-21|2002-06-26|Schering Aktiengesellschaft|Transdermal system comprising a highly potent progestin| US20020107230A1|2000-12-22|2002-08-08|Waldon R. Forrest|Methods and formulations for the treatment of female sexual dysfunction| US20020151530A1|2000-12-22|2002-10-17|Leonard Thomas W.|Method of treating hormonal deficiencies in women undergoing estrogen replacement therapy| FR2818905A1|2000-12-28|2002-07-05|Cll Pharma|MICELLAR COLLOIDAL PHARMACEUTICAL COMPOSITIONS COMPRISING A LIPOPHILIC ACTIVE INGREDIENT| EP1351678A2|2001-01-02|2003-10-15|Elizabeth Shanahan-Prendergast|Treatment for inhibiting neoplastic lesions using incensole and/or furanogermacrens| US20020132801A1|2001-01-11|2002-09-19|Schering Aktiengesellschaft|Drospirenone for hormone replacement therapy| US20020197286A1|2001-01-16|2002-12-26|Jane Brandman|Method for preventing and treating skin aging| FR2820320B1|2001-02-02|2003-04-04|Oreal|SUSPENSION OF LIPOPHILIC ACTIVE INGREDIENT NANOSPHERES STABILIZED BY WATER-DISPERSIBLE POLYMERS| US20030091640A1|2001-02-08|2003-05-15|Srinivasan Ramanathan|Enhanced oral and transcompartmental delivery of therapeutic or diagnostic agents| US7381427B2|2001-02-09|2008-06-03|Mickey Miller|Seborrheic keratosis treatment| NZ509894A|2001-02-09|2002-11-26|Interag|A "T" or "Y" shaped intravaginal device suitable for delivery of pharmaceuticals such as progesterone| US7303763B2|2001-02-12|2007-12-04|Watson Laboratories, Inc.|Compositions for conjugated estrogens and associated methods| US20040087548A1|2001-02-27|2004-05-06|Salvati Mark E.|Fused cyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function| AU2002326291A1|2001-02-28|2003-01-02|Hiroshi Deguchi|Plasma glucosylceramide deficiency as risk factor for thrombosis and modulator of anticoagulant protein c| FR2821555B1|2001-03-01|2003-05-16|Besins Int Lab|PROGESTIVE CO-MICRONIZED WITH A SURFACTANT, PHARMACEUTICAL COMPOSITION COMPRISING SAME, METHODS OF MAKING SAME AND USES THEREOF| US20020169150A1|2001-03-16|2002-11-14|Wyeth|Hormone replacement therapy| US20020142941A1|2001-03-30|2002-10-03|Pro Duct Health, Inc.|Intraductal treatment targeting methylated promoters in breast cancer| JP2005506297A|2001-03-30|2005-03-03|エラン ファーマシューティカルズ インコーポレイテッド|Pergolide transdermal delivery| WO2002078604A2|2001-03-30|2002-10-10|Elan Transdermal Technologies, Inc.|Transdermal delivery of bioactive material| US20040131670A1|2001-04-17|2004-07-08|Ping Gao|Pellicle-resistant gelatin capsule| US6860859B2|2001-04-20|2005-03-01|Monsanto Technology Llc|Apparatus and method for detection of estrus and/or non-pregnancy| US20070021360A1|2001-04-24|2007-01-25|Nyce Jonathan W|Compositions, formulations and kit with anti-sense oligonucleotide and anti-inflammatory steroid and/or obiquinone for treatment of respiratory and lung disesase| US20120322779A9|2001-04-25|2012-12-20|Rhonda Voskuhl|Estriol Therapy for Autoimmune and Neurodegenerative Diseases and Disorders| US6936599B2|2001-04-25|2005-08-30|The Regents Of The University Of California|Estriol therapy for multiple sclerosis and other autoimmune diseases| US20050209208A1|2001-04-25|2005-09-22|The Regents Of The University Of California|Use of estriol and other estranes, estrogens and estrogen receptor active compositions in the treatment of psoriasis and other autoimmune disorders| US8658627B2|2001-04-25|2014-02-25|The Regents Of The University Of California|Pregnancy hormone combination for treatment of autoimmune diseases| EP1390038A2|2001-05-16|2004-02-25|Endeavor Pharmaceuticals|Treatment of conditions relating to hormone deficiencies by administration of progestins| US8048869B2|2001-05-18|2011-11-01|Pantarhei Bioscience B.V.|Pharmaceutical composition for use in hormone replacement therapy| US20020193356A1|2001-05-23|2002-12-19|Van Beek Agatha Antonia Magdalena|Means and method for hormonal contraception| JP4865958B2|2001-05-23|2012-02-01|株式会社トクホン|Analgesic anti-inflammatory patch with local action| FR2825277B1|2001-05-30|2004-10-15|Oreal|COSMETIC AND / OR DERMATOLOGICAL AND / OR PHARMACEUTICAL COMPOSITION CONTAINING AT LEAST ONE ENZIME 3, B-HSD IHNIBITOR COMPOUND| ES2375105T3|2001-06-18|2012-02-24|Noven Pharmaceuticals, Inc.|IMPROVED ADMINISTRATION OF MEDICINES IN TRANSDERMAL SYSTEMS.| US20020193758A1|2001-06-18|2002-12-19|Sca Hygiene Products Ab|Product| US7094228B2|2001-07-31|2006-08-22|Zars, Inc.|Methods and formulations for photodynamic therapy| CA2448235A1|2001-07-31|2003-02-13|Pfizer Products Inc.|Pharmaceutical compositions, kits and methods comprising combinations of estrogen agonists/antagonists, estrogens and progestins| DE10141652B4|2001-08-24|2011-04-07|Lts Lohmann Therapie-Systeme Ag|Transdermal therapeutic system based on polyacrylate pressure-sensitive adhesives without functional groups and its use| EP1455888B1|2001-08-29|2009-04-29|PharmaKodex Limited|Topical administration device| US6911438B2|2001-09-12|2005-06-28|Jonathan V. Wright|Hormone replacement formulation| DE10146541A1|2001-09-21|2003-04-17|Kade Pharma Fab Gmbh|Medicinal products based on progestogens for dermal use| AU2002330102A1|2001-09-28|2003-04-14|Aspenbio, Inc.|Bovine pregnancy test| KR20040037097A|2001-09-29|2004-05-04|솔베이 파머슈티컬스 게엠베하|Estrogen/gestagen combination preparation and application thereof| WO2003028667A2|2001-10-04|2003-04-10|Cellegy Pharmaceuticals, Inc.|Semisolid topical hormonal compositions and methods for treatment| US8101209B2|2001-10-09|2012-01-24|Flamel Technologies|Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles| AR026386A1|2001-10-24|2003-02-12|Massara Julio Eduardo|AN INTRAVAGINAL DEVICE CONTAINING PROGESTERONE, USEFUL AS A HAIR INDUCTOR IN MEAT AND MILK PRODUCING BOVES, AND THE PROCEDURE FOR PARAPREPARATION| US7815936B2|2001-10-30|2010-10-19|Evonik Degussa Gmbh|Use of granular materials based on pyrogenically produced silicon dioxide in pharmaceutical compositions| FR2832065B1|2001-11-13|2004-11-05|Besins Int Belgique|PHARMACEUTICAL COMPOSITION BASED ON MICRONIZED PROGESTERONE, PREPARATION METHOD THEREOF AND USES THEREOF| US20070196415A1|2002-11-14|2007-08-23|Guohua Chen|Depot compositions with multiple drug release rate controls and uses thereof| PT1446128E|2001-11-15|2007-03-30|Pantarhei Bioscience Bv|Use of estrogenic compounds in combination with progestogenic compounds in hormone-replacement therapy| WO2003041741A1|2001-11-15|2003-05-22|Pantarhei Bioscience B.V.|Method of preventing or treating benign gynaecological disorders| US20030166509A1|2001-11-20|2003-09-04|Advanced Inhalation Research, Inc.|Compositions for sustained action product delivery and methods of use thereof| FR2832311B1|2001-11-21|2004-04-16|Besins Int Belgique|FILM-FORMING POWDER, COMPOSITIONS COMPRISING SAME, PREPARATION METHODS AND USES THEREOF| DE10159120B4|2001-12-01|2006-08-17|Lts Lohmann Therapie-Systeme Ag|Steroid hormone-containing transdermal therapeutic systems containing propylene glycol monocaprylate and its use| AU2002353118A1|2001-12-11|2003-07-24|Dor Biopharma, Inc.|Lipid particles and suspensions and uses thereof| ES2188426B1|2001-12-12|2004-11-16|Rosalia Pidal Fernandez|PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF PSORIASIS AND OTHER DERMOPATIAS.| TWI332400B|2001-12-14|2010-11-01|Solvay Pharm Gmbh|Preformulation for the tableting of natural mixtures of conjugated estrogens| US7087636B2|2001-12-19|2006-08-08|Bristol-Myers Squibb Company|Fused heterocyclic compounds and analogs thereof, modulators of nuclear hormone receptor function| US7329654B2|2001-12-19|2008-02-12|Janssen Pharmaceutica N.V.|Heteroatom containing tetracyclic derivatives as selective estrogen receptor modulators| US6962908B2|2001-12-21|2005-11-08|Warner Chilcott Company Inc.|Oral pharmaceutical products containing 17 β-estradiol-3-lower alkanoate, method of administering the same and process of preparation| US7011846B2|2001-12-21|2006-03-14|Shire Laboratories, Inc.|Oral capsule formulation with increased physical stability| FR2834212B1|2001-12-27|2004-07-09|Besins Int Belgique|USE OF IMMEDIATE RELEASE POWDER IN PHARMACEUTICAL AND NUTRACEUTICAL COMPOSITIONS| US8591951B2|2002-05-15|2013-11-26|Joachim B. Kohn|Tri-block copolymers for nanosphere-based drug delivery| US6878518B2|2002-01-22|2005-04-12|The Trustees Of The University Of Pennsylvania|Methods for determining steroid responsiveness| US6901278B1|2002-01-29|2005-05-31|Morris Notelovitz|Methods for reducing the risk of breast cancer in and improving the health of women| BR0307544A|2002-02-01|2004-12-07|Ariad Gene Therapeutics Inc|Phosphorus-containing compounds, components and composition as well as their use by treatment methods| EP1474069A1|2002-02-08|2004-11-10|Advanced Animal Technology Limited|Control of a biological function| NZ517094A|2002-02-08|2005-03-24|Advanced Animal Technology Ltd|Improvements in and relating to substance delivery device| GB0203276D0|2002-02-12|2002-03-27|Novartis Ag|Organic compounds| JP2006503545A|2002-02-14|2006-02-02|ラター，ウィリアムジェイ．|Chimeric molecules for cleavage in the treated host| DE10206390A1|2002-02-15|2003-08-28|Bionorica Ag|Use of phytoestrogen-containing extracts that selectively modulate the estrogen receptor beta| JP5037779B2|2002-02-21|2012-10-03|バイエルファーマアクチエンゲゼルシャフト|Pharmaceutical composition comprising one or more steroids, one or more tetrahydrofolate components and vitamin B12| US7727720B2|2002-05-08|2010-06-01|Ravgen, Inc.|Methods for detection of genetic disorders| US20030175333A1|2002-03-06|2003-09-18|Adi Shefer|Invisible patch for the controlled delivery of cosmetic, dermatological, and pharmaceutical active ingredients onto the skin| US7741116B2|2002-03-06|2010-06-22|University Of Cincinnati|Surgical device for skin therapy or testing| ES2269999T3|2002-03-11|2007-04-01|Janssen Pharmaceutica N.V.|HORMONAL SUBSTITUTE THERAPY INHIBITING PROGESTAGEN CONTINUOUS SULFATASE.| CA2478206A1|2002-03-11|2003-09-25|Patrick Michel Caubel|Sulfatase inhibiting continuous progestogen contraceptive regimens| UA78027C2|2002-03-11|2007-02-15|Schering Ag|Use of 5-{2-hydroxy-3-[1- cyclopropyl]propyonylamino}phtalide and relative compounds possessing modulating activity relative to progesterone receptor for contraception and hormone replacement therapy| US20030225047A1|2002-03-11|2003-12-04|Caubel Patrick Michel|Sulfatase inhibiting progestogen-only contraceptive regimens| CN1622810A|2002-03-14|2005-06-01|华生制药公司|Progesterone oral drug delivery system| DE10211832A1|2002-03-16|2003-10-02|Lohmann Therapie Syst Lts|Hormone-containing transdermal therapeutic system with a drug reservoir based on vinyl acetate-vinylpyrrolidone copolymer with improved cohesion| FR2837100B1|2002-03-18|2004-07-23|Flamel Tech Sa|MODIFIED RELEASE MICROCAPSULE-BASED TABLETS| WO2003082247A2|2002-03-26|2003-10-09|Teva Pharmaceutical Industries Ltd.|Drug microparticles| US7300926B2|2002-04-01|2007-11-27|University Of Florida Research Foundation, Inc.|Steroidal quinols and their use for estrogen replacement therapy| EP1492515A1|2002-04-03|2005-01-05|Jencap Research Ltd.|Pharmaceutical composition comprising an aromatase inhibitor and an estrogen suitable for hormone replacement therapy for a male| US20030191096A1|2002-04-03|2003-10-09|Leonard Thomas W.|Method of hormonal therapy| IL164163D0|2002-04-09|2005-12-18|Pharmacia Corp|Process for preparing a finely self-emulsifiable pharmaceutical composition| US6750291B2|2002-04-12|2004-06-15|Pacific Corporation|Film-forming agent for drug delivery and preparation for percutaneous administration containing the same| DE10218109A1|2002-04-23|2003-11-20|Jenapharm Gmbh|Process for the production of crystals, then available crystals and their use in pharmaceutical formulations| MXPA04010392A|2002-04-23|2005-08-18|Nutrition 21 Inc|Chromium compositions and methods for using the same for inhibiting drug-induced insulin resistance.| UA87437C2|2002-04-26|2009-07-27|Бристол-Майерс Сквибб Компани Айседжен Инк|Treatment of hypertension in women receiving hormone replacement therapy| AU2003223754B2|2002-04-30|2007-08-16|Merck Sharp & Dohme Corp.|4-azasteroid derivatives as androgen receptor modulators| AT353632T|2002-05-03|2007-03-15|Pr Pharmaceuticals Inc|COMPOSITIONS OF ESTRADIOL METABOLITES WITH CONTROLLED RELEASE| US6821524B2|2002-06-03|2004-11-23|Jan Marini Skin Research, Inc.|Cosmetic skin care compositions| US6943021B2|2002-06-07|2005-09-13|Mattek Corporation|Three dimensional vaginal tissue model containing immune cells| US7414043B2|2002-06-11|2008-08-19|Schering Ag|9-α-substituted estratrienes as selectively active estrogens| AU2003274941A1|2002-06-11|2003-12-22|Pantarhei Bioscience B.V.|A method of treating human skin and a skin care composition for use in such a method| US20040048900A1|2002-06-17|2004-03-11|Pamela Flood|Nicotine and/or nicotine agonists for the treatment of general anesthetic effects and side effects| US20050186141A1|2002-06-25|2005-08-25|Acrux Dds Pty Ltd.|Transdermal aerosol compositions| FR2841138B1|2002-06-25|2005-02-25|Cll Pharma|SOLID PHARMACEUTICAL COMPOSITION COMPRISING A LIPOPHILIC ACTIVE INGREDIENT, ITS PREPARATION PROCESS| KR100533458B1|2002-07-20|2005-12-07|대화제약 주식회사|Composition for solubilization of paclitaxel and preparation method thereof| EP1524983B1|2002-07-25|2008-01-02|Bayer Schering Pharma Aktiengesellschaft|Composition containing an androgenous 11-b-halogen steroid and a progestational hormone, and male contraceptive based on said composition| US6960337B2|2002-08-02|2005-11-01|Balance Pharmaceuticals, Inc.|Methods and compositions for treating benign gynecological disorders| US8268352B2|2002-08-05|2012-09-18|Torrent Pharmaceuticals Limited|Modified release composition for highly soluble drugs| TR200201966A2|2002-08-07|2004-02-23|Edko Pazarlama Tanitim Ti̇caret Li̇mi̇ted Şi̇rketi̇|Pharmaceutical composition.| AU2002950713A0|2002-08-09|2002-09-12|Vital Health Sciences Pty Ltd|Carrier| US20030049307A1|2002-08-15|2003-03-13|Gyurik Robert J.|Pharmaceutical composition| DE60330679D1|2002-08-20|2010-02-04|Univ Singapore|PHYTOPROGESTOGENIC EXTRACTS FROM RHIZOMA LIGUSTICUM CHUANXIONG AND ITS USES| RS20050184A|2002-08-28|2007-11-15|RobertCasper|Estrogen replacement regimen| US7497855B2|2002-09-04|2009-03-03|Microchips, Inc.|Method and device for the controlled delivery of parathyroid hormone| DE60330695D1|2002-09-05|2010-02-04|Pantarhei Bioscience Bv|ORAL PHARMACEUTICAL COMPOSITION CONTAINING 15-HYDROXYTESTOSTERONE AND ITS DERIVATIVES| US6967194B1|2002-09-18|2005-11-22|Susan Matsuo|Bio-identical hormones and method of use| GB0222522D0|2002-09-27|2002-11-06|Controlled Therapeutics Sct|Water-swellable polymers| US7458982B2|2002-10-04|2008-12-02|Photokinetix, Inc.|Photokinetic delivery of biologically active substances using pulsed incoherent light| DE10247399A1|2002-10-08|2004-04-29|Schering Ag|Pharmaceutical preparations, use of this preparation and methods for increasing the bioavailability of drugs to be administered orally| US20040146894A1|2002-10-14|2004-07-29|Warrington Janet A.|Methods of diagnosing and treating stress urinary incontinence| GB0224415D0|2002-10-21|2002-11-27|Medical Res Council|Compositions| DE60318092T2|2002-10-23|2008-11-27|Pantarhei Bioscience B.V.|PHARMACEUTICAL COMPOSITION CONTAINING ESTETROL DERIVATIVES AND APPLICATION IN CANCER TREATMENT| US20060018937A1|2002-10-25|2006-01-26|Foamix Ltd.|Steroid kit and foamable composition and uses thereof| NZ540166A|2002-10-25|2007-06-29|Foamix Ltd|Cosmetic and pharmaceutical foam| US20060193789A1|2002-10-25|2006-08-31|Foamix Ltd.|Film forming foamable composition| IL152486D0|2002-10-25|2003-05-29|Meir Eini|Alcohol-free cosmetic and pharmaceutical foam carrier| EP1562975A2|2002-10-25|2005-08-17|Yissum Research Development Company Of The Hebrew University Of Jerusalem|Steroid compounds comprising superoxide dismutase mimic groups and nitric oxide donor groups, and their use in the preparation of medicaments| US20080206161A1|2002-10-25|2008-08-28|Dov Tamarkin|Quiescent foamable compositions, steroids, kits and uses thereof| DE10249853A1|2002-10-25|2004-05-13|Liedtke, Rainer K., Dr.|Flexible, plaster-type chip heating system, for thermodynamic control of topical dermal systems, including supporting matrix, electrical energy source, controlling microprocessor and electric heater| US20070292359A1|2002-10-25|2007-12-20|Foamix Ltd.|Polypropylene glycol foamable vehicle and pharmaceutical compositions thereof| US20040087564A1|2002-10-31|2004-05-06|Wright D. Craig|Delivery composition and method| US20040138103A1|2002-11-07|2004-07-15|Procyte Corporation|Compositions containing peptide copper complexes and metalloproteinase inhibitors and methods related thereto| US20040093261A1|2002-11-08|2004-05-13|Vivek Jain|Automatic validation of survey results| US20040089308A1|2002-11-13|2004-05-13|Welch Robert A.|Cervical ring to deliver medication| US20040097468A1|2002-11-20|2004-05-20|Wimalawansa Sunil J.|Method of treating osteoporosis and other bone disorders with upfront loading of bisphosphonates, and kits for such treatment| US7674783B2|2002-11-22|2010-03-09|Dimera Inc.|Estrogen beta receptor agonists to prevent or reduce the severity of cardiovascular disease| AU2003291872A1|2002-12-04|2004-06-23|Inrs |An exopolysaccharides delivery system for active molecules| FR2848112B1|2002-12-10|2007-02-16|Besins Int Belgique|PHARMACEUTICAL COMPOSITION FOR TRANSDERMAL OR TRANSMUCTIVE DELIVERY COMPRISING AT LEAST ONE PROGESTATIVE AND / OR AT LEAST ONE OESTROGEN, PREPARATION METHOD AND USES THEREOF| US20040115226A1|2002-12-12|2004-06-17|Wenji Li|Free-flowing solid formulations with improved bio-availability of poorly water soluble drugs and process for making the same| EP1428526A1|2002-12-13|2004-06-16|Rijksuniversiteit Groningen|Formulation for fast dissolution of lipophilic compounds| US20040115287A1|2002-12-17|2004-06-17|Lipocine, Inc.|Hydrophobic active agent compositions and methods| US20040121003A1|2002-12-19|2004-06-24|Acusphere, Inc.|Methods for making pharmaceutical formulations comprising deagglomerated microparticles| US20050031651A1|2002-12-24|2005-02-10|Francine Gervais|Therapeutic formulations for the treatment of beta-amyloid related diseases| FR2849380A1|2002-12-27|2004-07-02|Ernest Loumaye|Treating sterility in female mammals, especially women, by administration of gonadotrophin-releasing hormone agonist in composition adapted for supporting the luteal phase| CA2552690C|2002-12-31|2014-12-09|Ultra-Sonic Technologies, L.L.C.|Transdermal delivery using encapsulated agent activated by ultrasound and/or heat| FR2849597B1|2003-01-08|2006-12-08|Oreal|COSMETIC COMPOSITION FOR THE CARE OF OIL SKIN CONTAINING A CARBOXYLIC FATTY ACID OR ONE OF ITS DERIVATIVES| US7572780B2|2003-01-21|2009-08-11|Dimera, Incorporated|Method and kit for reducing the symptoms of peripheral vascular disease| US20040146539A1|2003-01-24|2004-07-29|Gupta Shyam K.|Topical Nutraceutical Compositions with Selective Body Slimming and Tone Firming Antiaging Benefits| US20090318558A1|2003-02-12|2009-12-24|Jae-Hwan Kim|Solvent system of hardly soluble drug with improved dissolution rate| US20040161435A1|2003-02-14|2004-08-19|Gupta Shyam K.|Skin Firming Anti-Aging Cosmetic Mask Compositions| US20060194775A1|2003-02-20|2006-08-31|University Of Pittsburgh|Estradiol metabolites for the treatment of pulmonary hypertension| FR2851470B1|2003-02-20|2007-11-16|Besins Int Belgique|PHARMACEUTICAL COMPOSITION FOR TRANSDERMAL OR TRANSMUCTIVE DELIVERY| KR100704825B1|2003-02-21|2007-04-09|바이엘 쉐링 파마 악티엔게젤샤프트|Uv stable transdermal therapeutic plaster| FR2851918B1|2003-03-06|2006-06-16|IMPREGNATED POWDER ENHANCING BIOAVAILABILITY AND / OR SOLUBILITY AND METHOD OF MANUFACTURE| US20040198706A1|2003-03-11|2004-10-07|Carrara Dario Norberto R.|Methods and formulations for transdermal or transmucosal application of active agents| US7858607B2|2003-03-14|2010-12-28|Mamchur Stephen A|System for use by compounding pharmacists to produce hormone replacement medicine customized for each consumer| US6956099B2|2003-03-20|2005-10-18|Arizona Chemical Company|Polyamide-polyether block copolymer| AT515493T|2003-03-31|2011-07-15|Council Scient Ind Res|MERCAPOTOPHENYL NAPHTHYLMETHANE DERIVATIVES AND THEIR PREPARATION| US20040191207A1|2003-03-31|2004-09-30|Lipari John M.|Alpha-hydroxy acid ester drug delivery compositions and methods of use| WO2004096151A2|2003-04-29|2004-11-11|The General Hospital Corporation|Methods and devices for the sustained release of multiple drugs| US20050020550A1|2003-04-29|2005-01-27|Morris David J.|Selective testicular 11beta-HSD inhibitors and methods of use thereof| EP1620193B1|2003-04-29|2008-09-03|N.V. Organon|Antisolvent solidification process| US20040219124A1|2003-05-01|2004-11-04|Gupta Shyam K.|Cosmetic and Pharmaceutical Masks Based on Ion-Pair Delivery System| JP4422430B2|2003-05-14|2010-02-24|帝國製薬株式会社|External patch containing estrogen and / or progestogen| US7925519B2|2003-05-20|2011-04-12|Medencentive, Llc|Method and system for delivery of healthcare services| ES2274456T3|2003-05-22|2007-05-16|Pantarhei Bioscience B.V.|USE OF COMPOSITIONS THAT INCLUDE A STROGEN COMPONENT FOR THE TREATMENT AND PREVENTION OF MUSCLE SKELETY PAIN.| US20060165744A1|2003-05-22|2006-07-27|Neopharm, Inc|Combination liposomal formulations| TWI336627B|2003-05-23|2011-02-01|Organon Nv|Drug delivery system,and use and manufacturing method thereof| US20040243437A1|2003-05-30|2004-12-02|Grace Joseph P.|Compensated electronic consults| US7668735B2|2003-05-30|2010-02-23|Mdrxdirect Inc.|Compensated electronic consults| US20090227025A1|2003-06-06|2009-09-10|The Board Of Regents Of The University Of Texas System|Ex vivo human lung/immune system model using tissue engineering for studying microbial pathogens with lung tropism| US20040253319A1|2003-06-11|2004-12-16|Shrirang Netke|Pharmaceutical compositions and method for alleviating side-effects of estrogen replacement therapy| MX2008014654A|2003-06-13|2009-03-09|John Claude Savoir|Process for the manufacture of stable shaped particles consisting of estradiol and cholesterol.| US20040259852A1|2003-06-18|2004-12-23|White Hillary D.|Trandsdermal compositions and methods for treatment of fibromyalgia and chronic fatigue syndrome| US20110318405A1|2003-06-25|2011-12-29|Charles Erwin|Chemical Combination and Method for Increasing Delivery of Coenzyme Q10| CN1812746B|2003-06-27|2011-07-06|孕体有限公司|Methods and devices for occluding body lumens and/or for delivering therapeutic agents| US7074779B2|2003-07-02|2006-07-11|Ortho-Mcneil Pharmaceutical, Inc.|Estrieno[3,2-b]/[3,4-c]pyrrole derivatives useful as modulators of the estrogen receptors| MXPA06000117A|2003-07-08|2006-04-27|Novartis Ag|Use of rapamycin and rapamycin derivatives for the treatment of bone loss.| AU2004257674A1|2003-07-11|2005-01-27|Macrochem Corporation|Pharmaceutical compositions for topical application| US20050014729A1|2003-07-16|2005-01-20|Pharmacia Corporation|Method for the treatment or prevention of dermatological disorders with a cyclooxygenase-2 inhibitor alone and in combination with a dermatological treatment agent and compositions therewith| ES2237298B1|2003-07-16|2006-11-01|Italfarmaco, S.A.|SEMISOLID MUCOADHESIVE FORMULATIONS.| US20050042268A1|2003-07-16|2005-02-24|Chaim Aschkenasy|Pharmaceutical composition and method for transdermal drug delivery| US20050020552A1|2003-07-16|2005-01-27|Chaim Aschkenasy|Pharmaceutical composition and method for transdermal drug delivery| US20050025833A1|2003-07-16|2005-02-03|Chaim Aschkenasy|Pharmaceutical composition and method for transdermal drug delivery| US20070292461A1|2003-08-04|2007-12-20|Foamix Ltd.|Oleaginous pharmaceutical and cosmetic foam| US20080069779A1|2003-08-04|2008-03-20|Foamix Ltd.|Foamable vehicle and vitamin and flavonoid pharmaceutical compositions thereof| US7820145B2|2003-08-04|2010-10-26|Foamix Ltd.|Oleaginous pharmaceutical and cosmetic foam| US7704518B2|2003-08-04|2010-04-27|Foamix, Ltd.|Foamable vehicle and pharmaceutical compositions thereof| US8795693B2|2003-08-04|2014-08-05|Foamix Ltd.|Compositions with modulating agents| US8486374B2|2003-08-04|2013-07-16|Foamix Ltd.|Hydrophilic, non-aqueous pharmaceutical carriers and compositions and uses| WO2005023179A2|2003-08-29|2005-03-17|Aton Pharma, Inc.|Combination methods of treating cancer| KR101288265B1|2003-09-03|2013-07-26|미스콘 트레이딩 에스.에이.|Methods for the treatment of endometriosis| PT1663185E|2003-09-22|2009-02-16|Onepharm Res & Dev Gmbh|Prevention and treatment of inflammation-induced and/or immune-mediated bone loss| EP1670440B1|2003-09-29|2014-04-30|Novo Nordisk Femcare AG|Hrt formulations| EP1673071A1|2003-09-29|2006-06-28|Novo Nordisk Femcare AG|Improved stability of progestogen formulations| JP2005104862A|2003-09-29|2005-04-21|Meiji Milk Prod Co Ltd|Aged macular degeneration therapeutic agent| HU0303313A2|2003-10-09|2005-07-28|Richter Gedeon Vegyészeti Gyár Rt.|Transdermal pharmaceutical compositions| US7247625B2|2003-10-09|2007-07-24|Wyeth|6-amino-1,4-dihydro-benzo[d][1,3] oxazin-2-ones and analogs useful as progesterone receptor modulators| TW200517114A|2003-10-15|2005-06-01|Combinatorx Inc|Methods and reagents for the treatment of immunoinflammatory disorders| CA2542661A1|2003-10-16|2005-05-06|The Administrators Of The Tulane Educational Fund|Methods and compositions for treating cancer| WO2005039537A1|2003-10-22|2005-05-06|Lidds Ab|Composition comprising biodegradable hydrating ceramics for controlled drug delivery| EP1682074B1|2003-10-24|2012-02-08|Nora Therapeutics, Inc.|Compositions and methods for healthy pregnancy| US20050101579A1|2003-11-06|2005-05-12|Shippen Eugene R.|Endometriosis treatment protocol| DE60303854T2|2003-11-11|2006-08-10|Mattern, Udo|Nose formulation with controlled release of sex hormones| CN1878558A|2003-11-14|2006-12-13|沃纳奇尔科特公司|Graduated estrogen contraceptive| US7517994B2|2003-11-19|2009-04-14|Array Biopharma Inc.|Heterocyclic inhibitors of MEK and methods of use thereof| EP1535618A1|2003-11-26|2005-06-01|Schering Aktiengesellschaft|Pharmaceutical preparation for continuous hormonal treatment over a period of longer than 21-28 days comprising two estrogen and/or progestin compositions| US20050113350A1|2003-11-26|2005-05-26|Bernd Duesterberg|Extended use combination comprising estrogens and progestins| US20050186183A1|2003-12-08|2005-08-25|Deangelo Joseph|Stabilized products, processes and devices for preparing same| EP1727520A2|2003-12-09|2006-12-06|Medcrystalforms, Llc|Method of preparation of mixed phase co-crystals with active agents| US20050129756A1|2003-12-10|2005-06-16|Hans-Peter Podhaisky|UV-stable, liquid or semisolid transdermal pharmaceutical preparation with light sensitive active ingredient| CA2548596A1|2003-12-10|2005-06-23|Acrux Dds Pty Ltd.|Method of treatment for undesired effect following transdermal or topical drug delivery| MXPA06006810A|2003-12-17|2006-08-23|Pfizer Prod Inc|Continuous combination therapy with selective prostaglandin ep4, receptor agonists and an estrogen for the treatment of conditions that present with low bone mass.| US20050153946A1|2003-12-24|2005-07-14|Collegium Pharmaceuticals, Inc.|Temperature-stable formulations, and methods of development thereof| AU2004308594A1|2003-12-29|2005-07-14|Universitaetsklinikum Muenster|Means for stimulation and activation of hair growth by IL-15| IL159729D0|2004-01-06|2004-06-20|Doron I Friedman|Non-aqueous composition for oral delivery of insoluble bioactive agents| AU2005204685B2|2004-01-07|2007-06-21|E-L Management Corporation|Cosmetic composition and method for retarding hair growth| US20060084704A1|2004-01-28|2006-04-20|Charles Shih|Methods and compositions for enhancing degradation of nuclear receptor transcription factors and uses thereof| US20050182105A1|2004-02-04|2005-08-18|Nirschl Alexandra A.|Method of using 3-cyano-4-arylpyridine derivatives as modulators of androgen receptor function| US7820702B2|2004-02-04|2010-10-26|Bristol-Myers Squibb Company|Sulfonylpyrrolidine modulators of androgen receptor function and method| US20050271597A1|2004-02-13|2005-12-08|Keith Alec D|Prostate hypertrophy treatment composition and method| SI2351555T1|2004-02-23|2017-01-31|Euro-Celtique S.A.|Abuse resistance opioid transdermal delivery device| US8052669B2|2004-02-25|2011-11-08|Femasys Inc.|Methods and devices for delivery of compositions to conduits| US8147561B2|2004-02-26|2012-04-03|Endosphere, Inc.|Methods and devices to curb appetite and/or reduce food intake| US7378426B2|2004-03-01|2008-05-27|Bristol-Myers Squibb Company|Fused heterotricyclic compounds as inhibitors of 17β-hydroxysteroid dehydrogenase 3| US7417040B2|2004-03-01|2008-08-26|Bristol-Myers Squibb Company|Fused tricyclic compounds as inhibitors of 17β-hydroxysteroid dehydrogenase 3| US20050196434A1|2004-03-04|2005-09-08|Brierre Barbara T.|Pharmaceutical composition and method for the transdermal delivery of magnesium| MY142989A|2004-03-10|2011-02-14|Bayer Schering Pharma Ag|Stabilised supersaturated solids of lipophilic drugs| US20050220825A1|2004-03-10|2005-10-06|Adrian Funke|Molecular dispersions of drospirenone| BRPI0508612A|2004-03-10|2007-08-14|Schering Aktiengellschaft|compositions comprising molecularly dispersed drospirenone| US20050222106A1|2004-04-01|2005-10-06|Stefan Bracht|Drospirenone-containing preparations for transdermal use| WO2005099676A2|2004-04-07|2005-10-27|Dermatrends, Inc.|Transdermal delivery system for use with basic permeation enhancers| US20050228692A1|2004-04-08|2005-10-13|Hodgdon Darren W|Incentive based health care insurance program| US20050228718A1|2004-04-13|2005-10-13|Pop Insights Inc.|Point of purchase research device| US20050239747A1|2004-04-21|2005-10-27|Pharmaceutical Industry Technology And Development Center|Compositions and methods of enhanced transdermal delivery of steroid compounds and preparation methods| US20050239758A1|2004-04-21|2005-10-27|Roby Russell R|Hormone treatment of multiple sclerosis| RU2275930C2|2004-04-26|2006-05-10|ООО "РусГен"|Composition for correction of human endocrine system age-related changes and method for production of pharmaceutical formulation based on the same| US20050244522A1|2004-04-30|2005-11-03|Carrara Dario Norberto R|Permeation enhancer comprising genus Curcuma or germacrone for transdermal and topical administration of active agents| WO2005107719A2|2004-05-06|2005-11-17|Sandoz Ag|Pharmaceutical composition comprising hydrophobic drug having improved solubility| US20050250746A1|2004-05-06|2005-11-10|Matthew Iammatteo|Premenstrual dysphoric disorder medication| FR2870125B1|2004-05-12|2010-03-26|Dermaconcept Jmc|FORMULATION OF THE SPOT-ON TYPE USEFUL IN COSMETOLOGY AND DERMATOLOGY| US7899527B2|2004-05-13|2011-03-01|Palo Alto Investors|Treatment of conditions through modulation of the autonomic nervous system during at least one predetermined menstrual cycle phase| US8048017B2|2005-05-18|2011-11-01|Bai Xu|High-aspect-ratio microdevices and methods for transdermal delivery and sampling of active substances| US7534780B2|2004-05-21|2009-05-19|Bayer Schering Pharma Aktiengesellschaft|Estradiol prodrugs| US7101342B1|2004-05-24|2006-09-05|Caillouette James C|Detection of menopause status and treatment thereof| AU2005249401A1|2004-05-26|2005-12-15|Wyeth|Compositions and methods for treatment of premenstrual dysphoric disorder| US20070196453A1|2004-06-07|2007-08-23|Jie Zhang|Two or more non-volatile solvent-containing compositions and methods for dermal delivery of drugs| WO2005120517A1|2004-06-07|2005-12-22|Strides Arcolab Limited|Stable liquid suspension formulation comprising synthetic steroids and process for producing the same| DE102004028284A1|2004-06-11|2006-01-05|Hexal Ag|Matrix-controlled transdermal therapeutic system based on a hotmelt adhesive for the application of norelgestromin| US7485666B2|2004-06-17|2009-02-03|Kimberly-Clark Worldwide, Inc.|Vaginal health products| US7235563B2|2004-06-21|2007-06-26|Bristol-Myers Squibb Company|Spirocyclic compounds useful as modulators of nuclear hormone receptor function| SV2006002165A|2004-07-07|2006-05-09|Wyeth Corp|CYCLICAL PROGESTINE REGIMES AND KITS REF. AM101677| FR2873585B1|2004-07-27|2006-11-17|Aventis Pharma Sa|NEW GALENIC FORMULATIONS OF ACTIVE PRINCIPLES| KR101234885B1|2004-08-04|2013-02-19|카무러스 에이비|Compositions forming non-lamellar dispersions| GT200500185A|2004-08-09|2006-04-10|PROGESTERONE RECEIVER MODULATORS UNDERSTANDING PIRROL-OXINDOL DERIVATIVES AND THEIR USES| GT200500183A|2004-08-09|2006-04-10|PROGESTERONE RECEIVER MODULATORS UNDERSTANDING PIRROL-OXINDOL DERIVATIVES AND THEIR USES| US20060034889A1|2004-08-16|2006-02-16|Macromed, Inc.|Biodegradable diblock copolymers having reverse thermal gelation properties and methods of use thereof| TW200616604A|2004-08-26|2006-06-01|Nicholas Piramal India Ltd|Nitric oxide releasing prodrugs containing bio-cleavable linker| US7879830B2|2004-09-02|2011-02-01|Wiley Teresa S|Hormone replacement composition and method| US20070167418A1|2004-09-07|2007-07-19|Ferguson Steven W|Progesterone/testosterone cream for erectile dysfunction| ES2383193T3|2004-09-09|2012-06-19|Warburton Technology Limited|Trace elements| AR043476A1|2004-09-09|2005-08-03|Dvoskin Victor Oscar|REGULATED SUBSTANCE ADMINISTRATION DEVICE FOR INSERTION IN A BODY CAVITY AND PROCEDURE FOR MANUFACTURING A SUPPORT MEDIA FOR SUCH SUBSTANCES| JP2008513375A|2004-09-13|2008-05-01|ピーアールファーマシューティカルズ，インコーポレイテッド|Long-acting injectable crystalline formulations of estradiol metabolites and methods of use thereof| US8252321B2|2004-09-13|2012-08-28|Chrono Therapeutics, Inc.|Biosynchronous transdermal drug delivery for longevity, anti-aging, fatigue management, obesity, weight loss, weight management, delivery of nutraceuticals, and the treatment of hyperglycemia, alzheimer's disease, sleep disorders, parkinson's disease, aids, epilepsy, attention deficit disorder, nicotine addiction, cancer, headache and pain control, asthma, angina, hypertension, depression, cold, flu and the like| US20060058238A1|2004-09-15|2006-03-16|Lee Laurent-Applegate|Fetal skin cell protein compositions for the treatment of skin conditions, disorders or diseases and methods of making and using the same| US20070254314A1|2004-09-16|2007-11-01|Geier Mark R|Methods of treating autism and autism spectrum disorders| US7338973B2|2004-09-20|2008-03-04|Janssen Pharmaceutica N.V.|Tetracyclic heteroatom containing derivatives useful as sex steroid hormone receptor modulators| US20060062758A1|2004-09-21|2006-03-23|Nastech Pharmaceutical Comapny Inc.|Tight junction modulator peptide PN159 for enhanced mucosal delivery of therapeutic compounds| US20090197843A1|2004-09-27|2009-08-06|Pantarhei Bioscience B.V.|Treatment of Prevention of Unscheduled Bleeding in Women on Progestogen Containing Medication| WO2006036899A2|2004-09-27|2006-04-06|Corium International, Inc.|Transdermal systems for the delivery of estrogens and progestins| US20070111975A1|2004-10-07|2007-05-17|Duramed Pharmaceuticals, Inc.|Methods of Hormonal Treatment Utilizing Ascending-Dose Extended Cycle Regimens| US7569725B2|2004-10-21|2009-08-04|Britsol-Myers Squibb Company|Anthranilic acid derivatives as inhibitors of 17β-hydroxysteroid dehydrogenase 3| US8022053B2|2004-11-02|2011-09-20|Bayer Schering Pharma Aktiengesellschaft|Oral solid dosage forms containing a low dose of estradiol| WO2006051818A1|2004-11-10|2006-05-18|Hisamitsu Pharmaceutical Co., Inc.|Drug for external use and adhesive patch| US20060106004A1|2004-11-12|2006-05-18|Brody Steven A|Unique methods and formulations of bio-identical sex steroids for the treatment of pathophysiologic aberrations of menopause| US20060110415A1|2004-11-22|2006-05-25|Bioderm Research|Topical Delivery System for Cosmetic and Pharmaceutical Agents| US7465587B2|2004-12-03|2008-12-16|Genzyme Corporation|Diagnostic assay device| US8121886B2|2004-12-03|2012-02-21|Ryma Technology Solutions Inc.|Confidence based selection for survey sampling| AT501408B1|2004-12-07|2011-03-15|Physikalisches Buero Steinmueller Gmbh|BIOLOGICAL SURFACES| AU2005316833B2|2004-12-17|2012-03-08|Bionovo, Inc.|Estrogenic extracts of Morus alba and uses thereof| US20060134188A1|2004-12-20|2006-06-22|Hans-Peter Podhaisky|Transdermal pharmaceutical preparation with a progesterone A-specific ligand as active ingredient| US20070060589A1|2004-12-21|2007-03-15|Purandare Ashok V|Inhibitors of protein arginine methyl transferases| ITMI20050262A1|2005-02-21|2006-08-22|Carlo Ghisalberti|SUBSTANCES COMPOSITIONS AND METHODS OF TREATMENT OF ALOPECIA| US8703198B2|2005-03-02|2014-04-22|Aquatrove Biosciences|Water-based personal moisturizers and lubricants, in particular vaginal lubricants, and uses thereof| US7473687B2|2005-03-24|2009-01-06|Emory University|Methods for the treatment of a traumatic central nervous system injury| RU2406480C2|2005-04-08|2010-12-20|Озфарма Пти Лтд|Transbuccal delivery system| US20070154533A1|2005-04-13|2007-07-05|Dudley Robert E|Method of increasing testosterone and related steriod concentrations in women| WO2006113458A1|2005-04-15|2006-10-26|Bristol-Myers Squibb Company|Heterocyclic inhibitors of protein arginine methyl transferases| EP2985026A1|2005-04-15|2016-02-17|Clarus Therapeutics, Inc.|Pharmaceutical delivery systems for hydrophobic drugs and compositions comprising same| US9205047B2|2005-04-25|2015-12-08|The Governing Council Of The University Of Toronto|Tunable sustained release of a sparingly soluble hydrophobic therapeutic agent from a hydrogel matrix| US7767656B2|2005-04-25|2010-08-03|Molly S Shoichet|Blends of temperature sensitive and anionic polymers for drug delivery| US8962013B2|2005-05-02|2015-02-24|Bayer Intellectual Property Gmbh|Multi-layered transdermal system with triazine UV absorber| US20060252049A1|2005-05-04|2006-11-09|Shuler Richard O|Growth-promoting and immunizing subcutaneous implant| US20060251581A1|2005-05-09|2006-11-09|Mcintyre Jon T|Method for treatment of uterine fibroid tumors| US7862552B2|2005-05-09|2011-01-04|Boston Scientific Scimed, Inc.|Medical devices for treating urological and uterine conditions| US8663681B2|2005-05-26|2014-03-04|Teva Women's Health, Inc.|Oral dosage forms comprising progesterone and methods of making and using the same| CN102091079B|2005-06-03|2014-03-12|艾克若克斯Dds有限公司|Method and composition for transdermal drug delivery| ITBO20050388A1|2005-06-06|2006-12-07|Alfa Wassermann Spa|USEFUL FORMULATION OF MUCOADESIVES IN MEDICAL DEVICES IN PHARMACEUTICAL PREPARATIONS| US20060280795A1|2005-06-08|2006-12-14|Dexcel Pharma Technologies, Ltd.|Specific time-delayed burst profile delivery system| TW200716137A|2005-06-09|2007-05-01|Wyeth Corp|Tanaproget compositions containing ethinyl estradiol| EP1898880A2|2005-06-16|2008-03-19|Warner Chilcott Company Inc.|Gel compositions for topical administration| CA2612415A1|2005-06-16|2006-12-28|Warner Chilcott Company, Inc.|Estrogen compositions for vaginal administration| EP1904028A1|2005-06-16|2008-04-02|Warner Chilcott Company Inc.|Estrogen compositions for vaginal administration| TW200726473A|2005-06-28|2007-07-16|Wyeth Corp|Compositions and methods for treatment of cycle-related symptoms| US8461138B2|2005-06-29|2013-06-11|Warner Chilcott Company, Llc|Quadraphasis continuous graduated estrogen contraceptive| US20070010550A1|2005-07-08|2007-01-11|The Board Of Regents Of The University Of Texas|Scopolamine to Reduce or Eliminate Hot Flashes, Night Sweats, and Insomnia| US20070014839A1|2005-07-18|2007-01-18|Stefan Bracht|Decomposer film for transdermal patches| DE102005034498A1|2005-07-20|2007-01-25|Grünenthal GmbH|Oral contraception with Trimegeston| US8195403B2|2005-07-21|2012-06-05|The Invention Science Fund I, Llc|Selective resonance of bodily agents| US20070027107A1|2005-07-29|2007-02-01|Curt Hendrix|Compositions and methods for treating estrogen-dependent diseases and conditions| PE20070341A1|2005-07-29|2007-04-13|Wyeth Corp|PIRROL DERIVATIVES AS PROGESTERONE RECEPTOR MODULATORS| US10137135B2|2005-08-15|2018-11-27|Allergan Sales, Llc|Formulations and methods for providing progestin-only contraception while minimizing adverse side effects associated therewith| CA2622721A1|2005-09-16|2007-03-22|Cereuscience Ab|Method and means of preventing and treating sleep disordered breathing| US20070066628A1|2005-09-19|2007-03-22|Wyeth|5-Aryl-indan-1-ol and analogs useful as progesterone receptor modulators| US7319152B2|2005-09-19|2008-01-15|Wyeth|5-Aryl-indan-1-one and analogs useful as progesterone receptor modulators| US7414142B2|2005-09-19|2008-08-19|Wyeth|5-aryl-indan-1-one oximes and analogs useful as progesterone receptor modulators| CA2664629A1|2005-09-27|2007-04-05|Christopher Gregg|Oligodendrocyte precursor cell proliferation regulated by prolactin| EA200800974A1|2005-09-29|2008-10-30|Репрос Терапьютикс Инк.|COMPOSITIONS WITH IMPROVED BIO-ACCESSIBILITY, CONTAINING STEROID DERIVATIVE AND POLYGLYCOLIZED GLYCERID| US8372806B2|2005-10-06|2013-02-12|Pantec Biosolutions Ag|Transdermal delivery system for treating infertility| US7550458B2|2005-10-18|2009-06-23|Bristol-Myers Squibb Company|Tricycloundecane compounds useful as modulators of nuclear hormone receptor function| CA2626518A1|2005-10-19|2007-04-26|Scott Josephson|Improved reproductive management| JP5449775B2|2005-10-19|2014-03-19|チャバフピーティーワイエルティーディー|Reduction of side effects with aromatase inhibitors used to treat breast cancer| US8096940B2|2005-10-19|2012-01-17|Iversync Ii Llc|Reproductive management| DE102005050729A1|2005-10-19|2007-04-26|Schering Ag|Method of preventive on-demand hormonal contraception| EP1952162A2|2005-10-24|2008-08-06|Manawatu Biotech Investments Ltd. |Ovulation cycle monitoring and management| CA2626579A1|2005-10-25|2007-05-03|Abbott Laboratories|Formulation comprising a drug of low water solubility and method of use thereof| US20070093548A1|2005-10-25|2007-04-26|Wyeth|Use of progesterone receptor modulators| IE20050723A1|2005-10-28|2007-05-30|Patrick T Prendergast|Anti-mineralocorticoid therapy of infection| US8158152B2|2005-11-18|2012-04-17|Scidose Llc|Lyophilization process and products obtained thereby| EP1951216A2|2005-11-22|2008-08-06|SmithKline Beecham Corporation|Chemical compounds| US20080255089A1|2005-11-22|2008-10-16|Smithkline Beecham Corporation|Triphenylethylene Compounds Useful as Selective Estrogen Receptor Modulators| JP2009516746A|2005-11-22|2009-04-23|スミスクラインビーチャムコーポレーション|Compound| JP2009516696A|2005-11-22|2009-04-23|スミスクラインビーチャムコーポレーション|Chemical compound| EP1951217A4|2005-11-22|2009-08-12|Smithkline Beecham Corp|Chemical compounds| US20070116829A1|2005-11-23|2007-05-24|The Coca-Cola Company|Pharmaceutical Composition with High-Potency Sweetener| TWI389709B|2005-12-01|2013-03-21|Novartis Ag|Transdermal therapeutic system| GB0524961D0|2005-12-07|2006-01-18|Pharmakodex Ltd|Transdermal administration of active agents for systemic effect| WO2007070875A1|2005-12-15|2007-06-21|Aerosol Science Laboratories, Inc.|Treatment of active infections and related compositions| WO2007070851A2|2005-12-15|2007-06-21|Acusphere, Inc.|Processes for making particle-based pharmaceutical formulations for pulmonary or nasal administration| US20090093440A1|2005-12-20|2009-04-09|Howard Murad|Fragranced Therapeutic Delivery System| KR101697833B1|2005-12-22|2017-01-18|오츠카 세이야쿠 가부시키가이샤|Method of producing drug-containing wax matrix particles, extruder to be used in the method and sustained-release preparation containing cilostazol| EP1976869A2|2005-12-23|2008-10-08|Partnership&Corp. Technology Transfer|Synthetic peptides for use as inhibitors of neurotransmitter secretion and as inducers of muscle relaxation| US9393218B2|2005-12-23|2016-07-19|Epinamics Gmbh|Use of film-forming hair care polymers from the group of polyurethanes and pharmaceutical preparations and patches that contain these polymers| EP1971325A2|2005-12-27|2008-09-24|Duramed Pharmaceuticals, Inc.|Conjugated estrogen compositions, applicators, kits, and methods of making and use thereof| EA017682B1|2005-12-28|2013-02-28|Фресениус Каби Онколоджи Лтд.|Polymer and process for obtaining same, pharmaceutical composition in nanoparticulate form, process and kit for preparation thereof and method of treating pathological conditions in humans or animals| JP5285279B2|2005-12-28|2013-09-11|久光製薬株式会社|Transdermal preparation| KR100750320B1|2006-01-04|2007-08-17|학교법인 포항공과대학교|Gel comprising cucurbitril| BRPI0706280A2|2006-01-05|2011-03-22|Lifecycle Pharma As|disintegrating loadable tablet product and method for preparing a disintegrating loadable tablet| KR100784485B1|2006-01-18|2007-12-11|한국과학기술연구원|Biodegradable and thermosensitive polyorganophosphazene hydrogel, preparation method thereof and use thereof| WO2007085020A2|2006-01-20|2007-07-26|Pear Tree Pharmaceuticals, Inc.|Method of treating atrophic vaginitis| JP2009508852A|2006-01-23|2009-03-05|クワンジュインスティチュートオブサイエンスアンドテクノロジー|Conjugate in which pharmacologically active substance and mucoadhesive polymer are covalently bonded, and method for transmucosal delivery of pharmacologically active substance using the same| US20100278759A1|2006-02-08|2010-11-04|Howard Murad|Topical Therapeutic Delivery System| JP2009527551A|2006-02-24|2009-07-30|アクセラーエービー|Use of cyclolignans for the treatment of type 2 diabetes and as a contraceptive| WO2007106264A2|2006-03-02|2007-09-20|Warner Chilcott Company, Inc.|Extended cycle multiphasic oral contraceptive method| US20070207225A1|2006-03-03|2007-09-06|Francesco Squadrito|Genistein modulated reduction of cardiovascular risk factors| GB0604535D0|2006-03-07|2006-04-12|Sndv Sprl|Betulonic acid derivatives| CA2645080A1|2006-03-07|2007-09-13|Novavax,Inc.|Nanoemulsions of poorly soluble pharmaceutical active ingredients and methods of making the same| KR100746962B1|2006-04-04|2007-08-07|한국과학기술연구원|Thermosensitive polyphosphazene-bioactive molecule conjugates, preparation method thereof and use thereof| BRPI0709924A2|2006-04-05|2011-07-26|Wyeth Corp|Method for preventing or treating a condition arising from local estrogen deficiency| CA2648360A1|2006-04-07|2007-11-01|Novavax, Inc.|Nanostructured compositions having antibacterial, anti-fungal, anti-yeast, and/or anti-viral properties| WO2007118205A2|2006-04-07|2007-10-18|University Of Maryland, Baltimore|Compounds, compositions and methods for treating hormone-dependent maladies| WO2007120868A2|2006-04-14|2007-10-25|Stanley Kepka|Bioavailability enhancement of lipophilic drug by use solvent system| US8399012B2|2006-04-17|2013-03-19|Kimberly-Clark Worldwide, Inc.|Degradable therapeutic delivery device| NZ571460A|2006-04-21|2010-10-29|Antares Pharma Ipl Ag|Methods of treating hot flashes with formulations for transdermal or transmucosal application| US20080039405A1|2006-04-25|2008-02-14|Croda, Inc.|Modification of percutaneous absorption of topically active materials| US20070254858A1|2006-04-27|2007-11-01|Cronk Peter J|Contraceptive and Acne Medication Combination and Treatment of Acne and Other Diseases with Reduced Side Effects| CN101522174A|2006-05-10|2009-09-02|赢创德固赛有限责任公司|Use of roll compacted pyrogenically produced silicon dioxide in pharmaceutical compositions| EP2034984A4|2006-06-02|2013-03-06|Pear Tree Women S Health Care|Method of treating atrophic vaginitis| US20070287789A1|2006-06-07|2007-12-13|Stephen Ray Jones|Bleed-resistant colored microparticles| US20080113953A1|2006-06-08|2008-05-15|Warner Chilcott Company, Inc.|Methods to administer solid dosage forms of ethinyl estradiol and prodrugs thereof with improved bioavailability| US20070286819A1|2006-06-08|2007-12-13|Warner Chilcott Company, Inc.|Methods to administer ethinyl estradiol and prodrugs thereof with improved bioavailability| US20080021003A1|2006-06-13|2008-01-24|Vladimir Hanes|Extended step-down estrogen regimen| US20070292493A1|2006-06-15|2007-12-20|Brierre Barbara T|Pharmaceutical composition and method for the transdermal delivery of calcium| US8288366B2|2006-06-20|2012-10-16|Chochinov Ronald H|Formulation for hair growth| EP1872775A1|2006-06-29|2008-01-02|Polichem S.A.|Use of a hydrophilic matrix comprising a polyacrylic acid derivative, a cellulose ether and a disintegrant for the manufacture of a medicament for treating female genital disorders| WO2008006093A2|2006-07-06|2008-01-10|University Of Medicine And Dentistry Of New Jersey|Estrogen receptor modulators and uses thereof| US8617597B2|2006-07-06|2013-12-31|Bayer Intellectual Property Gmbh|Pharmaceutical composition containing a tetrahydrofolic acid| EP1880715A1|2006-07-19|2008-01-23|Abbott GmbH & Co. KG|Pharmaceutically acceptable solubilizing composition and pharmaceutical dosage form containing same| ES2391671T3|2006-07-22|2012-11-28|Oxagen Limited|Compounds with CRTH2 antagonist activity| DE102006035549A1|2006-07-27|2008-01-31|Evonik Röhm Gmbh|Pharmaceutical form with at least two-layer separating layer| US20080026040A1|2006-07-31|2008-01-31|Isaac Farr|Active agent-releasing dosage forms| US20080026062A1|2006-07-31|2008-01-31|Isaac Farr|Pharmaceutical compositions including nano-sized active agent| US20080038219A1|2006-08-07|2008-02-14|Calgenex Corporation|Novel Composition for a Topical Skin Treatment Base and Medicated Applications Thereof| US20080085877A1|2006-08-10|2008-04-10|Drugtech Corporation|Therapeutic methods of using estrogen compositions| US20080095831A1|2006-08-10|2008-04-24|Mc Graw Thomas L|Topical formulation of multilamellar vesicles composition for percutaneous absorption of pharmaceutically active agent| US20080038350A1|2006-08-10|2008-02-14|Hagen Gerecke|Low-dosage peroral medication for contraception containing crystalline dienogest and ethinyl estradiol| US20080166303A1|2006-09-08|2008-07-10|Dov Tamarkin|Colored or colorable foamable composition and foam| AU2007295179B2|2006-09-15|2013-05-30|Echo Pharmaceuticals B.V.|Dosage unit for sublingual, buccal or oral administration of water-insoluble pharmaceutically active substances| US20100086599A1|2006-09-16|2010-04-08|Kairosmed Gmbh|Oral modified release formulations| CA2664427C|2006-10-04|2012-06-05|M & P Patent Aktiengesellschaft|Controlled release delivery system for nasal application of neurotransmitters| US7790746B2|2007-10-12|2010-09-07|Supergen, Inc.|Quinoline derivatives for modulating DNA methylation| JP2010506856A|2006-10-12|2010-03-04|スーパージェン，インコーポレイテッド|Quinoline derivatives for regulating DNA methylation| US7939546B2|2007-10-12|2011-05-10|Supergen, Inc.|Quinoline derivatives for modulating DNA methylation| WO2008062466A2|2006-10-13|2008-05-29|Reliance Life Sciences Pvt. Ltd.|Cinnamic acid, vanillic acid and benzofuran derivatives for use in the treatment of inflammation and cancer| EP1930010A1|2006-10-20|2008-06-11|Bayer Schering Pharma Aktiengesellschaft|Application of estradiol valerate or 17ß-estradiol in combination with dienogest for oral therapy to maintain and/or increase the female libido| EP1915986A1|2006-10-23|2008-04-30|BIOPHARM GESELLSCHAFT ZUR BIOTECHNOLOGISCHEN ENTWICKLUNG VON PHARMAKA mbH|Lipid growth factor formulations| US8636787B2|2006-10-25|2014-01-28|Arterial Remodeling Technologies, S.A.|Method for expansion and deployment of polymeric structures including stents| DE102006050558B4|2006-10-26|2009-03-26|Lts Lohmann Therapie-Systeme Ag|Transdermal therapeutic system containing norelgestromin for contraception and hormone replacement| US20080103116A1|2006-11-01|2008-05-01|Jennings-Spring Barbara L|Method of treatment and compositions of D-chiro inositol and phosphates thereof| TW200833345A|2006-11-01|2008-08-16|Novacea Inc|Use of vitamin D compounds and mimics thereof to enhance delivery of therapeutics and oxygen to tumors and other tissues| US20090214474A1|2006-11-01|2009-08-27|Barbara Brooke Jennings|Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development| US20100143481A1|2006-11-08|2010-06-10|Dinesh Shenoy|Method of preparing solid dosage forms of multi-phasic pharmaceutical compositions| US7829116B2|2006-11-14|2010-11-09|Momentive Performance Materials Inc.|Adhesive-forming composition and blend of adhesives obtained therefrom| US20080260655A1|2006-11-14|2008-10-23|Dov Tamarkin|Substantially non-aqueous foamable petrolatum basedpharmaceutical and cosmetic compositions and their uses| DE102006054731B4|2006-11-21|2013-02-28|Lts Lohmann Therapie-Systeme Ag|Transdermal therapeutic system for administration of the active ingredient buprenorphine and use thereof in pain therapy| EP2097065A2|2006-11-29|2009-09-09|Foamix Ltd.|Foamable waterless compositions with modulating agents| WO2008067387A2|2006-11-29|2008-06-05|Wyeth|Estrogen/ serm and estrogen/ progestin bi-layer tablets| US20080132475A1|2006-12-05|2008-06-05|Charles Gerald Connor|Treatment for dry eye| US9918934B2|2006-12-12|2018-03-20|Edgar Joel Acosta-Zara|Linker-based lecithin microemulsion delivery vehicles| US20080145423A1|2006-12-14|2008-06-19|Ajmal Ali Khan|Chewable tablet and method of formulating| WO2008079898A1|2006-12-20|2008-07-03|Pharmwest, Inc.|Methods and topical formulations comprising colloidal metal for treating or preventing skin conditions| CN101679362A|2006-12-20|2010-03-24|拜尔保健公司|4-{4-[ phenyl]-1h-pyrazol-5-yl } carbamoyl)-amino] -3-fluorophenoxy} -N-methylpyridine-2-carboxamide as well as prodrugs and salts thereof for the treatment of cance| US20080153789A1|2006-12-26|2008-06-26|Femmepharma Holding Company, Inc.|Topical administration of danazol| TWI433674B|2006-12-28|2014-04-11|Infinity Discovery Inc|Cyclopamine analogs| GB2445539A|2006-12-29|2008-07-16|Ardana Bioscience Ltd|Bigel composition| US20090203658A1|2007-01-08|2009-08-13|Duke University|Neuroactive steroid compositions and methods of use therefor| AU2007343579B2|2007-01-11|2011-11-17|Acrux Dds Pty Ltd|Spreading implement| CN101631536A|2007-01-12|2010-01-20|惠氏公司|Tablet-in-tablet compositions| RU2009131749A|2007-01-22|2011-02-27|Новавакс, Инк. |MULTIPHASIC PHARMACEUTICAL COMPOSITIONS OF BADLY SOLUBLE MEDICINAL COMPOUNDS IN WATER TO REDUCE VARIABILITY WHEN RECEIVING AFTER FOOD / NORTH AMERICA AND TO IMPROVE ORAL ORAL BIOAVAILABILITY| US8828981B2|2007-02-06|2014-09-09|George Creasy|Progesterone for the treatment or prevention of spontaneous preterm birth| IL181217D0|2007-02-08|2007-07-04|Haim Levy|Pharmaceuticalcompositions based on a microemulsion| WO2008121447A1|2007-02-14|2008-10-09|Northwestern University|Self-assembling membranes and related methods thereof| CA2678496A1|2007-02-20|2008-08-28|Galderma Research & Development|A method for delivery of a therapeutic substance into the skin| US20080206156A1|2007-02-22|2008-08-28|Cronk Peter J|Continuous spray scalp therapy and dispensing systems for same| US20100105071A1|2007-02-28|2010-04-29|Children's Medical Center Corporation|Methods for predicting the onset of menarche| US20080214512A1|2007-03-01|2008-09-04|Christian Seitz|Pharmaceutical preparation containing a gestagen, and kit and method for treating endometriosis using the preparation| DE102007011486A1|2007-03-07|2008-09-11|Grünenthal GmbH|Medicament comprising at least one progestin| US20080226698A1|2007-03-16|2008-09-18|Mylan Technologies, Inc.|Amorphous drug transdermal systems, manufacturing methods, and stabilization| EP2136787B1|2007-03-22|2019-08-21|Berg LLC|Topical formulations having enhanced bioavailability| US20090017120A1|2007-03-23|2009-01-15|Humco Holding Group, Inc.|Phase stable lecithin organogel composition| ES2575554T3|2007-04-20|2016-06-29|Preglem S.A.|Selective progesterone modulators in the treatment of uterine hemorrhage| EP1988098A1|2007-04-27|2008-11-05|AEterna Zentaris GmbH|Novel Tetrahydrocarbazole Derivatives as Ligands of G-protein Coupled Receptors| EP2150271A1|2007-05-11|2010-02-10|The Texas A & M Univsersity System|Hormone normalization therapy and uses thereof| US20080312198A1|2007-06-14|2008-12-18|Rodriguez Gustavo C|Pharmaceutical products containing hormones and a 25-hydroxy vitamin d compound| US20080312197A1|2007-06-14|2008-12-18|Rodriguez Gustavo C|Pharmaceutical products containing hormones and a 25-hydroxy vitamin d compound| KR100968591B1|2007-06-14|2010-07-08|한국과학기술연구원|Polyorganophosphazene hydrogels for drug delivery, preparation method thereof and use thereof| US8367647B2|2007-06-21|2013-02-05|Pantarhei Bioscience B.V.|Treatment of meconium aspiration syndrome with estrogens| ES2310968B1|2007-06-25|2010-02-08|Italfarmaco, S.A.|USE OF ESTRIOL IN LOW DOSE.| WO2009003125A1|2007-06-26|2008-12-31|Warner Chilcott Company,Inc.|Intravaginal drug delivery devices for the delivery of macromolecules and water-soluble drugs| US8992977B2|2007-06-27|2015-03-31|Samos Pharmaceuticals, Llc|Multi-day delivery of biologically active substances| FR2918277B1|2007-07-06|2012-10-05|Coretecholding|NOVEL PROCESS FOR THE PRODUCTION OF HYDRODISPERSIBLE DRY PHARMACEUTICAL FORMS AND THE HYDRODISPERSIBLE COMPOSITIONS THUS OBTAINED| US8636982B2|2007-08-07|2014-01-28|Foamix Ltd.|Wax foamable vehicle and pharmaceutical compositions thereof| US8268806B2|2007-08-10|2012-09-18|Endorecherche, Inc.|Pharmaceutical compositions| KR100937625B1|2007-08-10|2010-01-20|주식회사 제닉|Dissolvable Web Porous Film and Preparing Method Thereof| US20090060997A1|2007-08-27|2009-03-05|Christian Seitz|Process for producing a pharmaceutical preparation for therapeutic treatment of endometriosis containing a combination of a gestagen and -5-methyltetrahydrofolate| US8617100B2|2007-09-04|2013-12-31|Foamix Ltd.|Device for delivery of a foamable composition| US20100204326A1|2007-09-06|2010-08-12|Regain Biotechnology Pvt Ltd|Novel agents for treatment of ailments and dysfunctions| AR068409A1|2007-09-14|2009-11-18|Drugtech Corp|PHARMACEUTICAL, TRANSDERMIC COMPOSITIONS WITHOUT ALCOHOL| US8507467B2|2007-09-20|2013-08-13|Shiseido Company, Ltd.|Transdermally absorbable preparation| AR066166A1|2007-09-21|2009-07-29|Organon Nv|DRUG SUPPLY SYSTEM| HUE043897T2|2007-09-25|2019-09-30|Solubest Ltd|Compositions comprising lipophilic active compounds and method for their preparation| AU2008309923B2|2007-10-08|2014-04-03|Fovea Pharmaceuticals|Aqueous ophthalmic formulations| US20090099149A1|2007-10-11|2009-04-16|Wyeth|Bioadhesive film| JP2011500793A|2007-10-25|2011-01-06|ルピン・リミテッド|Combination of antiemetics and oral contraceptives| ES2466676T3|2007-11-02|2014-06-10|Acrux Dds Pty Ltd|Transdermal administration system for hormones and steroids| US20090130029A1|2007-11-21|2009-05-21|Foamix Ltd.|Glycerol ethers vehicle and pharmaceutical compositions thereof| EP2219554A4|2007-11-29|2011-05-25|Gregg A Jackson|Progesterone-containing compositions and devices| US9439857B2|2007-11-30|2016-09-13|Foamix Pharmaceuticals Ltd.|Foam containing benzoyl peroxide| US8420624B2|2007-12-04|2013-04-16|Yung Shin Pharm. Ind. Co., Ltd.|Methods for treating or preventing symptoms of hormonal variations| US8518376B2|2007-12-07|2013-08-27|Foamix Ltd.|Oil-based foamable carriers and formulations| FR2924942B1|2007-12-14|2012-06-15|Pf Medicament|TRANSCUTANEOUS PHARMACEUTICAL COMPOSITIONS CONTAINING STEROIDAL HORMONE| US8762865B2|2007-12-19|2014-06-24|The Iams Company|Interactive survey feedback tool| EP2242476A2|2008-01-14|2010-10-27|Foamix Ltd.|Poloxamer foamable pharmaceutical compositions with active agents and/or therapeutic cells and uses| GB0801876D0|2008-02-01|2008-03-12|Vectura Group Plc|Suspension formulations| GB0802403D0|2008-02-08|2008-03-12|Probiox Sa|Compositions for the treatment of oxidative stress| TW201008569A|2008-08-08|2010-03-01|Bayer Schering Pharma Ag|Progestin-containing drug delivery system| US7960368B2|2008-03-05|2011-06-14|Everstra, Inc.|Bismethylene-17A carbolactones and related uses| US20090232897A1|2008-03-14|2009-09-17|Bijayananda Sahoo|Pharmaceutical compositions comprising conjugated estrogens| US20090258096A1|2008-04-11|2009-10-15|Bionovo, Inc.|Anticancer Methods Employing Extracts of Gleditsia sinensis Lam| US20110104289A1|2008-04-14|2011-05-05|Posi Visionary Solutions Llp|Method and pharmaceutical composition for obtaining the plasmatic progesterone levels required for different therapeutic indications| ES2327201B1|2008-04-23|2010-07-23|Ignacio Umbert Millet|PERSONALIZED PHARMACEUTICAL COMPOSITION FOR THE REJUVENATION OF SKIN CONTAINING RETINOIC ACID.| EP2293779A1|2008-04-24|2011-03-16|Evestra, Inc.|Oral contraceptive dosage forms comprising a progestogen dispersed in an enteric polymer and further comprising an estrogen| TWI477276B|2008-04-28|2015-03-21|Repros Therapeutics Inc|Antiprogestin dosing regimens| GB0807605D0|2008-04-28|2008-06-04|Diurnal Ltd|Lipid composition| US20090285869A1|2008-05-14|2009-11-19|Humco Holding Group, Inc.|Salt stable lecithin organogel composition| WO2009142743A1|2008-05-20|2009-11-26|Cantimer, Inc.|Methods, systems and devices for analyzing a surfactant-treated biological fluid sample| EP2283362A1|2008-05-20|2011-02-16|Cantimer Incorporated|Methods, systems and devices for analyzing a biological fluid sample following ion exchange| SI2285350T1|2008-06-16|2018-03-30|Pfizer Inc.|Methods for the preparation of targeting agent functionalized diblock copolymers for use in fabrication of therapeutic nanoparticles| US8613951B2|2008-06-16|2013-12-24|Bind Therapeutics, Inc.|Therapeutic polymeric nanoparticles with mTor inhibitors and methods of making and using same| WO2009158584A1|2008-06-27|2009-12-30|Wyeth|Dual adhesive technology| EP2140860A1|2008-07-03|2010-01-06|Bayer Schering Pharma Oy|An improved method of contraception| US20110190201A1|2008-07-24|2011-08-04|Searete Llc|Method, device, and kit for maintainingphysiological levels of steroid hormone in a subject| US20100028360A1|2008-07-26|2010-02-04|Craig Stephen Atwood|Methods for the modulation of brain progestagen signaling in the prevention and treatment of neurological disorders and neurodegenerative diseases| IT1392903B1|2008-07-29|2012-04-02|Marino Salin|COMPOSITION INCLUDING AN ASSOCIATION OF ACTIVE PRINCIPLES FOR USE IN THE TOPIC TREATMENT OF CALVIZIE| US20100040671A1|2008-08-12|2010-02-18|Ahmed Salah U|Intravaginal Devices With a Rigid Support, Methods of Making, and Uses Thereof| EP2331707A4|2008-08-28|2012-06-06|Dermtech Int|Determining age ranges of skin samples| EP2599497A3|2008-09-08|2013-09-25|Hoffman/Barrett, L.L.C.|Porphyrazine-chemotherapeutic agents conjugates| WO2010030763A2|2008-09-10|2010-03-18|Bind Biosciences, Inc.|High throughput fabrication of nanoparticles| GB2463565A|2008-09-12|2010-03-24|Critical Pharmaceuticals Ltd|Improvements in the absorption of therapeutic agents across mucosal membranes or the skin| CA2736707A1|2008-09-16|2010-03-25|Playtex Products, Llc|Dosages for menstrual suppression, contraception, and hormone replacement therapy, and methods of administering same| WO2010033832A2|2008-09-19|2010-03-25|Evestra, Inc.|Estriol formulations| EP2174650A1|2008-10-08|2010-04-14|Polichem SA|Modified release emulsions for application to skin or vaginal mucosa| US20110301087A1|2008-11-04|2011-12-08|Mcbride Edward|Crf1 receptor compounds| US20110300167A1|2008-11-04|2011-12-08|Mcmurry Thomas J|Cxcr5 receptor compounds| EP2218447B1|2008-11-04|2017-04-19|PharmaSol GmbH|Compositions containing lipid micro- or nanoparticles for the enhancement of the dermal action of solid particles| US20110294738A1|2008-11-04|2011-12-01|Yong Ren|Pthr1 receptor compounds| CN103396473A|2008-11-04|2013-11-20|安科治疗公司|Cxcr4 receptor compound| US20120028888A1|2008-11-04|2012-02-02|Jay Janz|Apj receptor compounds| JP5588993B2|2008-11-14|2014-09-10|イファユニバーシティ−インダストリーコラボレーションファウンデーション|Method for producing polymer fine sphere and polymer fine sphere produced by the method| US8394759B2|2008-11-21|2013-03-12|Cymbiotics, Inc.|Transdermal delivery of medicaments with combinations of cetylated fatty ester penetrant complexes| WO2010068500A2|2008-11-25|2010-06-17|Evestra, Inc.|PROGESTATIONAL 3- PROPIONIC ACID g-LACTONES| WO2010063080A1|2008-12-05|2010-06-10|Commonwealth Scientific And Industrial Research Organisation|Amphiphile prodrugs| CN102231953A|2008-12-06|2011-11-02|细胞内治疗公司|Organic compounds| CA2740394A1|2008-12-06|2010-06-10|Intra-Cellular Therapies, Inc.|Organic compounds| US8697710B2|2008-12-06|2014-04-15|Intra-Cellular Therapies, Inc.|Optionally substituted 3-amino-4--4,5-dihydro-2H-pyrazolo [3,4-d]pyrimidin-6-ones| KR20110098730A|2008-12-06|2011-09-01|인트라-셀룰라 써래피스, 인코퍼레이티드.|Organic compounds| CN102227167A|2008-12-06|2011-10-26|细胞内治疗公司|Organic compounds| AU2009322900A1|2008-12-06|2010-06-10|Intra-Cellular Therapies, Inc.|Organic compounds| EP2379059A4|2008-12-10|2012-10-31|Anhui Zhongren Technology Co Ltd|Controlled releasing composition| WO2010080543A1|2008-12-18|2010-07-15|Guthery B Eugene|Acne vulgaris treatment regimen| US20110318431A1|2008-12-30|2011-12-29|Endogenx|Pharmaceutical Compositions and Methods of Treating Neurological Insults| CA2749480C|2009-01-13|2015-03-31|Singularis, Inc.|Therapeutic modulation of vaginal epithelium boundary lubrication| BRPI1006984A2|2009-01-26|2015-08-25|Hal Witt|Preparation for estrous synchronization and effective hydreless protocols| US8158614B2|2009-01-27|2012-04-17|Wisconsin Alumni Research Foundation|Therapeutic treatment of cancer and dysplasia of the cervix or vagina using estrogen antagonists| WO2010088409A2|2009-01-30|2010-08-05|Emory University|Methods of neuroprotection using neuroprotective steroids and a vitamin d| WO2010093834A2|2009-02-12|2010-08-19|Incube Labs, Llc|Skin penetrating device and method for subcutaneous solid drug delivery| EP3045043B1|2009-02-26|2020-04-29|Relmada Therapeutics, Inc.|Extended release oral pharmaceutical compositions of 3-hydroxy-n-methylmorphinan and method of use| US8202736B2|2009-02-26|2012-06-19|The Governing Council Of The University Of Toronto|Method of hormone extraction using digital microfluidics| US20120015350A1|2009-03-10|2012-01-19|Northwestern University|Lateral flow strip and uses thereof| UY32492A|2009-03-17|2010-10-29|Organon Nv|ZOOTECH DRUG SUPPLY DEVICE.| US20120142645A1|2009-03-17|2012-06-07|Marx Christine E|Neuroactive steroid compositions and methods of use for lowering cholesterol| US9005608B2|2009-03-24|2015-04-14|Adds Pharmaceuticals Llc|Stabilized solubility-enhanced formulations for oral delivery| WO2010111488A1|2009-03-27|2010-09-30|Agile Therapeutics, Inc.|Transdermal delivery| US9011908B2|2009-04-06|2015-04-21|Banner Life Sciences Llc|Progesterone solutions for increased bioavailability| US8694358B2|2009-04-14|2014-04-08|Vital Insights Inc.|Systems, methods, and media for survey management| US20120065179A1|2009-04-14|2012-03-15|YKI, Ytemiska Institutet AB|Prodrug comprising beta-keto carboxylic acid, beta-keto carboxylic acid salt or beta-keto carboxylic acid ester for drug delivery| WO2010118461A1|2009-04-14|2010-10-21|Thierry Vancaillie|Gel compositions for administration of pharmaceutically active compounds| US20120128654A1|2009-04-23|2012-05-24|University Of Cincinnati|Allantoin Administration for the Treatment of Neurodegenerative Disease and Neurotrauma| US8344007B2|2009-04-23|2013-01-01|The Hong Kong Polytechnic University|Water-soluble polymer-based cantharimides as potentially selective anti-tumor agents| US20100273730A1|2009-04-27|2010-10-28|Innopharmax, Inc.|Self-emulsifying pharmaceutical compositions of hydrophilic drugs and preparation thereof| US20120087872A1|2009-04-28|2012-04-12|Foamix Ltd.|Foamable Vehicles and Pharmaceutical Compositions Comprising Aprotic Polar Solvents and Uses Thereof| US8568374B2|2009-05-04|2013-10-29|Merck Sharp & Dohme B.V.|Intrauterine system| US20120121692A1|2009-05-08|2012-05-17|Shandong University|Compounds and compositions comprising cdk inhibitors and methods for treatingcancer| GB0908129D0|2009-05-12|2009-06-24|Innovata Ltd|Composition| US9545360B2|2009-05-13|2017-01-17|Sio2 Medical Products, Inc.|Saccharide protective coating for pharmaceutical package| EP2437730A4|2009-05-20|2014-02-26|Lingual Consegna Pty Ltd|Buccal and/or sublingual therapeutic formulation| US8658628B2|2009-06-18|2014-02-25|Karan Y. Baucom|Hormone delivery system and method| WO2010146872A1|2009-06-19|2010-12-23|株式会社メドレックス|Composition for external application comprising aripiprazole and organic acid as active ingredients| ES2625950T3|2009-06-23|2017-07-21|Bayer Intellectual Property Gmbh|Pharmaceutical composition for emergency contraception| FR2947178B1|2009-06-29|2012-07-06|Effik|PHARMACEUTICAL COMPOSITION BASED ON MICRONIZED PROGESTERONE AND USES THEREOF| WO2011000210A1|2009-07-01|2011-01-06|润和生物医药科技有限公司|Composition of permeation enhancer and use thereof in transdermal drug delivery system| CN105412094A|2009-07-06|2016-03-23|爱尔皮奥治疗有限公司|Compounds, Compositions, And Methods For Preventing Metastasis Of Cancer Cells| DE102009034368A1|2009-07-20|2011-01-27|Bayer Schering Pharma Aktiengesellschaft|17-Hydroxy-17-pentafluoroethyl-estra-4,9 -diene-11-acyloxyalkylenephenyl derivatives, process for their preparation and their use for the treatment of diseases| DE102009034366A1|2009-07-20|2011-01-27|Bayer Schering Pharma Aktiengesellschaft|17-Hydroxy-17-pentafluoroethyl-estra-4,9 -diene-11-methyleneoxyalkylene aryl derivatives, process for their preparation and their use for the treatment of diseases| US8618083B2|2009-07-31|2013-12-31|Duquesne University Of The Holy Spirit|Combination hormone replacement therapy and melatonin to prevent and treat mammary cancer| KR101118587B1|2009-08-17|2012-06-12|포항공과대학교 산학협력단|Responsive polymer capsule, and method for preparing thereof| US8577716B2|2009-09-17|2013-11-05|Therapeuticsmd, Inc.|System and method of ongoing evaluation reporting and analysis| CA2776366C|2009-10-02|2017-07-18|Foamix Ltd.|Surfactant-free water-free foamable compositions, breakable foams and gels and their uses| US8882748B2|2009-10-08|2014-11-11|Palo Alto Research Center Incorporated|Transmucosal drug delivery device and method including chemical permeation enhancers| US20120269721A1|2009-10-12|2012-10-25|The Regents Of The University Of California|Targeted nanoclusters and methods of their use| US20110086825A1|2009-10-13|2011-04-14|Chatroux Sylvia S|Therapeutic vaginal emollient| CA2814237A1|2009-10-15|2011-04-21|Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College|Water soluble drug-solubilizer powders and their uses| IN2012DN02419A|2009-10-16|2015-08-21|Hemoteq Ag| AU2010308308B2|2009-10-19|2013-11-28|The Population Council, Inc.|Neuroprotection and myelin repair using nestorone®| US8637569B2|2009-10-22|2014-01-28|Api Genesis, Llc|Methods of increasing solubility of poorly soluble compounds and methods of making and using formulations of such compounds| US10080760B2|2009-10-27|2018-09-25|Besins Healthcare Luxembourg Sarl|Transdermal pharmaceutical compositions comprising active agents| EP2506867B1|2009-12-02|2014-10-08|Cardio3 Biosciences S.A.|Pharmaceutical compositions for the stimulation of stem cells.| WO2011073995A2|2009-12-14|2011-06-23|Lincoln Pharmaceuticals Limited|Liquid vaginal spray of progesterone| WO2011084668A1|2009-12-17|2011-07-14|The Population Council, Inc.|Nestorone®/estradiol transdermal gel| EP2512516B1|2009-12-18|2016-02-17|The Governing Council Of The University Of Toronto|Injectable polymer composition for use as a cell delivery vehicle| WO2011079047A1|2009-12-23|2011-06-30|Drugtech Corporation|Methods for reducing the occurrence of preterm delivery and other pregnancy-related conditions| BRPI1001367A2|2010-01-04|2012-07-17|Theraskin Farmaceutica Ltda|composition for topical application| TWI482645B|2010-01-07|2015-05-01|Teikoku Seiyaku Kk|External oily plaster containing diclofenac hydroxyethylpyrrolidine| US8709451B2|2010-01-20|2014-04-29|University Of Utah Research Foundation|Stable nanoemulsions for ultrasound-mediated drug delivery and imaging| US9162014B2|2010-01-25|2015-10-20|Concept Medical Research Private Limited|Method and an insertable medical device for delivering one or more pro-healing agents to a target site within a blood vessel post-deployment of a stent| EP2533799B8|2010-02-08|2019-12-25|Shenzhen Evergreen Therapeutics Co., Ltd.|Methods for the use of progestogen as a glucocorticoid sensitizer| US20130149314A1|2010-02-09|2013-06-13|Jörn Bullerdiek|p19Arf, HMGA2 and MDM2 For Use in the Diagnosis and Treatment of Aberrant Cell Growth| US20130072466A1|2010-02-22|2013-03-21|Industry-Academic Cooperation Foundation, Yeungnam University|Composition containing placenta extracts| WO2011109809A2|2010-03-05|2011-09-09|New Agriculture, Inc|A novel composition of matter for delivering lipid-soluble materials, and a method for producing it| EP2544707B1|2010-03-09|2018-11-21|Dignity Health|Methods for inhibiting preterm labor and uterine contractility disorders and preventing cervical ripening| WO2011112822A2|2010-03-10|2011-09-15|University Of Florida Research Foundation. Inc.|Implantable therapeutic device and methods of making| ES2384060B1|2010-03-24|2013-09-23|Lipotec S.A.|LIPID NANOPARTICLES CAPSULES.| US20130245253A1|2010-03-26|2013-09-19|Department Of Veterans Affairs|Conjugated Neuroactive Steroid Compositions And Methods Of Use| BR112012024835A2|2010-03-30|2016-06-07|Phosphagenics Ltd|transdermal patch adhesive| DE102010003494A1|2010-03-31|2011-10-06|Bayer Schering Pharma Aktiengesellschaft|Parenteral delivery system that releases aromatase inhibitors and progestins for the treatment of endometriosis| US20110250259A1|2010-04-12|2011-10-13|Kevin Buckman|Method of treating and preventing breast diseases and breast cancer with medicated formula| CA2796268A1|2010-04-13|2011-10-20|Johns Hopkins University|Methods for treatment of sleep-related breathing disorders| KR20180018827A|2010-04-15|2018-02-21|바이엘 인텔렉쳐 프로퍼티 게엠베하|Very low-dosed solid oral dosage forms for hrt| TW201138782A|2010-04-26|2011-11-16|Besins Healthcare Lu Sarl|Low-oil pharmaceutical emulsion compositions comprising progestogen| EP2575816B1|2010-05-28|2019-01-02|Nexgen Dermatologics, Inc.|Combination therapy for skin disorders| CN102258455B|2010-05-28|2014-09-17|上海市计划生育科学研究所|Film coating agent containing steroid hormone and its preparation method| EP2576551A4|2010-05-31|2014-04-16|Intra Cellular Therapies Inc|Organic compounds| US9371327B2|2010-05-31|2016-06-21|Intra-Cellular Therapies, Inc.|PDE1 inhibitor compounds| US9434730B2|2010-05-31|2016-09-06|Intra-Cellular Therapies, Inc.|PDE1 inhibitor compounds| TW201206937A|2010-05-31|2012-02-16|Intra Cellular Therapies Inc|Organic compounds| BRPI1002601E2|2010-06-01|2020-06-30|Embrapa Pesquisa Agropecuaria|nanostructured composition for veterinary use for drug administration| JP2012020991A|2010-06-16|2012-02-02|Takasago Internatl Corp|Transdermal absorption promoter, and external skin formulation thereof| AU2011268470B2|2010-06-17|2017-02-02|Momenta Pharmaceuticals, Inc.|Methods and compositions for promoting hair growth| US20110312928A1|2010-06-18|2011-12-22|Lipocine Inc.|Progesterone Containing Oral Dosage Forms and Related Methods| US20110312927A1|2010-06-18|2011-12-22|Satish Kumar Nachaegari|Progesterone Containing Oral Dosage Forms and Related Methods| US9375437B2|2010-06-18|2016-06-28|Lipocine Inc.|Progesterone containing oral dosage forms and kits| US8741373B2|2010-06-21|2014-06-03|Virun, Inc.|Compositions containing non-polar compounds| EP2399566A1|2010-06-28|2011-12-28|Laboratoire HRA Pharma|Once-a-month method of contraception| KR101209266B1|2010-06-30|2012-12-06|한국과학기술연구원|Biodegradable and thermosensitive poly-superparamagnetic nano-particle complex, preparation method and use thereof| EP2407157A1|2010-07-13|2012-01-18|Koninklijke Philips Electronics N.V.|Lipid bilayer carrier for drugs or imaging agents| KR20120011344A|2010-07-21|2012-02-08|에스케이케미칼주식회사|Method for preparing microspheres and microspheres produced thereby| BRPI1002486B1|2010-07-22|2017-07-18|Evidence Soluções Farmacêuticas Ltda Epp|STABILIZED TOPICAL COMPOSITION AND PROCESS OF OBTAINING COMPOSITION STABLE TOPIC| US10849857B2|2010-07-28|2020-12-01|Laboratorios Leon Farma Sa|Pharmaceutical compositions comprising active drugs, contraceptive kits comprising active drugs, and methods of administering the same| WO2012024361A1|2010-08-17|2012-02-23|Biosante Pharmaceuticals, Inc.|Commercial scale production methods for transdermal hormone formulations| US8435972B2|2010-09-02|2013-05-07|Emory University|Method for the treatment of central nervous system cancers and compositions related thereto| BRPI1003661A2|2010-09-15|2013-01-08|Libbs Farmaceutica Ltda|pharmaceutical combination to treat and / or prevent fibroid and / or endometriosis, use of resveratrol and progestogen, pharmaceutical composition for treatment and / or prevention of fibroid and / or endometriosis drug for treatment and / or prevention of fibroid and / or endometriosis, kit and Method for the treatment and / or prevention of fibroid and / or endometriosis| US20120064135A1|2010-09-15|2012-03-15|Norac Pharma|Benzoyl Peroxide Composition, Methods for Making Same, and Pharmaceutical or Cosmetic Formulations Comprising Same, and Uses Thereof| ES2386177B1|2010-09-21|2013-09-23|Lipotec, S.A.|NANOCAPSULES CONTAINING MICROEMULSIONS| EP2434285A1|2010-09-22|2012-03-28|IMBA-Institut für Molekulare Biotechnologie GmbH|Breast cancer diagnostics| EP2433644A1|2010-09-22|2012-03-28|IMBA-Institut für Molekulare Biotechnologie GmbH|Breast cancer therapeutics| DE102010047714A1|2010-10-06|2012-04-12|Justus-Liebig-Universität|Derivatives of steroid benzylamines with antiparasitic, antibacterial, antifungal and / or antiviral activity| US20120101073A1|2010-10-22|2012-04-26|Galleon Pharmaceutical, Inc.|Novel Method For Treating Breathing Disorders or Diseases| WO2012055814A1|2010-10-25|2012-05-03|Institut National De La Sante Et De La Recherche Medicale |Compound inducing lbpa accumulation for inhibiting cell-to-cell transmission of hiv| WO2012055840A1|2010-10-28|2012-05-03|Bayer Pharma Aktiengesellschaft|Composition and preparation for treatment of dysmenorrhea and menstrual pain and use of a hormonal agent and a zinc salt for treatment of menstrual disorders| JP2014532685A|2011-11-04|2014-12-08|バイエル・ファルマ・アクチェンゲゼルシャフトＢａｙｅｒ Ｐｈａｒｍａ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ|18-Methyl-6,7-methylene-3-oxo-17-pregna-4-ene-21,17β-carbolactone, pharmaceutical formulations containing said compound and its use in the treatment of endometriosis| WO2012061695A1|2010-11-04|2012-05-10|Board Of Regents Of The University Of Nebraska|Compositions and methods for the treatment of traumatic brain injury| ES2528650T3|2010-11-17|2015-02-11|Hexal Ag|Transdermal therapeutic system comprising buprenorphine| US20120295911A1|2010-11-29|2012-11-22|Galleon Pharmaceuticals, Inc.|Novel Compounds and Compositions for Treatment of Breathing Control Disorders or Diseases| CA2819633C|2010-12-03|2019-04-23|Allergan, Inc.|Pharmaceutical cream compositions and methods of use| US20140079686A1|2010-12-06|2014-03-20|Shikha P. Barman|Methods For Treating Baldness And Promoting Hair Growth| KR101424163B1|2010-12-24|2014-08-01|주식회사 삼양바이오팜|Polymeric microparticles containing a hydrophobic drug for sustained release thereof and method for preparing the same| DE102011002934A1|2011-01-20|2012-07-26|Bayer Schering Pharma Ag|CB2 agonists for the treatment and prevention of endometriosis| WO2012103039A1|2011-01-24|2012-08-02|Anterios, Inc.|Surfactant compositions| WO2012103037A1|2011-01-24|2012-08-02|Anterios, Inc.|Oil compositions| TW201309670A|2011-01-25|2013-03-01|Kissei Pharmaceutical|Indole derivative and pharmacologically acceptable salt of same| KR101376237B1|2011-01-25|2014-03-21|전북대학교산학협력단|Method of regulating fertilizing ability using cyclic adp-ribose, its derivatives and cd38| CA2825134A1|2011-01-25|2012-08-02|Kissei Pharmaceutical Co., Ltd.|Indole derivative, and pharmacologically acceptable salt thereof| US20140031323A1|2011-02-15|2014-01-30|Ramiro M. Perez|Transdermal hormone composition and combined static-cyclic delivery| EP2675914A1|2011-02-18|2013-12-25|Yale University, Inc.|The kras-variant and endometriosis| US9597340B2|2011-02-25|2017-03-21|Arena Pharmaceuticals, Inc.|Cannabinoid receptor modulators| WO2012118563A2|2011-03-03|2012-09-07|Vanderbilt University|6-alkyl-n--4-aryloxypicolinamide analogs as mglur5 negative allosteric modulators and methods of making and using the same| US9283251B2|2011-03-04|2016-03-15|Wake Forest University Health Sciences|Encapsulated cells for hormone replacement therapy| WO2012120365A1|2011-03-07|2012-09-13|Aurobindo Pharma Limited|Stable pharmaceutical composition comprising ethinyl estradiol| WO2012127501A2|2011-03-11|2012-09-27|Sanzyme Limited|Composition for improving endometrial thickness during ovarian stimulation| WO2012130336A1|2011-03-29|2012-10-04|Principium Europe S.R.L.|Delivery of large molecular weight biologically active substances| DK3238709T3|2011-04-28|2020-09-28|Platform Brightworks Two Ltd|IMPROVED PARENTERAL FORMULATIONS OF LIPOFILE PHARMACEUTICALS AND METHODS FOR THE PREPARATION AND USE OF THE SAME| AR082266A1|2011-05-13|2012-11-28|Univ Nac Del Litoral|INJECTABLE CONTROLLED LIBERATION MICROPARTICLE| CN109481394A|2011-05-15|2019-03-19|埃瑟尔斯医药有限公司|Intranasal testosterone bioadhesiveness gel preparation and its purposes for treating male hypogonadism| US11058793B2|2011-05-16|2021-07-13|Avery Dennison Corporation|Adhesive containing microparticles| KR101481859B1|2011-05-20|2015-01-14|에스케이케미칼주식회사|Method for preparing microparticles with reduced initial drug release and microparticles prepare thereby| US9084797B2|2011-05-23|2015-07-21|Besins Healthcare Luxembourg Sarl|Progesterone treatment for improving sleep quality| WO2012166909A1|2011-06-03|2012-12-06|Galleon Pharmaceuticals, Inc.|Compositions and methods for treating breathing control disorders or diseases| AU2012268068B2|2011-06-06|2016-10-13|Auritec Pharmaceuticals|Drug delivery device employing wicking release window| US10561656B2|2011-06-10|2020-02-18|Intra-Cellular Therapies, Inc.|Organic compounds| EP2717880B1|2011-06-13|2016-12-14|Parthenogen SAGL|Selective cns delivery of mifepristone to modulate the timing of the spontaneous lh surge during follicular stimulation cycles| US20130004619A1|2011-06-28|2013-01-03|Kemin Industries, Inc.|Method of Forming Encapsulated Compositions with Enhanced Solubility and Stability| EP2734189B1|2011-07-20|2018-08-22|Perrigo Israel Pharmaceuticals Ltd.|Topical oily foam compositions| US8951996B2|2011-07-28|2015-02-10|Lipocine Inc.|17-hydroxyprogesterone ester-containing oral compositions and related methods| US20140206717A1|2011-08-16|2014-07-24|John Higgins|Use of inorganic matrix and organic polymer combinations for preparing stable amorphous dispersions| KR101302557B1|2011-08-16|2013-09-02|충북대학교 산학협력단|Method For Preparing Polymeric Biomaterials Having Immobilized Drug Delivery System Comprising Bioactive Molecules Loaded Particulate Carrier| US20140227184A1|2011-08-19|2014-08-14|The Trustees Of Princeton University|C-halogen bond formation| EP2747563A4|2011-08-26|2015-06-24|Aegis Therapeutics Llc|Compositions and methods thereof for oral administration of drugs| KR101494594B1|2011-08-30|2015-02-23|주식회사 종근당|Sustained-release lipid pre-concentrate of pharmacologically active substance and pharmaceutical composition comprising the same| EP2741757B1|2011-09-11|2018-05-16|Minovia Therapeutics Ltd.|Compositions of functional mitochondria and uses thereof| US20150064155A1|2011-09-23|2015-03-05|Trustees Of Tufts College|Methods for treatment of cervical insufficiency| DE102011083595A1|2011-09-28|2013-03-28|Bayer Pharma AG|Inhibition of the effect of interleukin 1 beta for the treatment of endometriosis| JP2014528457A|2011-10-07|2014-10-27|フロリダ ステイト ユニバーシティ リサーチ ファウンデーション|Progesterone prophylactic and acute use for good outcomes related to concussion| US8721331B2|2011-10-11|2014-05-13|Puthalath Koroth Raghuprasad|Oral transmucosal drug delivery device| EP2768666A4|2011-10-17|2015-07-15|Univ Temple|Silica particles coated with beta-cyclodextrin for the removal of emerging contaminants from wastewater| US9120766B2|2011-10-21|2015-09-01|Amri Ssci, Llc|Methods of making cocrystals| US20140271884A1|2011-10-25|2014-09-18|The Trustees Of Princeton University|High-loading nanoparticle-based formulation for water-insoluble steroids| WO2013061161A2|2011-10-28|2013-05-02|Green Bcn Consulting Services Sl|New combination therapies for treating neurological disorders| CN103957899A|2011-11-04|2014-07-30|敏捷治疗公司|Dermal delivery compositions and methods| JP6563193B2|2011-11-13|2019-08-21|ブランシェット・ロックフェラー・ニューロサイエンスィズ・インスティテュート|Esters of DCPLA and methods of treatment using the same| US20130122051A1|2011-11-15|2013-05-16|Pharmaceutics International, Inc.|Methods of preparing progesterone pharmaceutical compositions| US20120128683A1|2011-11-22|2012-05-24|Shantha Totada R|Autism treatment| US9301920B2|2012-06-18|2016-04-05|Therapeuticsmd, Inc.|Natural combination hormone replacement formulations and therapies| MX365818B|2011-11-23|2019-05-30|Therapeuticsmd Inc|Natural combination hormone replacement formulations and therapies.| US10537581B2|2012-12-21|2020-01-21|Therapeuticsmd, Inc.|Vaginal inserted estradiol pharmaceutical compositions and methods| US20130338122A1|2012-06-18|2013-12-19|Therapeuticsmd, Inc.|Transdermal hormone replacement therapies| US10806740B2|2012-06-18|2020-10-20|Therapeuticsmd, Inc.|Natural combination hormone replacement formulations and therapies| RU2740059C2|2012-06-18|2020-12-31|Терапьютиксмд, Инк.|Capsules with soluble oestradiol for intravaginal introduction| US9334538B2|2011-12-06|2016-05-10|Annabelle Rodriguez Oquendo|Method for pre-screening and correlation of underlying SCARB1 gene variation to infertility in women and therapeutic use of progestational and other medications in treatment| EP2790685B1|2011-12-12|2017-08-16|LTS LOHMANN Therapie-Systeme AG|Transdermal delivery system comprising buprenorphine| KR101278204B1|2011-12-22|2013-06-27|경북대학교 산학협력단|Method for preparing biomedical metal/alloy material with multi-drug delivery system| US9282995B2|2011-12-22|2016-03-15|Previvo Genetics, Llc|Recovery and processing of human embryos formed in vivo| GB201200062D0|2012-01-04|2012-02-15|Innotesto Bvba|Estradiol oromucosal liquid compositions| CA2860740A1|2012-01-09|2013-07-18|Anchor Therapeutics, Inc.|Apj receptor compounds| US20150202211A1|2012-06-18|2015-07-23|Therapeuticsmd, Inc.|Progesterone formulations having a desirable pk profile| US20150196640A1|2012-06-18|2015-07-16|Therapeuticsmd, Inc.|Progesterone formulations having a desirable pk profile| PL2809307T3|2012-01-31|2018-06-29|Grünenthal GmbH|Pharmaceutical patch for transdermal administration of -6'-fluoro-n,n-dimethyl-4-phenyl-4',9'-dihydro-3'h-spiro[cyclohexane-1,1'-pyrano[3,4-b]indol]-4-amine| EP2630952A1|2012-02-23|2013-08-28|Novagali Pharma S.A.|Self-preserved oil dispersions comprising boric acid| WO2013130535A1|2012-02-27|2013-09-06|Newgen Biopharma Corporation|Topical delivery of hormonal and non hormonal nano formulations, methods of making and using the same| US20130225412A1|2012-02-28|2013-08-29|Soroush Sardari Lodriche|Silicon nanocarrier for delivery of drug, pesticides and herbicides , and for waste water treatment| KR20140131936A|2012-02-29|2014-11-14|베. 브라운 멜중엔 악티엔게젤샤프트|Hormone containing emulsion comprising krill phospholipids| US9682093B2|2012-03-30|2017-06-20|Charles R. Drew University Of Medicine And Science|Compositions and methods for treating or preventing metabolic syndrome disorders| FR2988609B1|2012-03-30|2015-09-04|Commissariat Energie Atomique|FORMULATION FOR HORMONOTHERAPY| FR2988610B1|2012-03-30|2014-10-31|Effik|PROGESTATIVE CO-MICRONIZED WITH A POLYMER CARRYING THE PYRROLIDONE GROUP, COMPOSITION AND USES| EP2839286B1|2012-04-18|2018-02-28|Siemens Healthcare Diagnostics Inc.|Compounds and methods for preparation of conjugate reagents| US20130317315A1|2012-05-22|2013-11-28|Tony V. Lu|Method of age management| ITMI20120913A1|2012-05-28|2013-11-29|Nicoletta Maxia|USE OF N-ACETHYL-5-METHOXY-RIPTAMIN OR ITS ANALOGUES TO ENCOURAGE THE EMBRYO PLANT MECHANISM, AND RELATIVE COMPOSITIONS AND MEANS OF CULTURE| MX363640B|2012-05-31|2019-03-28|Repros Therapeutics Inc|Formulations and methods for vaginal delivery of antiprogestins.| US10806697B2|2012-12-21|2020-10-20|Therapeuticsmd, Inc.|Vaginal inserted estradiol pharmaceutical compositions and methods| US20140370084A1|2013-06-18|2014-12-18|Therapeuticsmd, Inc.|Estradiol formulations and therapies| WO2014004424A1|2012-06-26|2014-01-03|Temple University - Of The Commonwealth System Of Higher Education|Method for detecting injury to the brian| CA2877083C|2012-06-27|2020-10-06|Medincell|Biodegradable drug delivery for hydrophobic compositions| WO2014009434A1|2012-07-11|2014-01-16|Sandoz Ag|Self-microemulsifying drug delivery system of abiraterone or abiraterone acetate| WO2014012117A1|2012-07-13|2014-01-16|South Dakota State University|Compositions and methods for localized drug delivery through mammary papillae| US20150272934A1|2012-07-25|2015-10-01|Sova Pharmaceuticals, Inc.|Use of cse inhibitors for the treatment of cutaneous injuries or conditions and sleep-related breathing disorders| AR091858A1|2012-07-25|2015-03-04|Sova Pharmaceuticals Inc|CISTATIONIN-g-LIASA INHIBITORS | AR091857A1|2012-07-25|2015-03-04|Sova Pharmaceuticals Inc|CISTATIONIN-g-LIASA INHIBITORS | CN104736144B|2012-07-27|2019-02-01|艾祖米科技有限公司|Outlet inhibitor combination and the method treated using this composition| CA2880027C|2012-07-27|2021-12-07|Rhodes Technologies|Progesterone compositions and treatment for eye diseases and disorders| KR101480363B1|2012-07-30|2015-01-09|한국과학기술연구원|Poly containing degradation-controllable ionic group, preparation method thereof and use thereof| AU2013305563B2|2012-08-24|2018-09-27|Integurx Therapeutics, Llc|Chemical compositions and methods for enhancing transdermal delivery of therapeutic agents| EP2708213A1|2012-09-13|2014-03-19|PAT&Co bvba|Multipurpose ethylene vinyl acetate fibrous drug delivery systems for long-term implantation or insertion| WO2014052792A1|2012-09-28|2014-04-03|Sio2 Medical Products, Inc.|Halogenated or parylene polymer coating| PL2716291T3|2012-10-08|2020-06-15|Universität Ulm|Combination of opioids and anticancer drugs for cancer treatment| US9381231B2|2012-10-09|2016-07-05|University Of Florida Research Foundation, Inc.|Use of relaxin to restore maternal physiology in pregnancies conceived by assisted reproductive technologies| WO2014066442A2|2012-10-24|2014-05-01|Emory University|Methods of managing childhood cerebral injury| US20140127185A1|2012-11-02|2014-05-08|Emory University|Methods and compositions using neuroprotective steroids and thrombolytic agents| WO2014074846A1|2012-11-09|2014-05-15|Celgene Corporation|Methods for the treatment of bone loss| WO2014076569A2|2012-11-14|2014-05-22|Trimel Biopharma Srl|Controlled release topical testosterone formulations and methods| EP2732824A1|2012-11-16|2014-05-21|Ceva Sante Animale|Compositions and methods for increasing reproduction performance in non human mammals using alpha-beta-linked follicle stimulating hormone| WO2014081598A1|2012-11-20|2014-05-30|The Brigham And Women's Hospital, Inc.|Diagnosis and treatment of endometriosis and related conditions| EA028830B1|2012-12-06|2018-01-31|Байер Фарма Акциенгезельшафт|Novel benzimidazole derivatives as receptor ep4 antagonists| EP2931274A1|2012-12-11|2015-10-21|Metabolic Solutions Development Company LLC|Ppar-sparing thiazolidinediones and combinations for the treatment of neurodegenerative diseases| US9180091B2|2012-12-21|2015-11-10|Therapeuticsmd, Inc.|Soluble estradiol capsule for vaginal insertion| US9498539B2|2012-12-27|2016-11-22|Molly Sandra Shoichet|Affinity-based controlled release system| US20140186332A1|2012-12-28|2014-07-03|NX Pharmagen|Biomarkers of preterm birth| KR101586789B1|2012-12-28|2016-01-19|주식회사 종근당|Sustained-release lipid pre-concentrate of cationic pharmacologically active substance and pharmaceutical composition comprising the same| US8992951B2|2013-01-09|2015-03-31|Sapna Life Sciences Corporation|Formulations, procedures, methods and combinations thereof for reducing or preventing the development, or the risk of development, of neuropathology as a result of trauma|US9795617B2|2009-06-18|2017-10-24|Baucom Institute for Longevity and Life Enhancement, Inc.|Hormone delivery system and method| WO2018031576A1|2016-08-08|2018-02-15|Baucom Karan Y|Hormone delivery system and method| WO2015130807A1|2014-02-25|2015-09-03|Baucom Institute for Longevity and Life Enhancement, Inc.|Hormone delivery system and method| US20130338122A1|2012-06-18|2013-12-19|Therapeuticsmd, Inc.|Transdermal hormone replacement therapies| US9301920B2|2012-06-18|2016-04-05|Therapeuticsmd, Inc.|Natural combination hormone replacement formulations and therapies| US10537581B2|2012-12-21|2020-01-21|Therapeuticsmd, Inc.|Vaginal inserted estradiol pharmaceutical compositions and methods| US10806740B2|2012-06-18|2020-10-20|Therapeuticsmd, Inc.|Natural combination hormone replacement formulations and therapies| MX365818B|2011-11-23|2019-05-30|Therapeuticsmd Inc|Natural combination hormone replacement formulations and therapies.| US20150196640A1|2012-06-18|2015-07-16|Therapeuticsmd, Inc.|Progesterone formulations having a desirable pk profile| US10806697B2|2012-12-21|2020-10-20|Therapeuticsmd, Inc.|Vaginal inserted estradiol pharmaceutical compositions and methods| US10568891B2|2012-12-21|2020-02-25|Therapeuticsmd, Inc.|Vaginal inserted estradiol pharmaceutical compositions and methods| US11246875B2|2012-12-21|2022-02-15|Therapeuticsmd, Inc.|Vaginal inserted estradiol pharmaceutical compositions and methods| US10471072B2|2012-12-21|2019-11-12|Therapeuticsmd, Inc.|Vaginal inserted estradiol pharmaceutical compositions and methods| US11266661B2|2012-12-21|2022-03-08|Therapeuticsmd, Inc.|Vaginal inserted estradiol pharmaceutical compositions and methods| US9180091B2|2012-12-21|2015-11-10|Therapeuticsmd, Inc.|Soluble estradiol capsule for vaginal insertion| KR20160137597A|2014-03-28|2016-11-30|쎄러퓨틱스엠디, 인코퍼레이티드|Progesterone formulations| EP2944324A1|2014-05-13|2015-11-18|LTS LOHMANN Therapie-Systeme AG|Use of semifluorinated alkanes in transdermal therapeutic systems| JP2017516768A|2014-05-22|2017-06-22|セラピューティックスエムディー インコーポレーテッドＴｈｅｒａｐｅｕｔｉｃｓｍｄ， Ｉｎｃ．|Natural combination hormone replacement therapy and therapy| BR112016029338A2|2014-07-29|2017-08-22|Therapeuticsmd Inc|transdermal cream| US10328087B2|2015-07-23|2019-06-25|Therapeuticsmd, Inc.|Formulations for solubilizing hormones| WO2017105512A1|2015-12-18|2017-06-22|Proinvet Innovations S.A.|Formulations and methods for controlling the reproductive cycle and ovulation| EP3435977A4|2016-04-01|2019-10-16|Therapeuticsmd, Inc.|Steroid hormone pharmaceutical composition| US10286077B2|2016-04-01|2019-05-14|Therapeuticsmd, Inc.|Steroid hormone compositions in medium chain oils|
法律状态:
2018-01-16| B07D| Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]| 2018-03-06| B06F| Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]| 2018-03-13| B06F| Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]| 2018-03-20| B06I| Publication of requirement cancelled [chapter 6.9 patent gazette]|Free format text: ANULADA A PUBLICACAO CODIGO 6.6.1 NA RPI NO 2462 DE 13/03/2018 POR TER SIDO INDEVIDA. | 2018-09-25| B07E| Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]|Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI | 2019-03-12| B06T| Formal requirements before examination [chapter 6.20 patent gazette]| 2019-12-10| B06A| Patent application procedure suspended [chapter 6.1 patent gazette]| 2020-05-12| B09A| Decision: intention to grant [chapter 9.1 patent gazette]| 2020-09-15| B16A| Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]|Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 18/06/2013, OBSERVADAS AS CONDICOES LEGAIS. |
优先权:
[返回顶部]
申请号 | 申请日 | 专利标题 US201261661302P| true| 2012-06-18|2012-06-18| US61/661,302|2012-06-18| US201261662265P| true| 2012-06-20|2012-06-20| US61/662,265|2012-06-20| US13/684,002|2012-11-21| US13/684,002|US8633178B2|2011-11-23|2012-11-21|Natural combination hormone replacement formulations and therapies| USPCT/US2013/023309|2013-01-25| PCT/US2013/023309|WO2013112947A1|2012-01-26|2013-01-25|Transdermal hormone replacement therapies| US13/843,362|2013-03-15| US13/843,362|US20130338122A1|2012-06-18|2013-03-15|Transdermal hormone replacement therapies| PCT/US2013/046442|WO2013192248A1|2012-06-18|2013-06-18|Progesterone formulations| 相关专利
Sulfonates, polymers, resist compositions and patterning process
Washing machine
Washing machine
Device for fixture finishing and tension adjusting of membrane
Structure for Equipping Band in a Plane Cathode Ray Tube
Process for preparation of 7 alpha-carboxyl 9, 11-epoxy steroids and intermediates useful therein an
国家/地区
|